 EXHIBIT 2.1        

 

 


 

 

 

AGREEMENT AND PLAN OF MERGER

 


 

 

between

 


 

 

IRC SUPERMAN MIDCO, LLC,

 


 

 

SUPERMAN MERGER SUB, INC.

 


 

 

and

 


 

 

AMERICAN RENAL ASSOCIATES HOLDINGS, INC.

 


 

 

Dated as of October 1, 2020

 


 

     

_TABLE OF CONTENTS_

 


 

 

Page

  
        

Article I THE MERGER

    |  

2

    
---|--- 
      |   
      |  

Section 1.1.

    |  

The Merger

    |  

2

    
      |  

Section 1.2.

    |  

Closing

    |  

2

    
      |  

Section 1.3.

    |  

Effective Time

    |  

2

    
      |  

Section 1.4.

    |  

Certificate of Incorporation; Bylaws

    |  

2

    
      |  

Section 1.5.

    |  

Directors and Officers

    |  

3

    
      |   |   |   
     

Article II EFFECT OF THE MERGER ON THE CAPITAL STOCK OF THE CONSTITUENT
CORPORATIONS

    |  

3

    
      |   
      |  

Section 2.1.

    |  

Effect on Capital Stock

    |  

3

    
      |  

Section 2.2.

    |  

Treatment of Equity Awards

    |  

4

    
      |  

Section 2.3.

    |  

Surrender of Shares

    |  

5

    
      |  

Section 2.4.

    |  

Appraisal Rights

    |  

7

    
      |  

Section 2.5.

    |  

Adjustments

    |  

8

    
      |   |   |   
     

Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY

    |  

8

    
      |   
      |  

Section 3.1.

    |  

Organization and Qualification; Subsidiaries

    |  

9

    
      |  

Section 3.2.

    |  

Organizational Documents

    |  

9

    
      |  

Section 3.3.

    |  

Capitalization

    |  

9

    
      |  

Section 3.4.

    |  

Authority

    |  

11

    
      |  

Section 3.5.

    |  

No Conflict; Required Filings and Consents

    |  

12

    
      |  

Section 3.6.

    |  

Compliance

    |  

13

    
      |  

Section 3.7.

    |  

SEC Filings; Financial Statements; Undisclosed Liabilities

    |  

13

    
      |  

Section 3.8.

    |  

Contracts

    |  

15

    
      |  

Section 3.9.

    |  

Absence of Certain Changes or Events

    |  

18

    
      |  

Section 3.10.

    |  

Absence of Litigation

    |  

18

    
      |  

Section 3.11.

    |  

Employee Benefit Plans

    |  

19

    
      |  

Section 3.12.

    |  

Labor and Employment Matters

    |  

20

    
      |  

Section 3.13.

    |  

Insurance

    |  

21

    
      |  

Section 3.14.

    |  

Properties

    |  

22

    
      |  

Section 3.15.

    |  

Tax Matters

    |  

23

    
      |  

Section 3.16.

    |  

Proxy Statement

    |  

25

    
      |  

Section 3.17.

    |  

Intellectual Property

    |  

25

    
      |  

Section 3.18.

    |  

Environmental Matters

    |  

25

    
      |  

Section 3.19.

    |  

Opinion of Financial Advisor

    |  

26

    
      |  

Section 3.20.

    |  

Regulatory Matters

    |  

26

    
      |  

Section 3.21.

    |  

Information Technology

    |  

29

    
      |  

Section 3.22.

    |  

Brokers

    |  

29

    
      |  

Section 3.23.

    |  

Takeover Statutes

    |  

29

    
      |  

Section 3.24.

    |  

Affiliate Party Transactions

    |  

29

    
      |  

Section 3.25.

    |  

No Other Representations or Warranties

    |  

30

    
    

 

i            |   |   |   
---|---|---|--- 
     

Article IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

    |  

30

    
      |   
      |  

Section 4.1.

    |  

Organization

    |  

30

    
      |  

Section 4.2.

    |  

Authority

    |  

31

    
      |  

Section 4.3.

    |  

No Conflict; Required Filings and Consents

    |  

31

    
      |  

Section 4.4.

    |  

Absence of Litigation

    |  

32

    
      |  

Section 4.5.

    |  

Operations and Ownership of Merger Sub

    |  

32

    
      |  

Section 4.6.

    |  

Absence of Certain Agreements

    |  

33

    
      |  

Section 4.7.

    |  

Proxy Statement

    |  

33

    
      |  

Section 4.8.

    |  

Brokers

    |  

33

    
      |  

Section 4.9.

    |  

Ownership of Shares

    |  

34

    
      |  

Section 4.10.

    |  

Vote/Approval Required

    |  

34

    
      |  

Section 4.11.

    |  

Subsequent Transaction Agreement; HSR Filing

    |  

34

    
      |  

Section 4.12.

    |  

Solvency

    |  

34

    
      |  

Section 4.13.

    |  

Financing

    |  

35

    
      |  

Section 4.14.

    |  

Parent Guarantee

    |  

36

    
      |  

Section 4.15.

    |  

No Other Information

    |  

36

    
      |  

Section 4.16.

    |  

Access to Information; Disclaimer

    |  

37

    
      |  

Section 4.17.

    |  

Portfolio

    |  

37

    
      |   |   |   
     

Article V CONDUCT OF BUSINESS PENDING THE MERGER

    |  

37

    
      |   
      |  

Section 5.1.

    |  

Conduct of Business of the Company Pending the Merger

    |  

37

    
      |  

Section 5.2.

    |  

Conduct of Business of Parent and Merger Sub Pending the Merger; Parent Vote

    |  

42

    
      |  

Section 5.3.

    |  

No Control of Other Party's Business

    |  

42

    
      |   |   |   
     

Article VI ADDITIONAL AGREEMENTS

    |  

43

    
      |   
      |  

Section 6.1.

    |  

Acquisition Proposals

    |  

43

    
      |  

Section 6.2.

    |  

Proxy Statement

    |  

49

    
      |  

Section 6.3.

    |  

Stockholders Meeting

    |  

50 
 

    
      |  

Section 6.4.

    |  

Regulatory Approvals

    |  

51

    
      |  

Section 6.5.

    |  

Access to Information; Confidentiality

    |  

54

    
      |  

Section 6.6.

    |  

Stock Exchange Delisting

    |  

55

    
      |  

Section 6.7.

    |  

Publicity

    |  

55

    
      |  

Section 6.8.

    |  

Employee Benefits

    |  

56

    
      |  

Section 6.9.

    |  

Directors' and Officers' Indemnification and Insurance

    |  

57

    
      |  

Section 6.10.

    |  

Transaction Litigation

    |  

60

    
      |  

Section 6.11.

    |  

Obligations of Merger Sub

    |  

60

    
      |  

Section 6.12.

    |  

Rule 16b-3

    |  

60

    
      |  

Section 6.13.

    |  

Takeover Statutes

    |  

60

    
      |  

Section 6.14.

    |  

Certain Affiliate Agreements

    |  

61

    
      |  

Section 6.15.

    |  

Financing

    |  

61

    
      |  

Section 6.16.

    |  

Financing Assistance

    |  

65

    
      |  

Section 6.17.

    |  

Payoff Letters

    |  

68

    
      |  

Section 6.18.

    |  

Notification of Certain Matters

    |  

69

    
    

 

ii          |   |   |   
---|---|---|--- 
     

Article VII CONDITIONS OF MERGER

    | 69  
      |   
      |  

Section 7.1.

    |  

Conditions to Obligation of Each Party to Effect the Merger

    |  

69 
 

    
      |  

Section 7.2.

    |  

Conditions to Obligations of Parent and Merger Sub

    |  

69 
 

    
      |  

Section 7.3.

    |  

Conditions to Obligations of the Company

    |  

70

    
      |  

Section 7.4.

    |  

Frustration of Closing Conditions

    |  

71

    
      |   |   |   
     

Article VIII TERMINATION, AMENDMENT AND WAIVER

    |  

71

    
      |   
      |  

Section 8.1.

    |  

Termination

    |  

71

    
      |  

Section 8.2.

    |  

Effect of Termination

    |  

73

    
      |  

Section 8.3.

    |  

Expenses

    |  

77

    
      |   |   |   
     

Article IX GENERAL PROVISIONS

    |  

77

    
      |   
      |  

Section 9.1.

    |  

Non-Survival of Representations, Warranties, Covenants and Agreements

    |  

77

    
      |  

Section 9.2.

    |  

Modification or Amendment

    |  

77

    
      |  

Section 9.3.

    |  

Waiver

    |  

78

    
      |  

Section 9.4.

    |  

Notices

    |  

78

    
      |  

Section 9.5.

    |  

Certain Definitions

    |  

79 
 

    
      |  

Section 9.6.

    |  

Severability

    |  

84

    
      |  

Section 9.7.

    |  

Entire Agreement; Assignment

    |  

84

    
      |  

Section 9.8.

    |  

Parties in Interest

    |  

84

    
      |  

Section 9.9.

    |  

Governing Law

    |  

85

    
      |  

Section 9.10.

    |  

Headings

    |  

85

    
      |  

Section 9.11.

    |  

Counterparts

    |  

85

    
      |  

Section 9.12.

    |  

Specific Performance

    |  

85

    
      |  

Section 9.13.

    |  

Jurisdiction

    |  

86

    
      |  

Section 9.14.

    |  

WAIVER OF JURY TRIAL

    |  

87

    
      |  

Section 9.15.

    |  

Transfer Taxes

    |  

87

    
      |  

Section 9.16.

    |  

Interpretation

    |  

87

    
      |  

Section 9.17.

    |  

Debt Financing Sources

    |  

88

    
    

 

iii         

INDEX OF DEFINED TERMS

    |   
---|--- 
      |   
     

Acceptable Confidentiality Agreement

    |  

79

    
     

Acquisition Proposal

    |  

48

    
     

Affiliate

    |  

79

    
     

Agreement

    |  

1

    
     

Alternative Financing

    |  

63

    
     

Alternative Financing Commitment Letter

    |  

63

    
     

Announcement

    |  

55

    
     

Antitrust Law

    |  

52 
 

    
     

Applicable Date

    |  

13

    
     

Bankruptcy and Equity Exception

    |  

12

    
     

Board of Directors

    |  

1

    
     

Book-Entry Share

    |  

3

    
     

Business Day

    |  

79

    
     

Bylaws

    |  

9

    
     

Cancelled Shares

    |  

3

    
     

Capitalization Date

    |  

9

    
     

Certificate of Incorporation

    |  

2

    
     

Certificate of Merger

    |  

2

    
     

Change of Recommendation

    |  

46

    
     

Clinic Joint Venture

    |  

79

    
     

Closing

    |  

2

    
     

Closing Date

    |  

2

    
     

Code

    |  

19

    
     

Collection Costs

    |  

75

    
     

Commitment Letters

    |  

35

    
     

Common Stock

    |  

9

    
     

Company

    |  

1

    
     

Company Disclosure Schedule

    |  

9 
 

    
     

Company Employees

    |  

19

    
     

Company Notice

    |  

47

    
     

Company Payoff Amount

    |  

68

    
     

Company Requisite Vote

    |  

12

    
     

Company Securities

    |  

10

    
     

Company Stock Plans

    |  

10 
 

    
     

Company Termination Fee

    |  

80 
 

    
     

Confidentiality Agreement

    |  

55

    
     

Continuing Employee

    |  

56

    
     

Continuing Employees

    |  

56

    
     

Contract

    |  

80 
 

    
     

control

    |  

80 
 

    
     

Credit Facilities

    |  

80 
 

    
     

DandO Insurance

    |  

59

    
     

Debt Commitment Letter

    |  

35 
 

    
     

Debt Financing

    |  

35

    
    

 

iv         

Debt Financing Sources

    |  

80 
 

    
---|--- 
     

Debt Financing Sources Related Party

    |  

80 
 

    
     

Definitive Financing Agreements

    |  

62 
 

    
     

DGCL

    |  

1

    
     

Dissenting Shares

    |  

7

    
     

DOJ

    | 51 
    
     

Effective Time

    |  

2

    
     

End Date

    | 71 
    
     

Environmental Laws

    |  

26

    
     

Equity Commitment Letter

    |  

35

    
     

Equity Financing

    |  

35

    
     

ERISA

    |  

19

    
     

Exchange Act

    |  

80 
 

    
     

Exchange Fund

    |  

5

    
     

Excluded Information

    |  

66

    
     

Excluded Party

    |  

48

    
     

Fee Letters

    |  

35

    
     

Financial Advisors

    |  

26

    
     

Financing

    |  

35

    
     

Financing Uses

    |  

36

    
     

FTC

    | 51 
    
     

GAAP

    |  

80 
 

    
     

Governmental Entity

    |  

81 
 

    
     

Guarantors

    |  

1

    
     

Hazardous Substances

    |  

26

    
     

Health Care Laws

    | 81 
    
     

HSR Act

    | 81 
    
     

HSR Approval

    |  

69

    
     

Indemnified Parties

    |  

57

    
     

Intellectual Property

    |  

81 
 

    
     

Intervening Event

    |  

48

    
     

IRS

    |  

19

    
     

Joint Venture Agreement

    |  

81 
 

    
     

knowledge

    | 81 
    
     

Law

    | 82 
    
     

Leased Real Property

    |  

22

    
     

Legal Restraint

    |  

69

    
     

Licenses

    |  

13

    
     

Liens

    |  

22

    
     

Material Adverse Effect

    | 82 
    
     

Material Contract

    |  

17

    
     

Merger

    |  

1

    
     

Merger Sub

    |  

1

    
     

No-Shop Period Start Date

    |  

43

    
     

Notice Period

    |  

47

    
     

NYSE

    |  

13

    
    

 

v         

Option

    |  

4

    
---|--- 
     

Owned Real Property

    |  

22

    
     

Parent

    |  

1

    
     

Parent Disclosure Schedule

    | 30 
    
     

Parent Group

    |  

51 
 

    
     

Parent Guarantee

    |  

1

    
     

Parent Related Parties

    |  

76

    
     

Parent Termination Fee

    |  

75

    
     

Parties

    |  

1

    
     

Party

    |  

1

    
     

Paying Agent

    |  

5

    
     

Payoff Letter

    |  

68

    
     

Per Share Merger Consideration

    |  

3

    
     

Permit

    | 83 
    
     

Permitted Liens

    |  

23

    
     

Person

    | 83 
    
     

Preferred Stock

    |  

9

    
     

Proceeding

    |  

57

    
     

Program Review

    |  

28

    
     

Proxy Statement

    |  

25

    
     

Recommendation

    |  

12

    
     

Reimbursement Obligations

    |  

68

    
     

Restricted Stock

    |  

4

    
     

RSU Award

    |  

4

    
     

SEC

    |  

13

    
     

SEC Reports

    |  

13

    
     

Securities Act

    |  

13

    
     

Share

    |  

3

    
     

Stockholders Meeting

    | 50 
    
    Sublease 
    | 22 
    
     

Subsequent Transaction

    |  

83 
 

    
     

Subsequent Transaction Buyer

    |  

54

    
     

Subsidiaries

    |  

83

    
     

Subsidiary

    |  

83

    
     

Superior Proposal

    |  

49

    
     

Surviving Corporation

    |  

2

    
     

Tax Return

    |  

25

    
     

Taxes

    |  

24

    
     

Taxing Authority

    |  

25

    
     

Transaction Litigation

    | 60 
    
     

WARN Act

    |  

21

    
     

Willful Breach

    |  

84

    
    

 

vi  

_AGREEMENT AND PLAN OF MERGER_

 


 

 

This AGREEMENT AND PLAN OF MERGER, dated as of October 1, 2020 (this "
_Agreement_ "), is entered into between IRC Superman Midco, LLC, a Delaware
limited liability company (" _Parent_ "), Superman Merger Sub,  Inc., a
Delaware corporation and a direct wholly owned Subsidiary of Parent (" _Merger
Sub_ "), and American Renal Associates Holdings, Inc., a Delaware corporation
(the " _Company_ " and, together with Parent and Merger Sub, the " _Parties_
"  and each, a " _Party_ ").

 


 

 

_RECITALS_

 


 

 

WHEREAS, the board of directors of the Company (the " _Board of Directors_ ")
has unanimously (i) determined that it is in the best interests of the Company
and its stockholders, and declared it fair and advisable, to  enter into this
Agreement, (ii) approved the execution, delivery and performance of this
Agreement and the consummation of the merger of Merger Sub with and into the
Company in accordance with the General Corporation Law of the State of
Delaware (the  " _DGCL_ ") (the " _Merger_ ") upon the terms and subject to
the conditions set forth in this Agreement and (iii) subject to _Section 6.1_
, resolved to recommend adoption of this Agreement by the stockholders of the
Company;

 


 

 

WHEREAS, the Board of Directors of Merger Sub has approved, adopted and
declared advisable, this Agreement and the Merger, upon the terms and subject
to the conditions set forth in this Agreement;

 


 

 

WHEREAS, as a material inducement to, and as a condition to, the Company
entering into this Agreement concurrently with the execution of this
Agreement, Nautic Partners VIII, L.P., Nautic Partners VIII-A, L.P., Nautic 
Partners IX, L.P. and Nautic Partners IX-A, L.P. (collectively, the "
_Guarantors_ ") have entered into a limited guarantee, dated as of the date
hereof, guaranteeing certain of Parent's and Merger Sub's obligations under
this Agreement, subject  to the terms and conditions contained therein (the "
_Parent Guarantee_ ");

 


 

 

WHEREAS, the Board of Directors of Parent has determined that it is in the
best interests of Parent and its stockholders to consummate the Merger
provided for herein;

 


 

 

WHEREAS, as a material inducement to, and as a condition to, Parent and Merger
Sub entering into this Agreement, concurrently with the execution of this
Agreement, Parent is entering into a voting agreement with  Centerbridge
Capital Partners, L.P., Centerbridge Capital Partners Strategic, L.P. and
Centerbridge Capital Partners SBS, L.P. (the " _Voting Agreement_ "); and

 


 

 

WHEREAS, the Company, Parent and Merger Sub desire to make certain
representations, warranties, covenants and agreements in connection with this
Agreement.

 


 

 

NOW, THEREFORE, in consideration of the premises, and of the representations,
warranties, covenants and agreements contained herein, the Parties agree as
follows:

     

ARTICLE I

 


 

 

THE MERGER

 


 

 

Section 1.1. _The Merger_. Upon the terms and subject to the conditions set
forth in this Agreement, and in accordance with the DGCL, at the Effective
Time, Merger Sub shall be merged with and into the  Company and the separate
corporate existence of Merger Sub shall thereupon cease. The Company shall be
the surviving corporation in the Merger (sometimes hereinafter referred to as
the " _Surviving Corporation_ ") and a wholly owned Subsidiary of  Parent,
and the separate corporate existence of the Company, with all of its rights,
privileges, immunities, powers and franchises, shall continue unaffected by
the Merger, except as set forth in _Article II_. Without limiting the
generality  of the foregoing and subject thereto, at the Effective Time, all
the property, rights, privileges, immunities, powers and franchises of the
Company and Merger Sub shall vest in the Company as the Surviving Corporation
and all claims, obligations,  debts, liabilities and duties of the Company
and Merger Sub shall become the claims, obligations, debts, liabilities and
duties of the Company as the Surviving Corporation. The Merger shall have the
effects set forth in this Agreement and specified  in the DGCL.

 


 

 

Section 1.2. _Closing_. The closing of the Merger (the " _Closing_ ") shall
take place at the offices of Latham and Watkins LLP, 885 Third Avenue, New York,
NY 10022, at 9:00 a.m., New York time, on  the second (2nd) Business Day
following the day on which the conditions set forth in _Article VII_ (other
than those conditions that by their nature are to be  satisfied at the
Effective Time, but subject to the fulfillment or (to the extent permitted by
applicable Law) waiver of those conditions at the Closing) have been satisfied
or (to the extent permitted by applicable Law) waived in accordance with 
this Agreement or at such other date, time or place as the Company and Parent
may agree in writing. The date on which the Closing occurs is referred to
herein as the " _Closing Date_ ".

 


 

 

Section 1.3. _Effective Time_. At the Closing, the Company and Parent will
cause the Merger to be consummated by filing a certificate of merger (the "
_Certificate of Merger_ ") with the Secretary of  State of the State of
Delaware in accordance with Section 251 of the DGCL. The Merger shall become
effective at the time when the Certificate of Merger has been duly filed with
the Secretary of State of the State of Delaware or at such later time as  may
be agreed by the Parties in writing and specified in the Certificate of Merger
in accordance with the DGCL (the effective time of the Merger being
hereinafter referred to as the " _Effective Time_ ").

 


 

 

Section 1.4. _Certificate of Incorporation; Bylaws_.

 


 

  (a) At the Effective Time, the certificate of incorporation of the 
Company, as in effect immediately prior to the Effective Time (the "
_Certificate of Incorporation_ "), shall be immediately amended and restated
in its entirety to be in the form of the certificate of incorporation of
Merger Sub (except with  respect to the name of the Surviving Corporation,
which from and after the Effective Time shall be the name of the Company),
until thereafter amended or restated as provided therein and by applicable
Law, in each case consistent with the obligations  set forth in _Section
6.9_. 

 

2   (b) At the Effective Time, the bylaws of the Surviving Corporation  shall
be amended and restated in their entirety to be in the form of the bylaws of
Merger Sub (except that the name of the Surviving Corporation shall be the
name of the Company), until thereafter amended or restated as provided
therein, by the  certificate of incorporation of the Surviving Corporation
and by applicable Law, in each case consistent with the obligations set forth
in _Section 6.9_. 


 

 

Section 1.5. _Directors and Officers_.

 


 

 

(a) The Parties shall take all actions necessary so that the  directors of
Merger Sub at the Effective Time shall, from and after the Effective Time, be
the directors of the Surviving Corporation until their successors have been
duly elected or appointed and qualified or until their earlier death,
resignation  or removal in accordance with the certificate of incorporation
and the bylaws of the Surviving Corporation.

 


 

  (b) The officers of Merger Sub at the Effective Time shall,  from and
after the Effective Time, be the officers of the Surviving Corporation until
their successors shall have been duly elected or appointed and qualified or
until their earlier death, resignation or removal in accordance with the
certificate of  incorporation and bylaws of the Surviving Corporation. 


 

 

ARTICLE II

 


 

 

EFFECT OF THE MERGER ON THE CAPITAL STOCK

 

OF THE CONSTITUENT CORPORATIONS

 


 

 

Section 2.1. _Effect on Capital Stock_. At the Effective Time, by virtue of
the Merger and without any action on the part of the Company, Parent, Merger
Sub or the holders of any of the following  securities:

 


 

  (a) _Merger Consideration_. Each share of Common Stock  issued and
outstanding immediately prior to the Effective Time (each, a " _Share_ ")
(other than (i) Shares owned by Parent, Merger Sub or any other direct or
indirect wholly owned Subsidiary of Parent immediately prior to the Effective
Time and  Shares owned by the Company, including Shares held in treasury by
the Company, and in each case not held on behalf of third parties
(collectively, the " _Cancelled Shares_ ") and (ii) the Dissenting Shares (as
defined below)) shall be converted  automatically into and shall thereafter
represent the right to receive $11.50 per share in cash, without interest (the
" _Per Share Merger Consideration_ "). At the Effective Time, all of the
Shares that have been converted into a right to receive  the Per Share Merger
Consideration as provided in this _Section 2.1(a)_ shall cease to be
outstanding, shall be cancelled and shall cease to exist, and each non-
certificated Share represented by book-entry (other than Cancelled Shares
and  Dissenting Shares) (a " _Book-Entry Share_ ") shall thereafter represent
only the right to receive the Per Share Merger Consideration to be paid in
consideration therefor in accordance with this _Article II_. 

 

3   (b) _Cancellation of Cancelled Shares_. Each Cancelled Share  shall cease
to be outstanding, be cancelled without any conversion thereof or payment of
any consideration therefor and shall cease to exist. 


 

  (c) _Merger Sub_. Each share of common stock, par value  $0.001 per
share, of Merger Sub, issued and outstanding immediately prior to the
Effective Time, shall be converted into and become one validly issued, fully
paid and non-assessable share of common stock, par value $0.001 per share, of
the Surviving  Corporation and together shall constitute the only outstanding
shares of capital stock of the Surviving Corporation. 


 

 

Section 2.2. _Treatment of Equity Awards_.

 


 

  (a) _Treatment          of Options_. Immediately prior to the
Effective Time, each outstanding option to purchase Shares (an " _Option_ ")
under any Company Stock Plan, shall, automatically and without any required
action on the part of the holder thereof, become  immediately vested and be
cancelled and shall only entitle the holder of such Option to receive (without
interest), at or promptly after the Effective Time, an amount in cash equal to
the product of (x) the total number of Shares subject to the Option 
_multiplied_ by (y) the excess, if any, of the Per Share Merger Consideration
over the exercise price per Share under such Option, less applicable Taxes
required to be withheld pursuant to _Section 2.3(e)_ with respect to such
payment. For  the avoidance of doubt, any Option which has a per Share
exercise price that is greater than or equal to the Per Share Merger
Consideration shall be cancelled at the Effective Time for no consideration or
payment. 


 

  (b) _Treatment of Restricted Stock_. Immediately prior to the  Effective
Time, each outstanding award of restricted stock (" _Restricted Stock_ ")
under any Company Stock Plan shall, automatically and without any required
action on the part of the holder thereof, become immediately vested and be
cancelled and  shall only entitle the holder of such award to receive
(without interest), at or promptly after the Effective Time, an amount in cash
equal to the product of (x) the total number of Shares subject to such award
immediately prior to the Effective Time _multiplied_   by (y) the Per Share
Merger Consideration, less applicable Taxes required to be withheld pursuant
to _Section 2.3(e)_ with respect to such payment. 


 

  (c) _Treatment of Restricted Stock Units_. Immediately prior  to the
Effective Time, each outstanding award of restricted stock units (an " _RSU
Award_ ") under any Company Stock Plan shall, automatically and without any
required action on the part of the holder thereof, become immediately vested
and be  cancelled and shall only entitle the holder of such award to receive
(without interest), at or promptly after the Effective Time, an amount in cash
equal to the product of (x) the total number of Shares subject to such award
immediately prior to the  Effective Time _multiplied_ by (y) the Per Share
Merger Consideration, less applicable Taxes required to be withheld pursuant
to _Section 2.3(e)_ with respect to such payment. 


 

  (d) _Corporate Actions_. At or prior to the Effective Time,  the Company,
the Board of Directors and the compensation committee of the Board of
Directors, as applicable, shall adopt any resolutions and take any actions
which are necessary to effectuate the provisions of _Section 2.2_. 

 

4  

Section 2.3. _Surrender of Shares_.

 


 

  (a) _Paying Agent_. 


 

  (i) Prior to the Effective Time, Parent or Merger Sub shall enter into an
agreement in form and substance reasonably  acceptable to the Company with a
paying agent selected by Parent with the Company's prior written approval,
which approval shall not be unreasonably conditioned, withheld or delayed, to
act as agent for the stockholders of the Company in connection  with the
Merger (the " _Paying Agent_ ") to receive payment of the aggregate Per Share
Merger Consideration to which the stockholders of the Company shall become
entitled pursuant to this _Article II_. Prior to the Effective Time, Parent 
shall deposit, or cause to be deposited, with the Paying Agent, an amount in
cash in immediately available funds sufficient in the aggregate to provide all
funds necessary for the Paying Agent to make payments under this _Article II_
(such cash  being hereinafter referred to as the " _Exchange Fund_ ") in
trust for the benefit of the holders of the Shares; _provided_ that the
Exchange Fund shall not include any amounts in excess of the Per Share Merger
Consideration with respect to  Dissenting Shares. The Paying Agent shall
invest the Exchange Fund as reasonably directed by Parent; _provided_ that
such investments shall be in direct short-term obligations of, or short-term
obligations fully guaranteed as to principal and  interest by, the United
States of America, and, in any such case, no such instrument shall have a
maturity exceeding one month. To the extent that there are losses with respect
to such investments, or the Exchange Fund diminishes for any reason below 
the level required to make prompt cash payment of the aggregate Per Share
Merger Consideration as contemplated hereby, Parent shall promptly replace or
restore, or cause to be replaced or restored, the cash in the Exchange Fund
lost through such  investments and other events so as to ensure that the
Exchange Fund is at all times maintained at a level sufficient to make such
cash payments. Any interest and other income resulting from such investment
shall become a part of the Exchange Fund, and  any amounts in excess of the
amounts payable under _Article II_ shall be promptly returned to Parent or the
Surviving Corporation, as requested by Parent. The funds deposited with the
Paying Agent pursuant to this _Section 2.3(a)_ shall not  be used for any
purpose other than as contemplated by this _Section 2.3(a)_.

 


 

 

(b) _Exchange Procedures_. 


 

  (i) _Transmittal Materials_. Promptly after the Effective Time (and in any
event within two (2) Business Days  thereafter), except as set forth in
_Section 2.3(b)(ii)_ , the Surviving Corporation shall cause the Paying Agent
to mail or otherwise provide to each holder of record of Shares (other than
holders of Cancelled Shares and Dissenting Shares) (A)  transmittal
materials, including a letter of transmittal in customary form as agreed by
the Parties, specifying that delivery shall be effected, and risk of loss and
title shall pass only upon delivery of an "agent's message" regarding the
book-entry  transfer of Book-Entry Shares (or such other evidence, if any, of
the transfer as the Paying Agent may reasonably request), such transmittal
materials to be in such form and have such other provisions as Parent and the
Company may reasonably agree, and  (B) instructions for use in effecting the
surrender of the Book-Entry Shares. 

 

5   (ii) _Book-Entry Shares_. Notwithstanding anything to the contrary
contained in this Agreement, any holder of  Book-Entry Shares shall not be
required to deliver any physical certificate representing any of the Shares or
an executed letter of transmittal to the Paying Agent to receive the aggregate
Per Share Merger Consideration that such holder is entitled to  receive as a
result of the Merger pursuant to _Section 2.1(a)_. In lieu thereof, each
holder of record of one or more Book-Entry Shares (other than Cancelled Shares
and Dissenting Shares) shall, upon receipt by the Paying Agent of an
"agent's  message" in customary form (it being understood that the holders of
Book-Entry Shares shall be deemed to have surrendered such Shares upon receipt
by the Paying Agent of such "agent's message" or such other evidence, if any,
as the Paying Agent may  reasonably request), be entitled to receive, and
Parent shall cause the Paying Agent to pay and deliver as promptly as
reasonably practicable after the Effective Time, a cash amount in immediately
available funds (after giving effect to any required  Tax withholdings as
provided in _Section 2.3(e))_ equal to the product obtained by _multiplying_
(A) the number of Shares represented by such Book-Entry Shares by (B) the Per
Share Merger Consideration. No interest will be paid or accrued  on any
amount payable upon due surrender of the Book-Entry Shares. 


 

  (iii) _Unrecorded Transfers; Other Payments_. In the event of a transfer
of ownership of Shares that is not  registered in the transfer records of the
Company or if payment of the applicable Per Share Merger Consideration is to
be made to a Person other than the Person in whose name the surrendered Book-
Entry Share is registered, a check for any cash to be  exchanged upon due
surrender of the Book-Entry Share may be issued to such transferee or other
Person if such transferee or other Person appears before the Paying Agent and
presents to the Paying Agent all documents required to evidence and effect
such  transfer and to evidence that any applicable transfer or other similar
Taxes have been paid or are not applicable. 


 

  (iv) Until surrendered as contemplated by this _Section 2.3(b)_ , each
Book-Entry Share (other than Cancelled  Shares and Dissenting Shares) shall
be deemed at any time after the Effective Time to represent only the right to
receive upon such surrender the applicable Per Share Merger Consideration as
contemplated by this _Article II_. The Surviving  Corporation shall pay all
charges and expenses, including those of the Paying Agent, in connection with
the exchange of Shares for the Per Share Merger Consideration. 


 

  (c) _Termination of Exchange Fund_. Any portion of the  Exchange Fund
(including the proceeds of any investments thereof) that remains unclaimed by
the stockholders of the Company for twelve months after the Effective Time
shall be delivered to the Surviving Corporation. Any holder of Shares (other
than  Cancelled Shares or Dissenting Shares) who has not theretofore complied
with this _Article II_ shall thereafter be entitled to look to the Surviving
Corporation for payment of the Per Share Merger Consideration (after giving
effect to any  required Tax withholdings as provided in _Section 2.3(e)_ )
upon acceptable evidence of ownership of Book-Entry Shares (which shall
include affidavits of ownership), without any interest thereon in accordance
with the provisions set forth in _Section  2.3(b)_ , and Parent shall remain
liable for (subject to applicable abandoned property, escheat or other similar
Laws) payment of any such holder's claim for the Per Share Merger
Consideration payable upon due surrender of such holder's Book-Entry  Shares.
Notwithstanding the foregoing, none of the Surviving Corporation, Parent, the
Company, the Paying Agent or any other Person shall be liable to any former
holder of Shares for any amount properly delivered to a public official
pursuant to  applicable abandoned property, escheat or similar Laws. 

 

6   (d) _Transfers_. From and after the Effective Time, the stock  transfer
books of the Surviving Corporation shall be closed and there shall be no
further registration of transfers on the stock transfer books of the Surviving
Corporation of the Shares that were outstanding immediately prior to the
Effective Time.   If, after the Effective Time, acceptable evidence of a
Book-Entry Share is presented to the Surviving Corporation, Parent or the
Paying Agent for transfer, it shall be cancelled and exchanged for the cash
amount in immediately available funds to which  the holder thereof is
entitled pursuant to this _Article II_. The Per Share Merger Consideration
paid upon receipt by the Paying Agent of an "agent's message", in the case of
Book-Entry Shares in accordance with the terms of this _Article II,_   shall
be deemed to have been paid in full satisfaction of all rights pertaining to
the Shares formerly represented by such Book-Entry Shares. 


 

  (e) _Withholding Rights_. Each of Parent, the Surviving  Corporation and
the Paying Agent shall be entitled to deduct and withhold from the
consideration otherwise payable pursuant to this Agreement to any holder of
Shares, Options, Restricted Stock or RSU Awards such amounts as it is required
to deduct and  withhold with respect to the making of such payment under the
Code or any other applicable state, local or foreign Tax Law. Parent shall (x)
use commercially reasonable efforts to provide prior notice to the Company of
any such deduction or  withholding (other than (i) payroll withholding
because of the compensatory nature of the applicable payment or (ii) U.S.
backup withholding) and (y) reasonably cooperate with the Company to minimize
or eliminate such deduction or withholding to the  extent permitted by Law.
To the extent that amounts are so deducted or withheld by the Surviving
Corporation or Parent, as the case may be, such deducted or withheld amounts
(i) shall be promptly remitted by Parent or the Surviving Corporation, as 
applicable, to the applicable Taxing Authority, and (ii) shall be treated for
all purposes of this Agreement as having been paid to the holder of Shares,
Options, Restricted Stock or RSU Awards (as the case may be) in respect of
which such deduction  and withholding was made by the Surviving Corporation
or Parent, as the case may be. 


 

 

Section 2.4. _Appraisal Rights_. Notwithstanding anything in this Agreement to
the contrary, if required by the DGCL (but only to the extent required
thereby), any Shares of Common Stock that are issued  and outstanding
immediately prior to the Effective Time (other than Cancelled Shares) and as
to which the holders thereof have continuously held such Shares through the
date shown on the Certificate of Merger giving effect to the Merger, have
not  voted in favor of the adoption of this Agreement or consented thereto in
writing and who have properly demanded appraisal with respect thereto in
accordance with, and who have complied with, Section 262 of the DGCL with
respect to any such Shares and  have not effectively withdrawn such demand
(collectively, " _Dissenting Shares_ ") shall not be converted into the right
to receive the Per Share Merger Consideration as provided in _Section 2.1(a)_
, unless and until such Person shall have  failed to perfect, effectively
withdrawn, waived or lost such Person's right to appraisal under the DGCL or
if a court of competent jurisdiction shall determine that such holder is not
entitled to the relief provided by Section 262 of the DGCL, at  which time
such Shares shall be treated as if they had been converted into and become
exchangeable for the right to receive, as of the Effective Time, the Per Share
Merger Consideration as provided in _Section 2.1(a)_ , without interest and 
after giving effect to any required Tax withholdings pursuant to _Section
2.3(e)_ and such Shares shall not be deemed Dissenting Shares, and such holder
thereof shall cease to have any other rights with respect to such Shares. Each
holder of  Dissenting Shares shall be entitled to receive only the payment
provided by Section 262 of the DGCL with respect to the Dissenting Shares. The
Company shall give Parent (i) prompt notice of any written demands received by
the Company for appraisal  and any instruments served pursuant to Section 262
of the DGCL that are received by the Company relating to stockholders' rights
of appraisal, withdrawals of such demands, and any other instruments received
by the Company in respect of Dissenting  Shares pursuant to Section 262 of
the DGCL and (ii) the opportunity to participate in all negotiations and
proceedings with respect to such notices and demands. Parent shall have the
right to direct and control all negotiations and proceedings with  respect to
any such demands, withdrawals or attempted withdrawals of such demands;
_provided_ that, after the date hereof until the Effective Time, Parent shall
consult with the Company with respect to such negotiations and proceedings.
The  Company shall not, except with the prior written consent of Parent (not
to be unreasonably withheld, conditioned or delayed), and prior to the
Effective Time, Parent shall not, except with the prior written consent of the
Company (not to be  unreasonably withheld, conditioned or delayed), make any
payment with respect to any demands for appraisal or offer to settle or
compromise, or settle or compromise, any such demands, or approve any
withdrawal of any such demands, or waive any  failure to timely deliver a
written demand for appraisal or otherwise to comply with Section 262 of the
DGCL, or otherwise agree to do any of the foregoing.

 

 

7  

Section 2.5. _Adjustments_. In the event that the number of Shares or
securities convertible or exchangeable into or exercisable for Shares issued
and outstanding after the date hereof and prior to the  Effective Time shall
have been changed into a different number of Shares or securities or a
different class as a result of a reclassification, stock split (including a
reverse stock split), combination, stock dividend or distribution, 
recapitalization, subdivision, merger, issuer tender or exchange offer, or
other similar transaction, the Per Share Merger Consideration shall be
equitably adjusted to provide to Parent and the holders of Shares the same
economic effect as  contemplated by this Agreement prior to such event;
_provided_ that nothing in this _Section 2.5_ shall be construed to permit the
Company, any Subsidiary of the Company or any other Person to take any action
that is otherwise prohibited  by _Sections 5.1(b)(i)_ or _5.1(b)(v)_ of this
Agreement.

 


 

 

ARTICLE III

 


 

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 


 

 

The Company hereby represents and warrants to Parent and Merger Sub, except
(i) as disclosed in the SEC Reports filed with, or furnished to, the SEC on or
after January 1, 2019 and prior to the date of this Agreement  (other than
any disclosures contained or referenced therein under the captions "Risk
Factors" or "Forward Looking Statements" and any other disclosures contained
therein that are predictive, cautionary or forward-looking in nature), it
being  acknowledged that nothing disclosed any such SEC Report will be deemed
to modify or qualify the representations and warranties set forth in _Section
3.3(a)_ , _Section 3.3(b)_ or _Section 3.3(d)_ , or (ii) as set forth on the 
corresponding sections or subsections of the disclosure schedules delivered to
Parent by the Company concurrently with entering into this Agreement (the "
_Company Disclosure Schedule_ "), it being acknowledged and agreed that
disclosure of any  item in any section or subsection of the Company
Disclosure Schedule shall also be deemed disclosure with respect to any other
section or subsection of this Agreement to which the relevance of such item is
reasonably apparent on the face of such  disclosure (for the avoidance of
doubt, no representations or warranties by the Company are made or given
taking into account any aspect of the Subsequent Transaction or any matter in
connection therewith):

 

 

8  

Section 3.1. _Organization and Qualification; Subsidiaries_. Each of the
Company and its Subsidiaries is a legal entity duly organized, validly
existing and, to the extent such concept is applicable, in  good standing
under the Laws of its respective jurisdiction of organization and has all
requisite corporate or similar power and authority to own, lease and operate
its properties and assets and to carry on its business as presently conducted
and is  duly qualified to do business and, to the extent such concept is
applicable, is in good standing as a foreign corporation or other legal entity
in each jurisdiction where the ownership, leasing or operation of its assets
or properties or present  conduct of its business requires such
qualification, except in each case where the failure to be so organized,
formed, existing, qualified or, to the extent such concept is applicable, in
good standing, or to have such power or authority, would not,  individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 


 

 

Section 3.2. _Organizational Documents_. The Company has furnished or
otherwise made available to Parent, prior to the date hereof, correct and
complete copies of (i) the Certificate of Incorporation and  the amended and
restated bylaws, as amended to date (the " _Bylaws_ "), of the Company as in
effect as of the date hereof and (ii) the certificate of incorporation and by-
laws, or equivalent organizational documents, as amended to date, of each of 
the Company's Subsidiaries and Clinic Joint Ventures, each as in effect as of
the date hereof. The Certificate of Incorporation, the Bylaws and the articles
of incorporation and bylaws, or equivalent organizational documents, of each
of the  Company's Subsidiaries and Clinic Joint Ventures, are in full force
and effect. The Company, any Subsidiary and, to the knowledge of the Company,
each Clinic Joint Venture is in compliance in all material respects with the
provisions of its articles  of incorporation or bylaws (or equivalent
organizational document).

 


 

 

Section 3.3. _Capitalization_. The authorized capital stock of the Company
consists of (i) 300,000,000 Shares, par value $0.01 per share (the " _Common
Stock_ "), and (ii) 1,000,000 shares of preferred  stock, par value $0.01 per
share (the " _Preferred Stock_ ").

 


 

  (a) As of the close of business on September 28, 2020 (the "
_Capitalization          Date_ "): 


 

  (i) 34,489,728 Shares were issued and outstanding (which number includes
1,011,426 shares of Restricted Stock); 


 

  (ii) no shares of Preferred Stock were issued or outstanding; and 


 

  (iii) there were (A) 3,757,338 Shares underlying outstanding Options, (B)
1,011,426 outstanding shares of Restricted  Stock and (C) no issued and
outstanding RSU Awards, in each such case, as granted or provided for under
the American Renal Holdings, Inc. 2005 Stock Incentive Plan, 2010 American
Renal Associates Holdings, Inc. Stock Incentive Plan, the 2011 American 
Renal Associates Holdings, Inc. Stock Option Plan for Non-Employee Directors
and the American Renal Associates Holdings, Inc. 2016 Omnibus Incentive Plan
(and applicable award agreements issued thereunder), as applicable
(collectively, the " _Company  Stock Plans_ "). 

 

9   (b) From the close of business on the Capitalization Date through  the
date of this Agreement, no options to purchase Shares have been granted and no
Shares have been issued, except for Shares issued pursuant to the exercise,
vesting or settlement of Options, Restricted Stock or RSU Awards, in each case
in accordance  with the terms of the Company Stock Plans. Except as set forth
in _Section 3.3(a)_ or on _Section 3.3(b)_ of the Company Disclosure Schedule
as of the date hereof, (i) there are no outstanding or authorized (A) shares
of capital stock or  other voting securities of the Company, (B) securities
of the Company convertible into or exchangeable for shares of capital stock or
voting securities of the Company or (C) options, warrants, calls, phantom
stock or other rights to acquire from the  Company, or obligations of the
Company to issue or sell, any capital stock, voting securities or securities
convertible into, exercisable for, or exchangeable for, or giving any Person a
right to subscribe for or acquire, any capital stock or voting  securities of
the Company (collectively, " _Company Securities_ "), and (ii) there are no
outstanding contractual obligations of the Company to repurchase, redeem or
otherwise acquire any Company Securities. Except as set forth in _Section
3.3(a)_   or on _Section 3.3(b)_ of the Company Disclosure Schedule, all
outstanding Shares, and all Shares reserved for issuance as noted in _Section
3.3(a)_ , when issued in accordance with the respective terms thereof, are or
will be duly  authorized, validly issued, fully paid and non-assessable and
free of preemptive rights. 


 

  (c) Each of the outstanding shares of capital stock (or other  equity
interest) of each of the Company's Subsidiaries and Clinic Joint Ventures held
by the Company or one of its Subsidiaries is duly authorized, validly issued,
fully paid and nonassessable and is free and clear of all Liens, agreements,
limitations  on voting rights, charges or other encumbrances of any nature
whatsoever, except (i) as set forth in the Joint Venture Agreements or (ii)
where any such failure to own any such shares free and clear would not
reasonably be expected to have,  individually or in the aggregate, a material
adverse effect on the Company and its Subsidiaries and Clinic Joint Ventures,
taken as a whole. The Company does not have outstanding any bonds, debentures,
notes or other obligations the holders of which  have the right to vote (or
which are convertible into or exercisable for securities having the right to
vote) with the stockholders of the Company on any matter. None of the
outstanding Shares are certificated. 


 

  (d) _Section 3.3(d)_ of the Company Disclosure Schedule sets  forth a
true and complete list of all holders, as of the Capitalization Date, of
outstanding Options, Restricted Stock and RSU Awards, indicating, as
applicable, the type of award granted, the number of Shares subject to such
award, and the exercise or  purchase price of such award (if applicable). The
Company has made available to Parent true and complete copies of all Company
Stock Plans and the forms of all stock option agreements evidencing
outstanding Options, restricted stock agreements  evidencing Restricted Stock
and restricted stock unit agreements evidencing outstanding RSU Awards. No
Option, Restricted Stock or RSU Award was granted pursuant to an agreement
that is materially different than the forms made available to Parent. Each 
Option, Restricted Stock and RSU Award was granted in compliance, in all
material respects, with all applicable Laws and the terms and conditions of
the Company Stock Plan pursuant to which such award was granted. 

 

10   (e) _Section 3.3(e)_ of the Company Disclosure Schedule sets  forth a
correct and complete list, as of the date hereof, of each of the Company's
Subsidiaries and Clinic Joint Ventures and the ownership interest of the
Company (or Subsidiary of the Company) in each such Subsidiary and Clinic
Joint Venture as of  the date hereof, as well as (x) the direct ownership
interest and, to the knowledge of the Company, the indirect ownership interest
of any other Person or Persons in each such Subsidiary and Clinic Joint
Venture and (y) each such Subsidiary's and  Clinic Joint Venture's place and
form of organization. Except as set forth on _Section 3.3(e)_ of the Company
Disclosure Schedule and except for securities held by the Company in
connection with its ordinary course treasury investment activities  or in any
non-active Clinic Joint Venture, neither the Company nor any of its
Subsidiaries owns, directly or indirectly, any capital stock or voting
securities of, or other equity interests in, or has any direct or indirect
equity participation or  similar interest in or any interest convertible into
or exchangeable or exercisable for, any capital stock or voting securities of,
or other equity interests in, any other Person. 


 

  (f) Except as contained in a Joint Venture Agreement or as would  not be
material to the Company and its Subsidiaries and Clinic Joint Ventures, taken
as a whole, neither the Company nor any Subsidiary of the Company nor any
Clinic Joint Venture may be required, by reason of (i) the execution, delivery
and  performance of this Agreement or the anticipated consummation of the
transactions contemplated hereby or (ii) the passage of time, to purchase or
redeem or to offer to purchase or redeem, any capital stock or voting
securities of, or other equity  interest in, any Subsidiary of the Company,
any Clinic Joint Venture or any other Person from any Person with an ownership
interest, directly or indirectly, in such Subsidiary, Clinic Joint Venture or
other Person. As of September 15, 2020, no put  right, tag-along right or
drag-along right had been exercised by the holder thereof under and pursuant
to any Joint Venture Agreement, the closing of which has not been
consummated. 


 

  (g) Except as contained in a Joint Venture Agreement or as would  not be
material to the Company and its Subsidiaries and Clinic Joint Ventures, taken
as a whole, neither the Company nor any Subsidiary of the Company nor any
Clinic Joint Venture may be required, by reason of (i) the execution, delivery
and  performance of this Agreement or the anticipated consummation of the
transactions contemplated hereby or (ii) the passage of time, to sell or to
offer to sell, any capital stock or voting securities of, or other equity
interest in, any Subsidiary of  the Company, any Clinic Joint Venture or any
other Person to any Person. As of September 15, 2020, no call right or
redemption right had been exercised by the holder thereof under and pursuant
to any Joint Venture Agreement, the closing of which has  not been
consummated. 


 

 

Section 3.4. _Authority_.

 


 

  (a) The Company has all requisite corporate power and authority,  and has
taken all corporate action necessary, to execute and deliver this Agreement,
to perform its obligations hereunder and to consummate the Merger, subject
only to the affirmative vote (in person or by proxy) of the holders of a
majority of all of  the outstanding Shares entitled to vote thereon at the
Stockholders Meeting, or any adjournment or postponement thereof, to adopt
this Agreement (the " _Company Requisite Vote_ ") and the filing of the
Certificate of Merger with the Secretary of  State of the State of Delaware.
The execution and delivery of this Agreement and the consummation by the
Company of the Merger have been duly authorized by the Board of Directors, and
this Agreement has been duly and validly executed and delivered by  the
Company and, assuming the due authorization, execution and delivery hereof by
Parent and Merger Sub, constitutes a legal, valid and binding obligation of
the Company enforceable against the Company in accordance with its terms,
subject to the  effects of applicable bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar Laws relating to or
affecting creditors' rights generally and general equitable principles
(whether considered in a Proceeding in equity  or at Law) (the " _Bankruptcy
and Equity Exception_ "). 

 

11   (b) The Board of Directors, at a duly called and held meeting, has 
unanimously (a) determined that the Merger is fair to and in the best
interests of the Company's stockholders, (b) approved and declared advisable
this Agreement and the Merger, (c) subject to _Section 6.1_ , resolved to
recommend that the  stockholders of the Company adopt this Agreement (the "
_Recommendation_ ") and (d) directed that this Agreement be submitted to the
stockholders of the Company for their approval. The only vote of the
stockholders of the Company required to  approve this Agreement and the
Merger is the Company Requisite Vote. 


 

 

Section 3.5. _No Conflict; Required Filings and Consents_.

 


 

  (a) The execution and delivery of this Agreement by the Company do  not,
and the consummation of the Merger and the other transactions contemplated
hereby will not (i) breach, violate or conflict with the Certificate of
Incorporation or Bylaws, (ii) the articles of incorporation and by-laws, or
equivalent  organizational documents, of each of the Clinic Joint Ventures
set forth in _Section 3.5(a)_ of the Company Disclosure Schedule (the "
_Material Clinic Joint Ventures_ "), (iii) assuming that all consents,
approvals and authorizations  contemplated by subsection (b) below have been
obtained, all filings described in such clauses have been made and the Company
Requisite Vote has been obtained, conflict with or violate any Law, rule,
regulation, order, judgment or decree applicable to  the Company, any of its
Subsidiaries or any Material Clinic Joint Venture or by which its or any of
their properties are bound or (iv) result in any breach or violation of or
constitute a default (or an event which with or without notice or lapse of 
time or both would become a default), require a consent or result in the loss
of a benefit under, or give rise to any right of termination, cancellation,
amendment or acceleration of, or result in the creation of a Lien (except a
Permitted Lien) on any  of the material assets of the Company, any of its
Subsidiaries or any Material Clinic Joint Venture pursuant to, any Material
Contract, except, in the case of clauses (ii), (iii) and (iv), for any such
breach, violation, default, consent, loss, right  or other occurrence which
would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. 


 

  (b) Subject to the accuracy of Parent's and Merger Sub's  representations
and warranties set forth in _Section 4.3(b)_ , the execution, delivery and
performance of this Agreement by the Company and the consummation of the
Merger by the Company do not and will not require any consent, approval, 
authorization or permit of, action by, filing with or notification to, any
Governmental Entity, except for (i) compliance with the applicable
requirements of the Exchange Act and the rules and regulations promulgated
thereunder (including the filing of  the Proxy Statement), and state
securities, takeover and "blue sky" Laws, (ii) the filing of a premerger
notification and report form by the Company under the HSR Act,
(iii)          compliance with the applicable requirements of the New
York Stock Exchange (the " _NYSE_ "), (iv) the filing with the Secretary of
State of the State of Delaware of the Certificate of Merger as required by the
DGCL and (v) any such consent,  approval, authorization, permit, action,
filing or notification the failure of which to make or obtain would not
reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. 

 

12  


 

 

Section 3.6. _Compliance_. Except as would not reasonably be expected to have,
individually  or in the aggregate, a material adverse effect on the Company,
its Subsidiaries and the Clinic Joint Ventures, taken as a whole, none of the
Company or any of its Subsidiaries, or to the knowledge of the Company, any
Clinic Joint Ventures, are in  violation of any Law (including Health Care
Laws) applicable to the Company, its Subsidiaries or any Clinic Joint
Ventures. The Company, its Subsidiaries and, to the knowledge of the Company,
the Clinic Joint Ventures, have the state-issued dialysis  licenses and
permits, CLIA certificates, biomedical waste licenses and permits, and
business licenses and permits (" _Licenses_ ") from Governmental Entities
required to conduct their respective businesses as being conducted as of the
date hereof  and own, lease and operate their respective assets and
properties as of the date hereof, except for any such Licenses the absence of
which would not reasonably be expected to have, individually or in the
aggregate, a material adverse effect on the  Company, its Subsidiaries and
the Clinic Joint Ventures, taken as a whole. Since the Applicable Date, except
as would not reasonably be expected to have, individually or in the aggregate,
a material adverse effect on the Company, its Subsidiaries and  the Clinic
Joint Ventures, taken as a whole, (i) the Company, its Subsidiaries and, to
the knowledge of the Company, the Clinic Joint Ventures have maintained, and
have been in compliance with all terms and conditions of, all Licenses and
all  Licenses are in full force and effect, and (ii) to the knowledge of the
Company, no default has occurred under, and there exists no event that, with
or without notice, lapse of time or both, would reasonably be expected to
result in a default under,  or would give to others any right of revocation,
non-renewal, adverse modification or cancellation of, any License.

 


 

 

Section 3.7. _SEC Filings; Financial Statements; Undisclosed Liabilities_.

 


 

  (a) The Company has filed or otherwise transmitted or furnished all 
forms, reports, statements, certifications and other documents (including all
exhibits and other information incorporated therein, amendments and
supplements thereto), in each case required to be filed or furnished by it
with the U.S. Securities and  Exchange Commission (the " _SEC_ ") since
January 1, 2017 (the " _Applicable Date_ ") through the date hereof (all such
forms, reports, statements, certificates and other documents filed or
furnished since the Applicable Date, including all  exhibits and other
information incorporated therein, amendments and supplements thereto,
collectively, the " _SEC Reports_ "). As of their respective filing dates, or
if amended or superseded by a subsequent filing made prior to the date of
this  Agreement, as of the date of the last such amendment or superseding
filing prior to the date of this Agreement, the SEC Reports complied as to
form in all material respects with the applicable requirements of the
Securities Act of 1933, as amended (the  " _Securities Act_ "), the Exchange
Act and the Sarbanes-Oxley Act of 2002, as the case may be, and the applicable
rules and regulations promulgated thereunder, each as in effect on the date of
any such filing. As of the time of filing with the SEC  (or, if amended or
superseded by a subsequent filing made prior to the date of this Agreement, as
of the date of the last such amendment or superseding filing prior to the date
of this Agreement), none of the SEC Reports so filed contained, when filed, 
any untrue statement of a material fact or omitted to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading, except to the  extent that the information in such SEC Reports
has been amended or superseded by a later SEC Report filed prior to the date
of this Agreement. None of the Subsidiaries of the Company is required to file
periodic reports with the SEC pursuant to the  Exchange Act. To the knowledge
of the Company, the Company has made available to Parent all comment letters
and all material formal correspondence between the SEC and the Company with
respect to the SEC Reports filed with, or furnished to, the SEC on  or after
January 1, 2018. Except as set forth in Section 3.7(a) of the Company
Disclosure Schedule, as of the date hereof, to the knowledge of the Company,
none of the SEC Reports is the subject of active, ongoing SEC review. 

 

13   (b) The audited consolidated financial statements of the Company 
(including all notes thereto) and its Subsidiaries included in the Company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed
with the SEC: (i) complied, as of its date of filing, as to form in all
material respects, with  the published rules and regulations of the SEC with
respect thereto; (ii) have been prepared in accordance with GAAP in all
material respects applied on a consistent basis throughout the periods
involved (except as may be indicated therein or in the  notes thereto); and
(iii) fairly present in all material respects the consolidated financial
position of the Company and its consolidated Subsidiaries at the respective
dates thereof (taking into account the notes thereto) and the consolidated 
statements of operations, comprehensive income (loss), change in equity and
cash flows for the periods indicated. The unaudited consolidated financial
statements of the Company (including any related notes thereto) for all
interim periods included in  the Company's quarterly reports on Form 10-Q
filed with the SEC since January 1, 2020 and included in the SEC Reports: (i)
complied as to form in all material respects with the published rules and
regulations of the SEC with respect thereto; (ii) have  been prepared in
accordance with GAAP in all material respects applied on a consistent basis
throughout the periods involved (except as may be indicated in the notes
thereto and except for the absence of footnote disclosures and normal period-
end  adjustments); and (iii) fairly present in all material respects the
consolidated financial position of the Company and its consolidated
Subsidiaries as of the respective dates thereof (taking into account the notes
thereto) and the consolidated  statements of operations and cash flows for
the periods indicated (subject to normal period-end adjustments). 


 

  (c) The Company maintains in all material respects disclosure  controls
and procedures required by Rules 13a-15 and 15d-15 of the Exchange Act. Such
disclosure controls and procedures are designed to ensure that material
information required to be disclosed by the Company is recorded and reported
on a timely  basis to the individuals responsible for the preparation of the
Company's filings with the SEC and other public disclosure documents. Based on
the Company's most recently completed evaluation of the Company's internal
control over financial reporting  prior to the date hereof, the Company has
not identified any fraud that involves the Company's management or other
employees who have a significant role in the Company's internal control over
financial reporting. Since the Applicable Date, except as  set forth in the
SEC Reports, the Company's principal executive officer and its principal
financial officer have disclosed, based on their evaluation of internal
control over financial reporting, to the Company's auditors and the audit
committee of the  Board of Directors any instances identified by them or of
which they have been made aware of "significant deficiencies," "material
weaknesses" or fraud. 

 

14   (d) As of the date hereof, except (i) as reflected, accrued or  reserved
against in the financial statements (including all notes and schedules
thereto) of the Company and its Subsidiaries included in the SEC Reports; (ii)
for liabilities or obligations incurred in the ordinary course of business
since June 30,  2020; (iii) for liabilities or obligations which have been
discharged or paid in full prior to the date of this Agreement; and (iv) for
liabilities or obligations permitted by this Agreement or incurred pursuant to
the transactions contemplated by this  Agreement, neither the Company nor any
of its Subsidiaries has any liabilities or obligations of a nature required by
GAAP to be reflected on a consolidated balance sheet of the Company and its
Subsidiaries (or the notes thereto), other than those  which would not
reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. _Section 3.7(d)_ of the Company Disclosure Schedule contains a
correct and complete list of all indebtedness for borrowed money of the 
Company and its Subsidiaries as of September 15, 2020, other than (v) loans
between the Company or any of its Subsidiaries or Clinic Joint Ventures, on
the one hand, and any of the Company's Subsidiaries or Clinic Joint Ventures,
on the other hand, (w)  indebtedness included in the SEC Reports, (x) any
indebtedness of the Clinic Joint Ventures, (y) indebtedness in an amount less
than $1,000,000 and (z) trade payables incurred in the ordinary course of
business consistent with past practice. 


 

 

Section 3.8. _Contracts_.

 


 

  (a) Except (i) for this Agreement, (ii) for the Contracts filed as 
exhibits to the SEC Reports, (iii) for the Company Plans and Company Stock
Plans or (iv) as set forth in _Section 3.8_ of the Company Disclosure
Schedule, as of the date hereof, neither the Company nor any of its
Subsidiaries (or the Clinic Joint  Ventures to the extent set forth in the
applicable subsection of this _Section 3.8(a)_ ) is party to or bound by any
of the following Contracts: 


 

  (i) the top 10 Contracts (other than leases of real property) measured by
the aggregate amount of payments by the  Company and its Subsidiaries within
the twelve (12) month period ended June 30, 2020; 


 

  (ii) Contracts with the top 10 payors measured by the aggregate amount of
payments to the Company and its  Subsidiaries within the twelve (12) month
period ended June 30, 2020; 


 

  (iii) any employment Contract of any director or officer of the Company or
its Subsidiaries or any other written  employment, severance, retention, deal
bonus, consulting or other Contract with any employee of the Company or any of
its Subsidiaries which will require (or reasonably likely require) the payment
of amounts by the Company or any of its Subsidiaries  during the one-year
period following the date hereof in excess of $200,000; 


 

  (iv) other than the Joint Venture Agreements, any Contract of the Company,
any of its Subsidiaries or, to the  knowledge of the Company, the Clinic
Joint Ventures, that limits the ability of the Company, any of its
Subsidiaries or a Clinic Joint Venture to compete in any line of business or
with any Person or in any geographic area or during any period of time,  in
each case in any respect material to the Company, its Subsidiaries and the
Clinic Joint Ventures, taken as a whole. 

 

15   (v) any Contract relating to material Intellectual Property (other than
Intellectual Property that is the subject of  a license for shrink wrap
software, license for other "off the shelf" software, or a license for
software for which the license fees, royalties, maintenance fees and support
fees do not exceed $500,000 on an annual basis) that is material to the 
Company and its Subsidiaries, taken as a whole, and that is not otherwise
terminable by any party thereto with sixty (60) days' notice (or less) without
payment or penalty; 


 

  (vi) any Contract under which the Company or any of its Subsidiaries has
incurred any indebtedness that is  outstanding on the date hereof or has
directly or indirectly guaranteed indebtedness, liabilities or obligations of
any Person (other than any indebtedness, liabilities or obligations solely by
and among the Company and its Subsidiaries) including with  respect to
indebtedness for borrowed money, in each case, in excess of $4,000,000; 


 

  (vii) any Contract containing (A) an earn-out, deferred purchase price, or
other similar contingent obligation, or (B)  ongoing indemnification
obligations on behalf of the Company or any of its Subsidiaries (other than
customary indemnification obligations pursuant to payor contracts or leases)
and, in each case of clauses (A) and (B), which would reasonably be  expected
to result in the receipt or making of future payments in excess of $2,000,000
individually or $5,000,000 in the aggregate; 


 

  (viii) any Contract involving or providing for the settlement (or proposed
settlement) of any Proceeding (A) with a  Governmental Entity, (B) that
involves payments after the date hereof in excess of $500,000 individually or
$2,000,000 in the aggregate or (C) that materially restricts or imposes
material obligations after the date of this Agreement on the Company and  its
Subsidiaries, taken as a whole; 


 

  (ix) any Contract that obligates the Company, any of its Subsidiaries or,
to the knowledge of the Company, any of the  Clinic Joint Ventures, to make
any capital investment or capital expenditure in excess of $500,000, which
capital investment or expenditure is outside the ordinary course of business
and is not contemplated by the capital expenditure budget set forth  on
_Section 5.1(b)(xvii)_ of the Company Disclosure Schedule and that is not
otherwise terminable by any party thereto with sixty (60) days' notice (or
less) without payment or penalty; 


 

  (x) any Contract that prohibits the payment of dividends or distributions
in respect of the capital stock of the  Company, any of its Subsidiaries or
any of the Clinic Joint Ventures or prohibits the pledging of the capital
stock of the Company, any Subsidiary of the Company or any Clinic Joint
Ventures, other than debt or financing documents entered into by any  Clinic
Joint Venture and made available to Parent and Merger Sub prior to the date
hereof or any Joint Venture Agreement; 


 

  (xi) any Contract that relates to the pending acquisition or disposition
of any business (whether by merger, sale of  stock, sale of assets or
otherwise) for consideration in excess of $1,000,000 and that is not otherwise
terminable by any party thereto with sixty (60) days' notice (or less) without
payment or penalty; 

 

16   (xii) any stockholders agreements, voting agreements, registrations rights
agreements, co-sale agreements and any  other similar Contracts between the
Company and any holder of Company capital stock; 


 

  (xiii) the Joint Venture Agreements for the Material Clinic Joint
Ventures; 


 

  (xiv) any Contract between the Company or any of its Subsidiaries and any
Governmental Entity and that is material to  the Company and its
Subsidiaries, taken as a whole; 


 

  (xv) any Contract that relates to any swap, forwards, or other similar
derivative transactions; 


 

  (xvi) any Material Leases; and 


 

  (xvii) any Contract that is required to be filed by the Company as a
"material contract" (as such term is defined in Item  601(b)(10) of
Regulation S-K of the Securities Act) that has not been filed with the SEC
prior to the date of this Agreement. 


 

  (b) Each Contract (i) set forth in _Section 3.8_ of the  Company
Disclosure Schedule or (ii) disclosed by the Company on its most recent Annual
Report on Form 10-K or any subsequent SEC Report prior to the date hereof as a
"material contract" (as such term is defined in Item 601(b)(10) of Regulation
S-K of  the Securities Act) (excluding any Company Plan), is referred to
herein as a " _Material Contract_ ". 


 

  (c) Except for those Material Contracts set forth as an exhibit to  a
filed SEC Report, the Company has made available to Parent true and correct
copies of all Material Contracts, including amendments and supplements
thereto. Each of the Material Contracts is a legal, valid and binding
obligation of, and enforceable  against, the Company or the Subsidiary of the
Company that is a party thereto and, to the knowledge of the Company, each
other party thereto, and is in full force and effect in accordance with its
terms, subject to the Bankruptcy and Equity Exception,  except (i) to the
extent that any Material Contract expires or terminates in accordance with its
terms in the ordinary course of business consistent with past practice, and
(ii) for such failures to be legal, valid and binding or to be in full force 
and effect that would not reasonably be expected to have, individually or in
the aggregate, a material adverse effect on the Company, its Subsidiaries and
the Clinic Joint Ventures, taken as a whole. 


 

  (d) The Company or its Subsidiary that is a party to each Material 
Contract is in compliance in all material respects with all terms and
requirements of each Material Contract, and no event has occurred that, with
notice or the passage of time, or both, would constitute a material breach or
default by the Company or  any of its Subsidiaries under any such Material
Contract, and, to the knowledge of the Company, no other party to any Material
Contract is in material breach or default (nor has any event occurred which,
with notice or the passage of time, or both,  would constitute such a
material breach or default) under any Material Contract, except in each case
where such violation, breach, default or event of default would not reasonably
be expected to be material to the Company and its Subsidiaries, taken as  a
whole. Except as would not reasonably be material to the Company and its
Subsidiaries, taken as a whole, as of the date hereof, neither the Company
nor, to the knowledge of the Company, any of its Subsidiaries have received
written notice from any  other party to a Material Contract that such other
party intends to terminate or renegotiate in any material respect the terms of
any such Material Contract (except in accordance with the terms thereof). 

 

17   (e) The Company has made available to Parent and Merger Sub all  Joint
Venture Agreements with respect to each Clinic Joint Venture, and each such
Joint Venture Agreement is a legal, valid and binding obligation of, and
enforceable against, the Company or the Subsidiary of the Company that is a
party thereto and, to  the knowledge of the Company, each other party
thereto, and is in full force and effect in accordance with its terms, subject
to the Bankruptcy and Equity Exception, except (i) to the extent that any such
Joint Venture Agreement expires or terminates  in accordance with its terms
in the ordinary course of business consistent with past practice, and (ii) for
such failures to be legal, valid and binding or to be in full force and effect
that would not reasonably be expected to have, individually or in  the
aggregate, a material adverse effect on the Company, its Subsidiaries and the
Clinic Joint Ventures, taken as a whole. 


 

  (f) _Section 3.8(f)_ of the Company Disclosure Schedule sets  forth a
list as of September 15, 2020 of all non-binding letters of intent or term
sheets that relate to the acquisition or disposition of any business (whether
by merger, sale of stock, sale of assets or otherwise) to which the Company or
any of its  Subsidiaries is party to for an amount greater than $500,000
individually. 


 

  (g) Except as set forth on _Section 3.8(g)_ of the Company  Disclosure
Schedule, to the knowledge of the Company, since December 31, 2018 to the date
hereof, neither the Company nor any of its Subsidiaries has received any
written notice from any (i) supplier listed on _Section 3.8(g)(i)_ of the
Company  Disclosure Schedule or (ii) payor listed on _Section 3.8(g)(ii)_ of
the Company Disclosure Schedule, in each case, indicating that such party has
or, to the knowledge of the Company, is threatening to terminate or not renew,
any Material  Contract, or terminating or, to the knowledge of the Company,
is threatening to terminate or materially modify its relationship or cease or
reduce its business, with the Company or any of its Subsidiaries, in each case
that remain outstanding or  otherwise have not been resolved. 


 

 

Section 3.9. _Absence of Certain Changes or Events_. Since June 30, 2020, (a)
except as contemplated by this Agreement or in connection with the formation
or financing or refinancing of any Clinic Joint  Ventures in the ordinary
course of business consistent with past practice, the Company and its
Subsidiaries have conducted their business in all material respects in the
ordinary course consistent with past practice and (b) there has not occurred
any  event, development, change, effect or occurrence that, individually or
in the aggregate, has had, or would reasonably be expected to have, a Material
Adverse Effect.

 

 

18  

Section 3.10. _Absence of Litigation_. As of the date of this Agreement, there
are no Proceedings pending or, to the knowledge of the Company, threatened
against the Company or any of its Subsidiaries nor  any of their respective
assets, rights or properties or, to the knowledge of the Company, any present
or former officer or director of the Company or any of its Subsidiaries in
such individual's capacity as an officer or director, other than any such 
Proceeding or arbitration that would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect. As of the date of
this Agreement, neither the Company nor any of its Subsidiaries is subject to
any order, writ,  judgment, injunction, decree or award except for those that
would not reasonably be expected to have, individually or in the aggregate, a
Material Adverse Effect. _Section 3.10_ of the Company Disclosure Schedule
sets forth a complete and  correct list of all Proceedings or, to the
Company's knowledge, investigations involving the Company, its Subsidiaries or
any of their respective directors or officers (in such individual's capacity
as such) during the past three (3) years that has  resulted in, or would
reasonably be expected to result in, a liability or loss to the Company or any
of its Subsidiaries in excess of $1,000,000 above the amount reasonably
expected to be payable by insurers.

 


 

 

Section 3.11. _Employee Benefit Plans_.

 


 

  (a) _Section 3.11(a)_ of the Company Disclosure Schedule  contains a true
and complete list, as of the date hereof, of each material Company Plan. For
purposes of this Agreement, "Company Plan" means any "employee benefit plan"
(within the meaning of Section 3(3) of the Employee Retirement Income Security
Act  of 1974, as amended (" _ERISA_ ")), stock option plans, stock purchase
plans, bonus or incentive award plans, severance pay plans, programs or
arrangements, deferred compensation arrangements or agreements and each other
material director and  employee plan, program, agreement or arrangement,
vacation or sick pay policy, fringe benefit plan, and compensation, severance,
change in control plans, programs or arrangements or employment agreement
contributed to, sponsored or maintained by the  Company or any of its
Subsidiaries as of the date hereof for the benefit of any current, former or
retired employee or director (or their spouses, dependents, or beneficiaries)
of the Company or any of its Subsidiaries (collectively, the " _Company 
Employees_ "). 


 

  (b) With respect to each Company Plan set forth on _Section  3.11(a)_ of
the Company Disclosure Schedule, the Company has made available to Parent a
true and complete copy thereof to the extent in writing and, to the extent
applicable, (i) any related trust agreement or other funding instrument, (ii)
the  most recent determination letter, if any, received from the Internal
Revenue Service (the " _IRS_ "), (iii) the most recent summary plan
description for each Company Plan for which such summary plan description is
required, and (iv) for the most  recent year (A) the Form 5500 and attached
schedules, (B) audited financial statements and (C) actuarial valuation
reports, if any. 


 

  (c) (i) Each Company Plan has been established and administered in  all
material respects in accordance with its terms and in material compliance with
the applicable provisions of ERISA, the Internal Revenue Code of 1986, as
amended (the " _Code_ "), and other applicable Laws, rules and regulations and
(ii) with  respect to each Company Plan, as of the date hereof, no material
actions, suits or claims (other than routine claims for benefits in the
ordinary course) are pending or, to the knowledge of the Company,
threatened. 


 

  (d) Each Company Plan which is intended to be qualified under  Section
401(a) of the Code has received a determination letter to that effect from the
IRS and, to the knowledge of the Company, no circumstances exist which would
reasonably be expected to materially adversely affect such qualification. 

 

19   (e) Neither the Company nor any ERISA Affiliate maintains, sponsors  or
contributes to or has in the past six years maintained, sponsored or
contributed to, or been required to contribute to (i) any employee benefit
plan that is or was subject to Title IV of ERISA, Section 412 of the Code,
Section 302 of ERISA, (ii) a  multiemployer plan within the meaning of
Section 3(37) of ERISA, (iii) any funded welfare benefit plan within the
meaning of Section 419 of the Code. Neither the Company nor any of its ERISA
Affiliates has incurred any liability under Title IV of ERISA  that has not
been paid in full as of the date hereof. Neither the Company nor any of its
Subsidiaries maintains, sponsors or contributes to any "multiple employer
plan" (within the meaning of Section 210 of ERISA or Section 413(c) of the
Code) or any  "multiple employer welfare arrangement" (as such term is
defined in Section 3(40) of ERISA). 


 

  (f) None of the Company Plans provides health care or any other  non-
pension benefits to any employees after their employment is terminated (other
than as required by Part 6 of Subtitle B of Title I of ERISA or similar state
Law). 


 

  (g) No Company Plan exists that as a result of the consummation of  the
transactions contemplated by this Agreement will (i) entitle any Company
Employee to severance pay, unemployment compensation or any other compensatory
payment, except as contemplated by this Agreement or as required by applicable
Law, (ii)  accelerate the time of payment, funding or vesting, or increase
the amount of compensation due any such Company Employee, except as
contemplated by this Agreement, (iii) result in payments which would not
reasonably be expected to be deductible under  Section 280G of the Code or
(iv) result in a requirement to pay any Tax "gross-up" or similar "make-whole"
payments to any employee, director or consultant of the Company or any of its
Subsidiaries. 


 

  (h) Each Company Plan that constitutes in any part a nonqualified 
deferred compensation plan within the meaning of Section 409A of the Code has
been operated and maintained in all material respects in operational and
documentary compliance with Section 409A of the Code and applicable guidance
thereunder. 


 

  (i) No Company Plan is subject to the Laws of any jurisdiction  outside
the United States. 


 

 

Section 3.12. _Labor and Employment Matters_.

 


 

  (a) The Company has made available a complete and accurate list of  all
Company Employees (other than per diem employees) as of September 15, 2020 by:
his or her position or title; whether classified as exempt or non-exempt for
wage and hour purposes; whether paid on a salary, hourly or commission basis;
the employee's  actual annual base salary or other rates of compensation; and
business location. 


 

  (b) As of September 15, 2020, approximately eleven (11) independent 
contractors were engaged by the Company and its Subsidiaries. 

 

20   (c) The Company is not a party to any collective bargaining  agreement
with any labor organization representing any Company Employees nor, to the
knowledge of the Company, is any such agreement being negotiated by the
Company as of the date hereof. To the knowledge of the Company, there are no
organizing  activities pending or under discussion with any labor
organization or group of Company Employees. There is no material strike,
slowdown, work stoppage or lockout pending against or affecting the Company.
To the knowledge of the Company, there is no  unfair labor practice charge
pending before the National Labor Relations Board (or equivalent regulatory
body, tribunal or authority) against the Company, which, if adversely decided,
would reasonably be expected, individually or in the aggregate, to  have a
Material Adverse Effect. There is no arbitration hearing or arbitration award
pending or, to the knowledge of the Company, threatened in writing against the
Company, which, if adversely decided, would reasonably be expected,
individually or in  the aggregate, to have a Material Adverse Effect. 


 

  (d) The Company is, and since the Applicable Date has been, in 
compliance with all applicable laws respecting labor and employment matters,
including fair employment practices, harassment and discrimination, the
classification of independent contractors and employees, workplace safety and
health, work  authorization and immigration, unemployment compensation,
workers' compensation, affirmative action, pay equity, terms and conditions of
employment, employee leave and wages and hours, including payment of minimum
wages and overtime, except as would  not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. 


 

  (e) There are no material internal investigations being conducted  by or
on behalf of the Company or material private dispute resolution procedures
pending against the Company, in each case with respect to employment or labor
matters (including but not limited to allegations of employment discrimination
or sexual  harassment). To the knowledge of the Company, there is no
threatened in writing claim or claim reported through the Company's compliance
hotline of sexual harassment, other unlawful harassment or unlawful
discrimination or retaliation against or  involving any Company officer or
director. 


 

  (f) During the ninety (90) day period preceding the date hereof,  the
Company has not experienced a "plant closing," "business closing," or "mass
layoff" as defined in the federal Worker Adjustment and Retraining
Notification Act (the " _WARN Act_ ") or any similar state, local or foreign
law or regulation  affecting any site of employment of the Company or one or
more facilities or operating units within any site of employment or facility
of the Company. 


 

 

Section 3.13. _Insurance_. Except as would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect, (a) all insurance
policies of the Company and its Subsidiaries  are in full force and effect,
(b) all premiums due with respect to such material insurance policies have
been paid in accordance with the terms thereof (other than retroactive or
retrospective insurance premium adjustments that are not yet, but may  be,
required to be paid with respect to any period ending before the Closing Date)
and (c) neither the Company nor any of its Subsidiaries have received any
written notice of termination, cancellation or non-renewal with respect to any
such policy  nor, to the knowledge of the Company, are any of the foregoing
threatened and there is no claim pending under any such insurance policies as
to which coverage has been denied or disputed by the underwriters of such
policies, other than "reservation  of rights" or similar letters or
communications.

 

 

21  

Section 3.14. _Properties_.

 


 

  (a) _Owned Real Property_. _Section 3.14(a)_ of the  Company Disclosure
Schedule contains a true and complete list of all of the real property owned
by the Company or any of its Subsidiaries as of the date hereof (the " _Owned
Real Property ")_. Except as listed on _Section 3.14(a)_ of the  Company
Disclosure Schedule, none of the currently Owned Real Property is leased or
licensed to any Person (other than the Company or any of its Subsidiaries or
any Clinic Joint Venture) in a manner that gives such Person the right to use
or occupy the  Owned Real Property. 


 

  (b) _Leased Real Property_. _Section 3.14(b)_ of the  Company Disclosure
Schedule contains a true and complete list, as of September 1, 2020, of all of
the existing leases pursuant to which the Company or any of its Subsidiaries
uses or occupies any real property with a current annual base rent amount in 
excess of $200,000 (such property, the " _Leased Real Property_ ," and each
such lease, a " _Material Lease_ "). Except as set forth on _Section 3.14(b)_
of the Company Disclosure Schedule, (i)  neither the Company nor any of its
Subsidiaries is in material default under any Material Lease nor, to the
knowledge of the Company, has the Company or any of its Subsidiaries received
any written notice alleging any material default thereunder; (ii)  the
Company, its Subsidiaries and the Clinic Joint Ventures have not granted any
subleases to any Person, other than the Company, any of its Subsidiaries or a
Joint Venture Clinic, giving such Person any right to use or occupy on a full
time basis the  Owned Real Property or the Leased Real Property, except as
set forth on _Section 3.14(b)(ii)_ of the Company Disclosure Schedule (each, a
" _Sublease_ "); and (iii) no consent of any landlord or other superior
interest holder with respect to a  Material Lease is required in connection
with the transactions contemplated hereby. 


 

  (c) Since the Applicable Date, to the knowledge of the Company,  neither
the Company nor any of its Subsidiaries has received any written notice of any
material violation or claimed material violation of any applicable building,
zoning, subdivision or other land use or similar Laws affecting its interests
in Owned  Real Property or Leased Real Property, that, in each case,
individually or in the aggregate, is material to the Company and its
Subsidiaries, taken as a whole. 


 

  (d) Except as would not be, individually or in the aggregate,  material
to the Company and its Subsidiaries, taken as a whole, the Company or a
Subsidiary of the Company owns and has good and valid title to, or holds a
valid leasehold interest in, the Owned Real Property or the Leased Real
Property, as applicable,  together with all items of personal property that
are material to the Company and its Subsidiaries, taken as a whole, in each
case free and clear of all liens, encumbrances, mortgages, pledges, security
interests, claims and defects, and imperfections  of title (" _Liens_ ")
(except in all cases for (A) Liens set forth on _Section 3.14(d)_ of the
Company Disclosure Schedules or reflected on the consolidated financial
statements of the Company, (B) statutory liens securing payments not yet  due
or which are being contested in good faith by appropriate Proceeding and for
which adequate reserves have been provided, (C) such imperfections or
irregularities of title, Liens, charges, easements, covenants and other
restrictions or encumbrances  as do not materially affect the use of the
properties or assets subject thereto or affected thereby or otherwise
materially impair business operations at such properties; easements, rights of
way, options, reservations or other similar matters or  restrictions or
exclusions which would be shown by a current title report or other similar
report; and any condition or other matter, if any, that may be shown or
disclosed by a current and accurate survey or physical inspection of the real
property,  (D) encumbrances for current Taxes or other governmental charges
not yet due and payable or for Taxes that are being contested in good faith by
appropriate Proceeding and for which adequate reserves have been established
in accordance with GAAP, (E)  pledges or deposits made in the ordinary course
of business to secure obligations under workers' compensation, unemployment
insurance, social security, retirement and similar Laws or similar legislation
or to secure public or statutory obligations, (F)  mechanics', carriers',
workmen's, repairmen's or other like encumbrances arising or incurred in the
ordinary course of business for amounts not yet due or payable or which are
being contested in good faith by appropriate Proceedings and for which 
adequate reserves have been established in accordance with GAAP, (G) Liens in
favor of lessors and licensors under the Material Leases and licenses and
liens to which the fee simple interest (or any superior leasehold interest)
are subject, (H)  mortgages, or deeds of trust, security interests or other
encumbrances on title related to indebtedness reflected on the consolidated
financial statements of the Company), (I) Liens arising under the Joint
Venture Agreements and (J) any other Liens  that would not be, individually
or in the aggregate, material to the Company and its Subsidiaries, taken as a
whole (items in clauses (A) through (I) are referred to herein as " _Permitted
Liens_ "). 

 

22  

Section 3.15. _Tax Matters_. Except as would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect:

 


 

  (a) All Tax Returns required to be filed by, or on behalf of, the 
Company or any of its Subsidiaries have been timely filed, or will be timely
filed (taking into account any extensions of time in which to file). The
Company and each of its Subsidiaries has paid (or has had paid on its behalf)
in full all Taxes that  are due and payable (whether or not shown to be due
on such Tax Returns), except for any Taxes contested in good faith or for
which adequate reserves have been established in accordance with GAAP. 


 

  (b) There are no Liens with respect to Taxes upon any of the assets  or
properties of either the Company or its Subsidiaries, other than Permitted
Liens. 


 

  (c) There is no outstanding audit, assessment, examination or claim 
concerning any Tax liability of the Company or any of its Subsidiaries that is
currently pending with a Taxing Authority or that has occurred within the past
year. 


 

  (d) No written claim has ever been made by any Taxing Authority in  a
jurisdiction where neither the Company nor any of its Subsidiaries files Tax
Returns that it is or may be subject to taxation by that jurisdiction, which
claim has not been resolved in full. 


 

  (e) Neither the Company nor any of its Subsidiaries (A) is or has  ever
been a member of an affiliated group within the meaning of Section 1504(a) of
the Code (other than a group the common parent of which is or was the Company
or one of its Subsidiaries) filing a consolidated federal income Tax Return or
(B) has any  liability for Taxes of any Person (other than the Company or its
Subsidiaries) under Treasury Regulation Section 1.1502-6 or any analogous
provision of state, local or foreign Law or as a transferee or successor. 

 

23   (f) The Company has not been a United States real property holding 
corporation within the meaning of Section 897(c)(2) of the Code during the
applicable period specified in Section 897(c)(1)(A)(ii) of the Code. 


 

  (g) None of the Company or any of its Subsidiaries is a party to,  is
bound by or has any obligation under any Tax sharing, Tax allocation or Tax
indemnity agreement, other than (i) any agreement solely between or among the
Company and/or any of its Subsidiaries or (ii) any agreement that does not
relate primarily to  Taxes. 


 

  (h) None of the Company or any of its Subsidiaries has been either  a
"distributing corporation" or a "controlled corporation" in a distribution
occurring during the last two (2) years in which the parties to such
distribution treated the distribution as one to which Section 355 of the Code
is applicable. 


 

  (i) None of the Company or any of its Subsidiaries has received or 
applied for a private letter ruling or other similar written Tax ruling from
any Taxing Authority. 


 

  (j) None of the Company or any of its Subsidiaries will be required  to
include any item of income in, or exclude any item of deduction from, taxable
income for any period (or any portion thereof) ending after the Closing Date
as a result of any: (i) change in method of accounting for a taxable period
ending on or prior  to the Closing Date under Section 481 of the Code (or any
corresponding provision of state, local or other income Tax Law) that was made
or requested prior to the Closing, (ii) installment sale or open transaction
disposition made prior to the Closing,  (iii) prepaid amount received prior
to the Closing (including, without limitation, pursuant to Sections 451(c),
455 or 456 of the Code, Treasury Regulations Section 1.451-5 and Revenue
Procedure 2004-34), (iv) "closing agreement" as described in  Section 7121 of
the Code (or any corresponding provision of state, local or other Tax Law)
entered into prior to the Closing or (v) intercompany transaction or excess
loss account described in the Treasury Regulations under Section 1502 of the
Code  existing prior to the Closing. 


 

  (k) For U.S. federal income Tax purposes, (i) the Company is  classified
as a domestic "C" corporation and (ii) each Clinic Joint Venture is classified
as a domestic partnership. 


 

  (l) Neither the Company nor any of its Subsidiaries has  participated in
any "listed transaction" within the meaning of Treasury Regulations Section
1.6011-4(b)(2). 


 

 

Notwithstanding anything else in this Agreement, the representations and
warranties set forth in this _Section 3.15_ shall constitute the only
representations and warranties by the Company with respect to Tax  matters.
For purposes of this Agreement:

 


 

  (i) " _Taxes_ " means all federal, state, local and foreign income,
profits, franchise, gross receipts,  environmental, customs duty, capital
stock, severance, stamp, payroll, sales, employment, unemployment, disability,
use, property, withholding, excise, license, production, value added,
occupancy and other taxes imposed by any Taxing Authority,  together with all
interest, penalties and additions imposed by such Taxing Authority with
respect to such amounts; 

 

24   (ii) " _Tax Return_ " means all returns and reports (including
declarations of estimated Taxes and information  returns) required to be
filed with a Taxing Authority including any amendments thereto and any
schedules or attachments thereto; and 


 

  (iii) " _Taxing Authority_ " means any Governmental Entity exercising any
authority to impose, regulate or  administer the imposition of Taxes. 


 

 

Section 3.16. _Proxy Statement_. None of the information supplied or to be
supplied by the Company or the Subsidiaries of the Company for inclusion or
incorporation by reference in the proxy statement to  be sent to the
stockholders of the Company in connection with the Stockholders Meeting (such
proxy statement, as amended or supplemented, the " _Proxy Statement_ ") will,
on the date it (and any amendment or supplement thereto) is first filed with 
the SEC or at the time it is first mailed to the stockholders of the Company
or at the time of the Stockholders Meeting, contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary in  order to make the statements therein, in light of the
circumstances under which they are made, not misleading. The Proxy Statement
will, at the date it is filed with the SEC, comply as to form in all material
respects with the applicable  requirements of the Exchange Act and the rules
and regulations promulgated thereunder. Notwithstanding the foregoing, the
Company makes no representation or warranty with respect to any information
supplied by or on behalf of Parent or Merger Sub or  any of their respective
Representatives which is contained or incorporated by reference in the Proxy
Statement.

 


 

 

Section 3.17. _Intellectual Property_. _Section 3.17_ of the Company
Disclosure Schedule contains a complete and accurate list of all registered
and material unregistered trademarks, registered  copyrights, and internet
domain names registered to or owned or purported to be owned by the Company or
any of its Subsidiaries. Except as would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect: (a) the  Company
and its Subsidiaries own, free and clear of all Liens except Permitted Liens,
or have the right to use, all material Intellectual Property used in their
business as currently conducted, (b) the conduct of the Company's business as
currently  conducted does not infringe or violate the Intellectual Property
(other than patents, and with respect to patents, to the knowledge of the
Company) of any Person, (c) there are no pending or, to the knowledge of the
Company, threatened claims against  the Company, any Subsidiary or any of
their employees alleging that any activity by the Company or such Subsidiary
infringes or violates (or in the past infringed or violated) the rights of
others in or to any Intellectual Property, (d) to the  knowledge of the
Company, no Person is infringing or violating the Intellectual Property owned
by the Company or its Subsidiaries and (e) the Company has obtained and
possesses valid licenses to use all of the software programs present on the 
computers and other software-enabled electronic devices that it owns or leases
or that it has otherwise provided to its employees for their use in connection
with the Company's business.

 


 

 

 

25  

Section 3.18. _Environmental Matters_. Except as would not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect:

 


 

 

 


  (a) The Company and its  Subsidiaries are, and for the past three (3)
years from the date hereof have been, operating in compliance with all
applicable Environmental Laws, including having all permits required under any
applicable Environmental Law for the operation of the  business and complying
in all material respects with the terms and conditions of such permits; 


 

  (b) Neither the Company nor any of its Subsidiaries, to the  knowledge of
the Company, has released any Hazardous Substances into the environment on,
at, under, in or from any real property owned or operated by the Company or
any Subsidiary of the Company that is (i) currently subject to any
investigation,  remediation or monitoring, or (ii) reasonably likely to
result in liability to the Company or any Subsidiary, in either case (i) or
(ii) under any applicable Environmental Laws; 


 

  (c) Neither the Company nor any of its Subsidiaries is a party to  any
pending or threatened Proceeding alleging that it is in violation of or has
liability under any Environmental Laws; and 


 

  (d) Neither the Company nor, to the knowledge of the Company, any  of its
Subsidiaries has received any written claim, notice or information request
alleging that the Company or any of its Subsidiaries is in material violation
of, or may have material liability under, Environmental Laws, which remains
unresolved. 


 

 

The representations and warranties set forth in this _Section 3.18_ shall
constitute the only representations and warranties by the Company with respect
to environmental matters. For purposes of this Agreement, the  following
terms shall have the meanings assigned below:

 


 

 

" _Environmental Laws_ " shall mean all Laws concerning pollution or
protection of the environment.

 


 

 

" _Hazardous Substances_ " shall mean any hazardous waste, material, or
substance, any pollutant or contaminant, and any other terms of similar
meaning, as defined in any applicable Environmental Law, and includes 
petroleum, medical or infectious waste, polychlorinated biphenyls and
asbestos.

 


 

 

Section 3.19. _Opinion of Financial Advisor_. Prior to the execution of this
Agreement, Goldman Sachs and Co. LLC (the " _Financial Advisor_ ") has delivered
to the Board of Directors its written  opinion (or oral opinion to be
confirmed in writing), dated as of the date hereof, as to the fairness of the
Per Share Merger Consideration, from a financial point of view, to be paid to
the stockholders of the Company (other than Parent and its  Affiliates), as
of the date of such opinion and based upon and subject to the factors,
assumptions, qualifications and limitations set forth in such opinion. A
signed and complete copy of such opinion will promptly be made available to
Parent for  informational purposes only following receipt thereof by the
Board of Directors; _provided_ that such opinion may not be relied on by
Parent or any of its Affiliates, directors, officers or employees.

 


 

 

 

26  

 


 

Section 3.20. _Regulatory Matters_.

  
  (a) Except as would not reasonably be expected to have, individually or in
the aggregate, a  material adverse effect on the Company and its
Subsidiaries, taken as a whole, the activities of the Company and its
Subsidiaries and, to the knowledge of the Company, their respective directors,
officers, and employees, while acting for or on behalf  of such Company or
Subsidiary, are currently, and since the Applicable Date, have been, conducted
in compliance with all applicable Health Care Laws. 


 

  (b) Neither the Company nor any of its Subsidiaries, nor, except as 
would not reasonably be expected to have, individually or in the aggregate, a
material adverse effect on the Company and its Subsidiaries, taken as a whole,
any of their respective employees, directors or officers, and, to the
knowledge of the Company,  any of their respective consultants, vendors or
suppliers, is as of the date hereof or has been since the Applicable Date
excluded, suspended, debarred from participation, or otherwise terminated from
or ineligible to participate in, any federal health  care program, as such
term is defined in 42 U.S.C.  1320a-7b(f) (a " _Federal Health Care Program_
"). Neither the Company nor any of its Subsidiaries have received any written
notice from any Governmental Entity of any pending or threatened  Proceeding
that would reasonably be expected to result in the revocation, withdrawal,
suspension, non-renewal, termination, revocation, or adverse modification or
limitation of the Company's participation in any Federal Health Care Program,
except as  would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. Since the Applicable Date, neither
the Company nor any of its Subsidiaries nor, except as would not reasonably be
expected to have, individually or  in the aggregate, a material adverse
effect on the Company and its Subsidiaries, taken as a whole, to the knowledge
of the Company, any of their respective employees, consultants, directors or
officers: (i) has been convicted of or, to the knowledge of  the Company,
charged with any criminal offense relating to the delivery of an item or
service under any Federal Health Care Program or state Health Care Program;
(ii) has been convicted of or, to the knowledge of the Company, charged with
or  investigated for, any violation of Law related to fraud, theft,
embezzlement, breach of fiduciary responsibility, financial misconduct,
obstruction of an investigation, or controlled substances, or (iii) has had a
civil monetary penalty assessed  against it, him or her under Section 1128A
of the Social Security Act. 


 

  (c) Since the Applicable Date, neither the Company nor any of its 
Subsidiaries nor, to the knowledge of the Company, any of those entities'
directors, officers, or employees has with respect to the operations of the
business of the Company and its Subsidiaries made a voluntary disclosure
pursuant to the OIG's  self-disclosure protocol or otherwise, or has been
subject to any reporting obligations pursuant to any settlement agreement with
the OIG or any other Governmental Entity concerning compliance with any Health
Care Law. Since the Applicable Date,  neither the Company nor any of its
Subsidiaries nor, to the knowledge of the Company, any of their respective
directors, officers or employees (x) has been notified in writing or the
knowledge of the Company, orally that it is the subject of any  Federal
Health Care Program investigation or commercial or other third party payor
program investigation, except as would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect on the Company and
its  Subsidiaries, taken as a whole, (y) has been notified in writing that it
is a defendant in any qui tam/ false claims act litigation, or (z) has been
served with or received any search warrant, subpoena or civil investigative
demand from any  Governmental Entity concerning compliance with any Health
Care Law. 

 

27   (d) Except as would not reasonably be expected to have,  individually or
in the aggregate, a material adverse effect on the Company and its
Subsidiaries, taken as a whole, the Company and its Subsidiaries are in
compliance with applicable Health Care Laws and contractual obligations
applicable to billing  third-party payors, including Federal Health Care
Programs and insurance companies, health care service plans, health
maintenance organizations, self-funded groups, or other payors with respect to
their commercial and Federal Health Care Program  business. To the knowledge
of the Company, since the Applicable Date, the Company and its Subsidiaries
has paid, caused to be paid, attempted to pay or has scheduled to pay all
known and undisputed refunds and overpayments to the applicable  third-party
payors, including Federal Health Care Programs and insurance companies, in
accordance with applicable Health Care Laws and contractual obligations,
except as would not reasonably be expected to have, individually or in the
aggregate, a  material adverse effect on the Company and its Subsidiaries,
taken as a whole. Since the Applicable Date, other than regularly scheduled
audits and reviews or reviews or audits that would not reasonably be expected
to have, individually or in the  aggregate, a material adverse effect on the
Company and its Subsidiaries, taken as a whole, no audits, coding validation
reviews or program integrity reviews, or credentialing or privileging reviews
has been conducted by any entity, commission, board  or agency having
responsibility over such company's involvement with the Federal Health Care
Programs or third party payors (collectively, a " _Program Review_ "), and
neither the Company nor any of its Subsidiaries has received written notice
that  any such Program Reviews are scheduled or pending. 


 

  (e) Except as would not reasonably be expected to have,  individually or
in the aggregate, a material adverse effect on the Company and its
Subsidiaries, taken as a whole, since the Applicable Date, the Company and its
Subsidiaries have filed all reports, statements, documents, registrations,
filings, and  submissions required to be filed by it under applicable Health
Care Laws. Except as would not reasonably be expected to have, individually or
in the aggregate, a material adverse effect on the Company and its
Subsidiaries, taken as a whole, since the  Applicable Date, neither the
Company nor its Subsidiaries have knowingly or willfully made or cause to be
made, or induced or sought to induce the making of, any false statement or
representation (or knowingly or willfully omitting to state a fact  required
to be stated therein or necessary to make the statements contained therein not
misleading) of a fact to a Governmental Entity. Except as would not reasonably
be expected to have, individually or in the aggregate, a material adverse
effect on  the Company and its Subsidiaries, taken as a whole, since the
Applicable Date, no written notice has been received by the Company or any of
its Subsidiaries from any Governmental Entity alleging a violation of any
Health Care Law. 


 

  (f) Neither the Company nor any of its Subsidiaries is a party to  or has
any ongoing reporting obligations pursuant to or under any corporate integrity
agreements, deferred prosecution agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by, any
Governmental  Entity with respect to any Health Care Law. 


 

  (g) The Company and its Subsidiaries use commercially reasonable  efforts
to protect the privacy of sensitive data, including non-public information,
personal information and protected or regulated health information, that the
Company or any of its Subsidiaries collects, uses, stores, maintains,
processes or  transmits and to prevent unauthorized access to, and use or
disclosure of, such data by any unauthorized Person, except as would not have,
individually or in the aggregate, a Material Adverse Effect. Each of the
Company and its Subsidiaries that are  Covered Entities or Business
Associates (as defined under HIPAA) are now and since the Applicable Date have
been in compliance with HIPAA including having undertaken all necessary risk
assessments or risk analyses required under HIPAA, except as would  not have,
individually or in the aggregate, a Material Adverse Effect. Neither the
execution, delivery or performance of this Agreement, nor the consummation of
any of the transactions contemplated by this Agreement, including any transfer
of Protected  Health Information (as defined in 45 C.F.R.  160.103)
resulting from such transactions, will violate any policies of the Company or
its Subsidiaries or any privacy agreements to which the Company or its
Subsidiaries are a party as such policies or  privacy agreements currently
exist, except as would not have, individually or in the aggregate, a Material
Adverse Effect. 

 

28   Section 3.21. _Information Technology_. The Company takes commercially
reasonable steps and  implements commercially reasonable procedures designed
to protect and safeguard their information technology systems used in
connection with the operation of the business of the Company and its
Subsidiaries from unauthorized access. The Company  employs commercially
reasonable disaster recovery and business continuity plans, procedures and
facilities for the business of the Company and its Subsidiaries and takes
commercially reasonable steps to safeguard the information technology
systems  utilized in the operation of the business of the Company and its
Subsidiaries. To the knowledge of the Company, since the Applicable Date,
there have been no material breaches of or material failures in the security
systems or measures related to the  Company's information technology systems
that have resulted in unauthorized access to personally identifiable
information. 


 

 

Section 3.22. _Brokers_. No broker, finder, investment banker or financial
advisor (other than the Financial Advisor) is entitled to any brokerage,
finder's or other fee or commission in connection with  the transactions
contemplated by this Agreement based upon arrangements made by and on behalf
of the Company or any of its Subsidiaries.

 


 

 

Section 3.23. _Takeover Statutes_. Assuming the accuracy of the
representations and warranties contained in _Section 4.10_ , no "fair price",
"moratorium", "control share acquisition" or other similar  antitakeover
statute or regulation enacted under state or federal Laws in the United States
applicable to the Company, or any anti-takeover provisions in the Certificate
of Incorporation or the Bylaws, is applicable to this Agreement or the 
transactions contemplated hereby, including the Merger. The Company is not
party to any stockholder rights plan, "poison pill" or similar anti-takeover
agreement or plan.

 


 

  Section 3.24. _Affiliate Party Transactions_. Since March 31, 2020, there
are no transactions,  agreements, arrangements or understandings between (a)
the Company or any of its Subsidiaries on the one hand, and (b) any
stockholders, directors, officers or employees of the Company on the other
hand, in each case that would be required to be  disclosed under Item 404
under Regulation S-K under the Securities Act and that have not been so
disclosed in the SEC Reports filed with, or furnished to, the SEC prior to the
date of this Agreement, other than employment agreements in the ordinary 
course of business consistent with past practice and similar employee
arrangements otherwise set forth on the Company Disclosure Schedule. _Section
3.24_ of the Company Disclosure Schedule sets forth a correct and complete
list as of September  15, 2020, to the knowledge of the Company, of all
leases or full-time Subleases between the Company and any of its Subsidiaries,
on the one hand, and any Affiliate of the Company or any Clinic Joint Venture,
on the other hand (including any doctor who  is a direct or indirect owner of
such Clinic Joint Venture which is the party to such Lease or full-time
Sublease, or any Affiliate of such doctor). 

 

29  

Section 3.25. _No Other Representations or Warranties_. Except for the
representations and warranties expressly set forth in this _Article III_ ,
none of the of the Company or any of its stockholders,  Subsidiaries,
directors, employees, Affiliates, advisors, agents or any other
Representatives or Person on behalf of the Company makes any express or
implied representation or warranty with respect to the Company, its
Subsidiaries or their respective  businesses or with respect to any
information provided, or made available, to Parent, Merger Sub or their
respective Representatives or Affiliates in connection with the transactions
contemplated hereby, including the accuracy or completeness  thereof. Without
limiting the foregoing, neither the Company nor any other Person will have or
be subject to any liability, responsibility or other obligation to Parent,
Merger Sub, their respective Representatives or Affiliates or any other
Person  on any basis resulting from Parent's, Merger Sub's or any of their
respective Representative's or Affiliates' use of any information, documents
or other materials made available or otherwise provided to them, including any
information made available  in the electronic data room maintained by the
Company, management presentations, functional "break-out" discussions,
responses to questions submitted by or on behalf of Parent, Merger Sub or
their respective Representatives or Affiliates or in any  other form in
connection with the transactions contemplated by this Agreement, and each of
Parent and Merger Sub acknowledges and agrees to the foregoing. The Company
acknowledges that Parent and Merger Sub make no representations or warranties
as  to any matter whatsoever except as expressly set forth in _Article IV_.
The representations and warranties set forth in _Article IV_ are made solely
by Parent and Merger Sub, and no Representative of Parent or Merger Sub shall
have any  responsibility or liability related thereto.

 


 

 

ARTICLE IV.

 


 

 

REPRESENTATIONS AND WARRANTIES OF

 

PARENT AND MERGER SUB

 


 

 

Parent and Merger Sub each hereby represent and warrant to the Company that,
except as set forth on the corresponding sections or subsections of the
disclosure schedules delivered to the Company by Parent and Merger Sub 
concurrently with entering into this Agreement (the " _Parent Disclosure
Schedule_ "), it being acknowledged and agreed that disclosure of any item in
any section or subsection of the Parent Disclosure Schedule shall also be
deemed disclosure with  respect to any other section or subsection of this
Agreement to which the relevance of such item is reasonably apparent on the
face of such disclosure:

 


 

 

Section 4.1. _Organization_. Each of Parent and Merger Sub is a legal entity
duly organized, validly existing and in good standing under the Laws of its
respective jurisdiction of organization and has all  requisite corporate,
limited liability company or similar power and authority to own, lease and
operate its properties and assets and to carry on its business as presently
conducted and is duly qualified and licensed to do business and, to the
extent  such concept is applicable, is in good standing as a foreign
corporation or other legal entity in each jurisdiction where the ownership,
leasing or operation of its assets or properties or conduct of its business
requires such qualification or  licensing, except where the failure to be so
organized, qualified, licensed or, to the extent such concept is applicable,
in such good standing, or to have such power or authority, would not,
individually or in the aggregate, reasonably be expected  to have a material
adverse effect on the ability of Parent or Merger Sub to timely consummate the
Merger and the other transactions contemplated hereby. Parent has made
available to the Company prior to the date of this Agreement a correct and 
complete copy of the certificate of incorporation and bylaws (or other
comparable governing documents) of Parent and Merger Sub, each as amended to
the date of this Agreement, and each as so delivered in full force and effect.

 

 

30  

Section 4.2. _Authority_. Each of Parent and Merger Sub has all requisite
corporate or limited liability company, as applicable, power and authority,
and has taken all corporate or other action necessary,  in order to execute,
deliver and perform its obligations under, this Agreement and to consummate
the Merger and the other transactions contemplated hereby. The execution, and
delivery of this Agreement by each of Parent and Merger Sub and the 
consummation by each of Parent and Merger Sub of the transactions contemplated
hereby have been duly and validly authorized by all necessary corporate or
similar action by the Boards of Directors (or equivalent) of Parent and Merger
Sub and Parent  has approved and adopted this Agreement and the transactions
contemplated hereby, including the Merger, in its capacity as sole stockholder
of Merger Sub and delivered to the Company evidence of its vote or action by
written consent approving and  adopting this Agreement in accordance with
applicable Law and the certificate of incorporation and bylaws of Merger Sub,
and no other corporate Proceeding or stockholder or similar action on the part
of Parent or Merger Sub or any of their Affiliates  is necessary to authorize
this Agreement, to perform their respective obligations hereunder, or to
consummate the transactions contemplated hereby (other than the filing with
the Secretary of State of the State of Delaware of the Certificate of  Merger
as required by the DGCL). This Agreement has been duly executed and delivered
by each of Parent and Merger Sub and is a valid and binding agreement of
Parent and Merger Sub, enforceable against each of Parent and Merger Sub in
accordance with  its terms, subject to the Bankruptcy and Equity Exception.

 


 

 

Section 4.3. _No Conflict; Required Filings and Consents_.

 


 

  (a) The execution and delivery of this Agreement by Parent and  Merger
Sub do not, and the consummation of the Merger and the other transactions
contemplated hereby, including the Financing, the ownership and operation of
the Company and its Subsidiaries following the Effective Time, and the
compliance with the  provisions of this Agreement will not (i) breach,
violate or conflict with the certificate of formation or operating agreement
or other governing documents of Parent, the certificate of incorporation and
bylaws of Merger Sub or the comparable governing  instruments of any of their
respective Subsidiaries, (ii) assuming that all consents, approvals and
authorizations contemplated by subsection (b) below have been obtained, and
all filings described in such clauses have been made, breach conflict with 
or violate any Law, rule, regulation, order, judgment or decree applicable to
Parent or Merger Sub or by which either of them or any of their respective
properties are bound or (iii) result in any breach or violation of or
constitute a default (or an  event which with or without notice or lapse of
time or both would become a default), require a consent or result in the loss
of a benefit under, or give rise to any right of termination, cancellation,
amendment or acceleration of, or result in the  creation of a Lien (except a
Permitted Lien) on any of the material assets of Parent or Merger Sub pursuant
to, any Contracts to which Parent or Merger Sub, or any Affiliate thereof, is
a party or by which Parent or Merger Sub or any of their  Affiliates or its
or their respective properties are bound (including any Contract to which an
Affiliate of Parent or Merger Sub is a party) except, in the case of clause
(iii), for any such breach, violation, default, loss, right or other
occurrence  which would not reasonably be expected to have a material adverse
effect on the ability of the Parent and Merger Sub to timely consummate the
Merger and the other transactions contemplated hereby. 

 

31   (b) The execution, delivery and performance of this Agreement by  each of
Parent and Merger Sub and the consummation of the Merger and the other
transactions contemplated hereby by each of Parent and Merger Sub do not and
will not require any consent, approval, authorization or permit of, action by,
filing with or  notification to, any Governmental Entity, except for (i) the
applicable requirements, if any, of the Exchange Act and the rules and
regulations promulgated thereunder and state securities, takeover and "blue
sky" Laws, (ii) the filing of a premerger  notification and report form by
Parent and Merger Sub under the HSR Act for the transactions as contemplated
solely by this Agreement (and not the Subsequent Transaction), (iii)
compliance with the applicable requirements of the NYSE, (iv) the filing 
with the Secretary of State of the State of Delaware of the Certificate of
Merger as required by the DGCL, and (v) any such consent, approval,
authorization, permit, action, filing or notification the failure of which to
make or obtain would not  reasonably be expected to have a material adverse
effect on the ability of the Parent and Merger Sub to timely consummate the
Merger and the other transactions contemplated hereby. 


 

 

Section 4.4. _Absence of Litigation_. As of the date of this Agreement, there
are no civil, criminal, administrative or other suits, claims, actions,
Proceedings or arbitrations pending or, to the  knowledge of Parent,
threatened against Parent or Merger Sub or any of their respective
Subsidiaries, other than any such suit, claim, action, Proceeding or
investigation that would not or would not reasonably be expected to have a
material adverse  effect on the ability of the Parent and Merger Sub to
timely consummate the Merger and the other transactions contemplated hereby .
Neither Parent nor any of its Subsidiaries nor any of their respective
properties is subject to any order, writ,  judgment, injunction, decree or
award that would, or would reasonably be expected to, have a material adverse
effect on the ability of the Parent and Merger Sub to timely consummate the
Merger and the other transactions contemplated hereby.

 


 

 

Section 4.5. _Operations and Ownership of Merger Sub_. The authorized capital
stock of Merger Sub consists solely of one thousand (1,000) shares of common
stock, par value $0.001 per share, all of which  are validly issued and
outstanding. All of the issued and outstanding capital stock of Merger Sub is,
and at and immediately prior to the Effective Time will be, owned by Parent.
Merger Sub has been formed solely for the purpose of engaging in the 
transactions contemplated hereby and prior to the Effective Time will have
engaged in no other business activities and will have no assets, liabilities
or obligations of any nature other than (i) as expressly contemplated herein
and (ii) liabilities  and obligations incidental to its formation and the
maintenance of its existence.

 

 

32  

Section 4.6. _Absence of Certain Agreements_. Except as set forth on _Section
4.6_ of the Parent Disclosure Schedule, as of the date of this Agreement, none
of Parent, Merger Sub or any of their  respective Affiliates (including any
Guarantor or any of its Affiliates) has entered into any agreement,
arrangement or understanding (in each case, whether oral or written), or
authorized, committed or agreed to enter into any agreement, arrangement  or
understanding (in each case, whether oral or written), (i) with the Subsequent
Transaction Buyer, any of its Affiliates or any other Person that relates in
any way to the Company or any of its Subsidiaries or other assets or the
Subsequent  Transaction (or any other transaction involving the Company or
any of its Subsidiaries or other assets), the Merger or the other transactions
contemplated hereby (each, whether arising prior to, on or after the date
hereof, a " _Prohibited Agreement_ "),          (ii) with any holder
of Shares, Options or Restricted Stock (or any Affiliate of any such holder)
or any member of the Company's management or Board of Directors that is
related to the transactions contemplated by this Agreement, (iii) with any
third  party that would in any way limit Parent's or Merger Sub's ability to
comply with its obligations under this Agreement, (iv) with any third party
that could delay or prevent the consummation of the transactions contemplated
hereby, or (v) without  limiting the generality of the foregoing, pursuant to
which (A) any holder of Shares would be entitled to receive consideration of a
different amount or nature than the Per Share Merger Consideration or pursuant
to which any stockholder of the  Company agrees to vote to approve this
Agreement or the Merger or agrees to vote against any Superior Proposal, other
than the Voting Agreement, (B) any holder of Options or Restricted Stock would
be entitled to receive consideration of a different  amount or nature than
the consideration payable pursuant to _Section 2.2_ , (C) any third party has
agreed to provide, directly or indirectly, equity or other capital to Parent
or the Company or any of their Subsidiaries to finance in whole or  in part
the transactions contemplated herein, or (D) any Company Employee has agreed
to remain as an employee of the Company or any of its Subsidiaries or to
become an employee or consultant of Parent or any of its Subsidiaries
following the  Effective Time. Parent has shared with the Company true and
complete copies of (or where not in written form, written summaries of) all
agreements, arrangements or understandings set forth on _Section 4.6_ of the
Parent Disclosure Schedule,  and such agreements, arrangements or
understandings have not been amended or modified since the date of this
Agreement, except pursuant to _Section 5.2_ hereof. Parent is not aware of any
matter related to Parent, Merger Sub or their  respective Affiliates or
Representatives that would reasonably be expected, individually or in the
aggregate, to materially delay, impede or interfere with the consummation of
the transactions contemplated by this Agreement.

 


 

 

Section 4.7. _Proxy Statement_. None of the information supplied or to be
supplied by or on behalf of each of Parent and Merger Sub for inclusion or
incorporation by reference in the Proxy Statement will,  on the date it (and
any amendment or supplement thereto) is first filed with the SEC, at the time
it is first mailed to the stockholders of the Company or at the time of the
Stockholders Meeting, contain any untrue statement of a material fact or 
omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under
which they are made, not misleading, except that no representation or warranty
is made by Parent  and Merger Sub with respect to statements made or
incorporated by reference therein based on information supplied by or on
behalf of Company.

 


 

 

Section 4.8. _Brokers_. No broker, finder or investment banker (other than
Guggenheim Securities, LLC, whose fee shall be paid by Parent) is entitled to
any brokerage, finder's or other fee or commission  in connection with the
transactions contemplated by this Agreement based upon arrangements made by
and on behalf of Parent or Merger Sub.

 

 

33  

Section 4.9. _Ownership of Shares_. None of Parent, Merger Sub or any of their
respective Subsidiaries, or to the knowledge of Parent, Affiliates
beneficially owns (as defined in Rule 13d-3 under the  Exchange Act) any
Shares or any securities that are convertible into or exchangeable or
exercisable for Shares, or holds any rights to acquire or vote any Shares, or
any option, warrant, convertible security, stock appreciation right, swap
agreement  or other security, contract right or derivative position, whether
or not presently exercisable, that provides Parent, Merger Sub, or any of
their respective Affiliates or Subsidiaries with an exercise or conversion
privilege or a settlement payment  or mechanism at a price related to the
value of the Shares or a value determined in whole or in part with reference
to, or derived in whole or part from, the value of the Shares. None of Parent,
Merger Sub or, to the knowledge of Parent, any of their  "affiliates" or
"associates" is, or at any time during the last three (3) years has been, an
"interested stockholder" of the Company, in each case as defined in Section
203 of the DGCL. As of the date hereof, there are no contracts,
undertakings,  commitments, agreements, obligations or understandings,
whether written or oral, between Parent or Merger Sub, the Guarantor or any of
their Affiliates, on the one hand, and any beneficial owner of more than five
percent (5%) of the outstanding  Shares or any member of the Company's
management or the Board of Directors, on the other hand, relating in any way
to the transactions contemplated by this Agreement or to the management of the
Surviving Corporation after the Effective Time, other  than the Voting
Agreement.

 


 

 

Section 4.10. _Vote/Approval Required_. No vote or consent of the holders of
any class or series of capital stock of Parent or any of its Affiliates is
necessary to approve this Agreement or the  transactions contemplated hereby,
including the Merger. The vote or consent of Parent as the sole stockholder of
Merger Sub (which shall have occurred immediately following the execution of
this Agreement) is the only vote or consent of the holders  of any class or
series of capital stock of Merger Sub necessary to approve this Agreement or
the transactions contemplated hereby, including the Merger.

 


 

  Section 4.11. _Subsequent Transaction Agreement; HSR Filing_. The
Subsequent Transaction  Agreement will by its terms automatically terminate
on the date that is ninety (90) days after the date of this Agreement, should
the condition set forth in _Section 7.1(c)_ not have been satisfied prior to
such date. As of the date hereof,  Parent has provided to the Company's
outside counsel copies of all documents that Parent reasonably believes will
be submitted to the FTC, the DOJ or any other Governmental Entity in
connection with Parent's initial HSR Filing. 


 

 

Section 4.12. _Solvency_. Assuming that (a) the conditions to the obligations
of Parent and Merger Sub to consummate the Merger set forth in _Section 7.1_
and _Section 7.2_ have been satisfied  or waived, and (b)(i) the
representations and warranties set forth in _Article III_ (other than those
qualified by materiality or "Material Adverse Effect") are true and correct in
all material respects and (ii) the representations and  warranties set forth
in _Article III_ that are qualified by materiality or "Material Adverse
Effect" are true and correct in all respects, then immediately following the
Effective Time and after giving effect to all of the transactions 
contemplated by this Agreement, including the Debt Financing, any alternative
financing, and the payment of the aggregate consideration to which the
stockholders of the Company are entitled under _Article II_ , funding of any
obligations of the  Surviving Corporation or its Subsidiaries which become
due or payable by the Surviving Corporation and its Subsidiaries in connection
with, or as a result of, the Merger and payment of all related fees and
expenses, the Surviving Corporation and each  of its Subsidiaries, on a
consolidated basis, will not: (i) have debts, including contingent and other
liabilities, greater than the fair market value of its assets or have assets
the fair saleable value of which is less than the amount required to  pay its
liability on its existing debts, including contingent and other liabilities,
as they mature); (ii) have unreasonably small capital for the operation of the
businesses in which it is engaged; or (iii) have incurred debts, including
contingent  and other liabilities, beyond its ability to pay them as they
become due.

 

 

34  

Section 4.13. _Financing_. Parent and Merger Sub have delivered to the Company
true, correct and complete copies of (a) the executed debt commitment letter,
dated as of October 1, 2020 among Parent, Merger  Sub and the Debt Financing
Sources party thereto (including all exhibits, schedules and annexes thereto,
as amended from time to time after the date hereof to the extent not
prohibited by this Agreement, the " _Debt Commitment Letter_ "), pursuant  to
which the Debt Financing Sources have committed, subject only to the terms and
conditions set forth therein, to lend the aggregate amounts set forth therein
(such lending and funding, the " _Debt Financing_ ") for the purposes set
forth  therein, (b) the fee letter entered into by Parent, Merger Sub and the
Debt Financing Sources in connection with the Debt Financing (the " _Fee
Letter_ "); _provided_ that specific fee amounts and specific "market flex"
terms, if any, none  of which imposes, nor do they permit the imposition of,
any new conditions (or the modification or expansion of any existing
conditions) may have been redacted, and (c) the executed equity commitment
letter, dated as of October 1, 2020, among Parent,  the Guarantors and the
other parties thereto (including all exhibits, schedules and annexes thereto,
as amended from time to time after the date hereof to the extent not
prohibited by this Agreement, the " _Equity Commitment Letter_ " and, 
together with the Debt Commitment Letter, the " _Commitment Letters_ "),
pursuant to which the Guarantors have committed, subject to the terms and
conditions set forth therein, to make a cash equity contribution in the
aggregate amount set forth  therein (such equity contribution, the " _Equity
Financing_ " and, together with the Debt Financing, the " _Financing_ ") for
the purposes set forth therein. The Equity Commitment Letter provides that the
Company is a third-party beneficiary  thereto in accordance with the terms
thereof. As of the date hereof, none of the Commitment Letters has been
amended, supplemented or modified, no such amendment, supplement or
modification is contemplated or pending (other than amendments,  supplements
or modifications to the Debt Commitment Letter solely to add additional
lenders, arrangers, bookrunners and similar entities), and the respective
commitments contained in the Commitment Letters have not been withdrawn,
terminated or  rescinded in any respect and, to the knowledge of Parent and
Merger Sub, no such withdrawal, termination or rescission is contemplated.
Except for the Fee Letter and the Commitment Letters, there are no side
letters or Contracts to which Parent,  Merger Sub or any Affiliate of either
thereof is a party related to the terms, provision, lending, funding or
investing, as applicable, of the Financing or the transactions contemplated
hereby. As of the date hereof, Parent and Merger Sub have fully  paid (or
caused to be paid) any and all commitment fees or other fees that are required
to be paid pursuant to the Commitment Letters on or prior to the date hereof.
The Commitment Letters are in full force and effect and are the legal,
valid,  binding and enforceable obligations of Parent, Merger Sub and, to the
knowledge of Parent, each of the other parties thereto, to fund the full
amount of the Financing subject only to the satisfaction or waiver of the
Financing Conditions, in each  case subject to the Bankruptcy and Equity
Exceptions. There are no conditions precedent to funding the full amount of
the Financing (including pursuant to any market flex provisions with respect
to the Fee Letter delivered in connection with the  Debt Financing), other
than as expressly set forth in the Commitment Letters delivered to the Company
prior to the date hereof or as amended from time to time to the extent not
prohibited by the terms of this Agreement (such conditions, the "
_Financing          Conditions_ "). As of the date hereof, no event
has occurred which, with or without notice, lapse of time or both, would or
would reasonably be expected to (i) constitute a default or breach on the part
of Parent or Merger Sub or any of their  respective Affiliates or, to the
knowledge of Parent, any other party thereto under any of the Commitment
Letters, in each case that would reasonably be expected to prevent, delay or
impede the Closing or (ii) result in any portion of the amounts to  be
provided, loaned, funded or invested in accordance with the Commitment Letters
being unavailable on the Closing Date. As of the date hereof and assuming
satisfaction or waiver of the conditions set forth in _Article VII_ , Parent
has no  reason to believe that any of the conditions precedent to the
Financing contemplated by the Commitment Letters within the control of Parent
and Merger Sub will not be satisfied or that the full amount of the Financing
will not be made available to  Parent and Merger Sub in full on the Closing
Date. Parent is not aware of the existence of any fact or event that would or
would reasonably be expected to cause such conditions precedent to the
Financing contemplated by the Commitment Letters within  the control of
Parent and Merger Sub not to be satisfied or the full amount of the Financing
not to be made available to Parent on the Closing Date. As of the date hereof,
and assuming satisfaction or waiver of the conditions set forth in
_Article           VII_ and the funding of the Financing in
accordance with the Commitment Letters, Parent and Merger Sub will have on the
Closing Date funds sufficient to pay all amounts payable by Parent or Merger
Sub pursuant to _Article II_ on the  Closing Date and to pay any and all fees
and expenses required to be paid by Parent and Merger Sub in connection with
the transactions contemplated by this Agreement and the Financing
(collectively, the " _Financing Uses_ "). Notwithstanding  anything herein to
the contrary, each of Parent and Merger Sub acknowledges and agrees that
neither the receipt by Parent or Merger Sub nor the availability to Parent or
Merger Sub of the Financing or any other financing shall be a condition to
the  obligations of Parent or Merger Sub to consummate any of the
transactions contemplated hereby.

 

 

35  

Section 4.14. _Parent Guarantee_. Parent has furnished the Company with a
true, correct and complete copy of the Parent Guarantee. The Parent Guarantee
is in full force and effect and has not been amended  or modified. The Parent
Guarantee is a (i) legal, valid and binding obligation of the Guarantors and
(ii) enforceable in accordance with its respective terms against the
Guarantors subject to the Bankruptcy and Equity Exception. There is no
default  under the Parent Guarantee by the Guarantors, and no event has
occurred that with the lapse of time or the giving of notice or both would
constitute a default thereunder by the Guarantors.

 


 

 

Section 4.15. _No Other Information_. Except for the representations and
warranties expressly set forth in this _Article IV_ , none of Parent, Merger
Sub or any of their respective stockholders,  Subsidiaries, directors,
employees, Affiliates, advisors, agents or any other Representatives or Person
on behalf of Parent and Merger Sub makes any express or implied representation
or warranty with respect to Parent or Merger Sub, its Subsidiaries  or their
respective businesses or with respect to any information provided, or made
available, to the Company or its Representatives or Affiliates in connection
with the transactions contemplated hereby, including the accuracy or
completeness  thereof.

 

 

36  

Section 4.16. _Access to Information; Disclaimer_. Parent and Merger Sub
acknowledge that the Company makes no representations or warranties as to any
matter whatsoever except as expressly set forth in _Article         
III_. The representations and warranties set forth in _Article III_ are made
solely by the Company, and no Representative of the Company shall have any
responsibility or liability related thereto. Each of Parent and Merger Sub
acknowledges  and agrees that it (a) has had an opportunity to discuss the
business of the Company and its Subsidiaries with the management of the
Company, (b) has had access to (i) the books and records of the Company and
its Subsidiaries,(ii) the documents  provided by the Company for purposes of
the transactions contemplated by this Agreement and (iii) the documents and
other materials requested or desired to be reviewed for the purposes of the
transactions contemplated by this Agreement, (c) has been  afforded the full
opportunity to ask questions of and receive answers from officers of the
Company and (d) has conducted its own independent investigation of the Company
and its Subsidiaries, their respective businesses and the transactions 
contemplated hereby, and has not relied on any representation, warranty
(express or implied) or other statement by any Person on behalf of the Company
or any of its Affiliates, other than the representations and warranties of the
Company expressly  contained in _Article III_ of this Agreement, and that all
other representations and warranties are specifically disclaimed. Without
limiting the foregoing, each of Parent and Merger Sub further acknowledges and
agrees that, except as expressly  set forth in _Article III_ , none of the
Company or any of its stockholders, directors, officers, employees,
Affiliates, advisors, agents or other Representatives has made any
representation or warranty, express or implied, concerning any  estimates,
projections, forecasts, business plans or other forward-looking information
regarding the Company, its Subsidiaries or their respective businesses and
operations. Each of Parent and Merger Sub hereby acknowledges that there are 
uncertainties inherent in attempting to develop such estimates, projections,
forecasts, business plans and other forward-looking information with which
Parent and Merger Sub are familiar, that Parent and Merger Sub are taking full
responsibility for  making their own evaluation of the adequacy and accuracy
of all estimates, projections, forecasts, business plans and other forward-
looking information furnished to them (including the reasonableness of the
assumptions underlying such estimates,  projections, forecasts, business
plans and other forward-looking information), and that Parent and Merger Sub
will have no claim against the Company or any of its stockholders, directors,
officers, employees, Affiliates, advisors, agents or other  Representatives
with respect thereto.

 


 

 

Section 4.17. _Portfolio_. Parent has provided the Company a list of entities
in which the Guarantors or any of their respective Affiliates has an interest
greater than five percent (5%).

 

ARTICLE V

 


 

 

CONDUCT OF BUSINESS PENDING THE MERGER

 


 

 

Section 5.1. _Conduct of Business of the Company Pending the Merger_. From the
date of this Agreement until the earlier of the Effective Time and the
termination of this Agreement in accordance with _Article         
VIII_ , except (i) as otherwise contemplated by this Agreement, (ii) as set
forth in _Section 5.1_ of the Company Disclosure Schedule, (iii) as required
by applicable Laws or (iv) unless Parent shall otherwise consent in writing
(which  consent shall not be unreasonably withheld, conditioned or delayed),
(a) the Company shall and shall cause its Subsidiaries to, conduct their
respective businesses in all material respects in the ordinary course of
business consistent with past  practice and the Company shall use its
commercially reasonable efforts to preserve substantially intact in all
material respects its business organization and material business
relationships, _provided_ , _however_ , that no action by the  Company or its
Subsidiaries with respect to matters specifically addressed by any provision
of _Section 5.1(b)_ shall be deemed a breach of this sentence unless such
action would constitute a breach of such provision of _Section 5.1(b)_ ,  and
(b) without limiting the foregoing, the Company shall not, and shall not
permit any of its Subsidiaries (including Clinic Joint Ventures, but only to
the extent the Company or its Subsidiaries has the ability, contractual or
otherwise, to  exercise control thereon or negative control rights to
prevent) to:

 

 

37   (i) amend the Certificate of Incorporation or the Bylaws or amend other
similar organizational documents of any of  its Subsidiaries or Clinic Joint
Ventures, except, in the case of Subsidiaries and Clinic Joint Ventures, for
amendments that would not be materially adverse to the Company or any
Subsidiary or Clinic Joint Venture or adversely impact the transactions 
contemplated hereby; 


 

  (ii) except with respect to transactions among wholly-owned Subsidiaries
of the Company, make any acquisition of  (whether by merger, consolidation or
acquisition of stock or substantially all of the assets or otherwise), or make
any investment in any interest in, any Person, in each case, except for (A)
purchases of equipment, inventory and other assets in the  ordinary course of
business consistent with past practice or pursuant to the express terms of
existing Contracts, (B) acquisitions or investments that do not exceed
$2,000,000 in the aggregate, (C) acquisitions of or investments in Clinic
Joint  Ventures that are not (x) in accordance with _Section 5.1(b)(x),_ (y)
set forth on Section 3.8(f) of the Company Disclosure Schedule or (y) in an
aggregate amount exceeding $5,000,000 and (D) acquisitions of equity interests
or investments in  existing Clinic Joint Ventures as required pursuant to the
terms of the governing documents of such Clinic Joint Ventures or the
acquisition of the interests of defaulting partners in any Clinic Joint
Venture; 


 

  (iii) issue, sell, grant, pledge, encumber or dispose of (or authorize the
issuance, sale, grant, pledge, encumbrance  or disposition of), any shares of
capital stock, ownership interests or voting securities, or any options,
warrants, convertible securities or other rights of any kind to acquire or
receive any shares of capital stock, any other ownership interests or  any
voting securities (including stock appreciation rights, phantom stock or
similar instruments), of the Company, any of its Subsidiaries or any Clinic
Joint Ventures (except (A) for the issuance of Shares upon the exercise,
vesting or settlement of  Options, Restricted Stock or RSU Awards outstanding
as of the date hereof, (B) for any issuance, sale or disposition to the
Company or a wholly-owned Subsidiary of the Company by any Subsidiary of the
Company, (C) the issuance of equity interests in  Clinic Joint Ventures as
required pursuant to the terms of the governing documents of such Clinic Joint
Ventures), or (D) for sales or dispositions with respect to any of the
Company's Subsidiaries or any Clinic Joint Venture to physicians or other 
providers at such Clinic Joint Ventures in the ordinary course of business
consistent with past practice so long as, in each case of this clause (D), the
Company maintains, directly or indirectly, a majority equity ownership
interest in such Subsidiary  or Clinic Joint Venture following such sale or
disposition; it being understood that the Company or any of its Subsidiaries
shall not sell or dispose of any equity interests in any Clinic Joint Venture
where it does not otherwise own the majority of  the outstanding equity
interests in such Clinic Joint Venture; 

 

38   (iv) amend the terms of any Joint Venture Agreement, other than (A) to
account for transactions permitted by _Section  5.1(b)(ii)_ or _Section
5.1(b)(iii)_ , (B) pursuant to applicable Law or regulatory safe harbors or
(C) for amendments that would not be materially adverse to the Company, its
Subsidiaries or any Clinic Joint Venture or adversely impact the 
transactions contemplated hereby. 


 

  (v) reclassify, combine, split, subdivide, redeem, purchase or otherwise
acquire any shares of capital stock,  ownership interests or voting
securities of the Company or any of its Subsidiaries (except (A) for the
acquisition of Shares tendered by directors or employees in connection with a
cashless or net settled exercise of Options or in order to pay the  exercise
price or Taxes in connection with the exercise, vesting or settlement of
Options, Restricted Stock or RSU Awards or (B) as expressly contemplated by
this Agreement); 


 

  (vi) other than Permitted Liens, create or incur any Lien on any material
assets of the Company or its Subsidiaries  (other than existing Liens on the
assets of Subsidiaries acquired following the date hereof or other than in
connection with indebtedness permitted to be incurred pursuant to _Section
5.1(b)(x)_ ); 


 

  (vii) sell or otherwise dispose of (whether by merger, consolidation or
disposition of stock or assets or otherwise)  the capital stock or other
equity interest in any Person or otherwise sell, assign, transfer, license,
abandon or dispose of any material assets, rights or properties of any Person
other than (A) as permitted pursuant to _Section 5.1(b)(iii)_ ,  (B) sales,
dispositions or licensing of equipment and/or inventory and other assets in
the ordinary course of business consistent with past practice or pursuant to
the express terms of existing Contracts or (C) other sales, assignments or
dispositions  of assets, rights or properties to the Company or of assets,
rights or properties with a value of less than $2,000,000 in the aggregate; 


 

  (viii) declare, set aside, make or pay any dividend or other distribution,
payable in cash, stock, property or  otherwise, with respect to any of its
capital stock or other equity interests (except for (A) any dividend or
distribution by a Subsidiary of the Company to the Company or to a wholly-
owned Subsidiary of the Company or (B) solely with respect to any  Clinic
Joint Venture, any cash dividend or cash distribution made to all equity
owners of such Clinic Joint Venture in proportion to their equity ownership
thereof as required pursuant to the terms of the governing documents of such
Clinic Joint  Ventures, as may be amended subject to _Section 5.1(a)(iv)_
above); 


 

  (ix) other than in the ordinary course of business consistent with past
practice or as required by Law, (A) modify,  terminate, assign (other than to
a Subsidiary of the Company or any Clinic Joint Venture) or amend in any
material respect any Material Contract or (B) enter into a new Contract that,
if entered into prior to the date of this Agreement, would have been  a
Material Contract (other than as permitted pursuant to _Section 5.1(b)(x)_ );
provided, that the Company and its Subsidiaries shall not take the actions set
forth in item 1 of _Section 5.1(b)(ix)_ of the Company Disclosure Schedules; 

 

39   (x) except for (A) revolver borrowings and/or letters of credit under the
Company's and its Subsidiaries' Credit  Facilities in an amount not to exceed
the sum of $2,000,000 plus the fees, costs and expenses incurred, or to be
incurred, by the Company and its Subsidiaries in connection with the
transactions contemplated hereby and the matters set forth in Section 
5.1(b)(x)(A) of the Company Disclosure Schedule, (B) the item set forth in
Section 5.1(b)(x)(B) of the Company Disclosure Schedule, (C) intercompany
loans between the Company and any of its Subsidiaries or between any
Subsidiaries incurred in the  ordinary course of business consistent with
past practice, (D) loans between the Company and any of its Subsidiaries, on
the one hand, and any Clinic Joint Venture, on the other hand, in the ordinary
course consistent with past practice or (E) the  refinancing of any
indebtedness outstanding as of the date hereof for a principal amount that is
equal to or less than the principal amount of such indebtedness outstanding as
of the date hereof, (i) create or incur indebtedness in excess of $4,000,000 
in the aggregate or (ii) modify in any material respect in a manner adverse to
the Company the terms of or extend the maturity of, any such indebtedness, or
assume, guarantee or endorse the obligations of any Person (other than a
Subsidiary of the  Company or a Clinic Joint Venture), in each case, in
excess of $1,000,000 in the aggregate; 


 

  (xi) except as required pursuant to the terms of any Company Plan, (A)
increase the compensation or benefits of any  of its directors, officers or
other employees other than in the ordinary course of business consistent with
past practice, (B) grant any severance or termination pay to any of its
directors, officers or other employees not provided for under any  Company
Plan, other than in the ordinary course of business consistent with past
practice, (C) enter into any employment, consulting or severance agreement or
arrangement with any of its directors, officers or other employees that
provides for annual  expected payments of greater than $200,000, (D) take any
action to accelerate the vesting or payment, or the funding of any payment or
benefit under, any Company Plan, (E) establish, adopt, enter into, modify or
amend in any material respect or  terminate any Company Plan, except as would
not materially increase the costs to the Company or (F) hire or terminate the
employment or services of any employee with annual expected compensation of
greater than $200,000, other than a replacement hiring  or a termination for
cause or due to permanent disability; 


 

  (xii) make any material change in the financial accounting policies or
procedures used by the Company or any of its  Subsidiaries or any of the
methods of reporting income, deductions or other items for financial
accounting purposes used by the Company or any of its Subsidiaries, except as
required by GAAP or applicable Law; 


 

  (xiii) other than in the ordinary course of business or as required by
applicable Law or GAAP, (A) make or change any  material Tax election, (B)
settle, consent to or compromise any material Tax claim or assessment, (C)
surrender any material claim for a refund of Taxes, (D) enter into any
material closing agreement with respect to material Taxes with a Taxing 
Authority, or (E) amend any material Tax Return, in the case of each of (A),
(B), (D) and (E), that would materially increase the Taxes payable by the
Company and its Subsidiaries; 

 

40   (xiv) other than as required by applicable Law, enter into or amend in any
material respect any material collective  bargaining agreement with any labor
organization representing any Company Employees; 


 

  (xv) settle or compromise any pending or threatened Proceeding, other than
settlements or compromises of Proceedings  that involve only the payment by
the Company or its Subsidiaries of monetary damages not in excess of
$1,000,000 individually or $3,000,000 in the aggregate, in either case in
excess of amounts paid by an insurer, it being understood that no 
Transaction Litigation shall be settled or compromised other than in
accordance with _Section 6.10_ ; 


 

  (xvi) implement any "mass layoffs" or "plant closings" that would
reasonably be expected to trigger notification  requirements pursuant to the
WARN Act (as such terms are defined by the WARN Act); 


 

  (xvii) other than as contemplated by the capital budget of the Company set
forth on _Section 5.1(b)(xvii)_ of the  Company Disclosure Schedules, make
any capital expenditures that exceed $5,000,000 in the aggregate; 


 

  (xviii) adopt a rights plan, "poison pill" or similar agreement that is,
or at the Effective Time will be, applicable to  Parent and its controlled
affiliates in connection with this Agreement or the Merger; 


 

  (xix) enter into a plan of complete or partial liquidation, dissolution,
merger, consolidation or recapitalization of  the Company or enter into a new
line of business; 


 

  (xx) engage in any transaction with, or enter into any agreement,
arrangement or understanding with, any Affiliate of  the Company or other
Person covered by Item 404 of Regulation S-K promulgated by the SEC that would
be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated
by the SEC; 


 

  (xxi) fail to maintain in full force and effect material insurance
policies or comparative replacement policies  covering the Company and its
Subsidiaries and their respective properties, assets and businesses in a form
and amount consistent with past practice; or 


 

  (xxii) agree, authorize or commit to take any of the foregoing actions
prohibited by this _Section 5.1(b)_. 


 

 

Notwithstanding anything to the contrary in this Agreement: (i) any action
taken, or omitted to be taken, by the Company or any of its Subsidiaries
pursuant to any applicable Law or any other directive, pronouncement or 
guideline issued by a Governmental Entity or industry group providing for
business closures, "sheltering-in-place" or other restrictions that relates
to, or arises out of, any pandemic (including COVID-19), epidemic or disease
outbreak shall in no  event be deemed to constitute a breach of this _Section
5.1_ and shall be deemed to be in the ordinary course of business consistent
with past practices for all purposes under this Agreement; and (ii) any action
taken, or omitted to be taken,  by the Company of any of its Subsidiaries
that may be reasonably necessary to protect health and safety as a result of
any pandemic (including COVID-19), epidemic or disease outbreak, in each case
as determined by the Company and its Subsidiaries in  their sole discretion
and that is reasonable in light of the applicable circumstances, shall in no
event be deemed to constitute a breach of this _Section 5.1_ and shall be
deemed to be in the ordinary course of business consistent with past 
practices for all purposes under this Agreement.

 

 

41   Section 5.2. _Conduct of Business of Parent and Merger Sub Pending the
Merger; Parent Vote_. 


 

  (a) Each of Parent and Merger Sub agrees that, between the date of  this
Agreement and the earlier of the Effective Time and the termination of this
Agreement in accordance with _Article VIII_ , it shall not, and it shall cause
each of its Affiliates not to, directly or indirectly: 


 

  (i) take any action  (including any action with respect to a third party)
that would, or would reasonably be expected to, individually or in the
aggregate, prevent, delay or impede the consummation of the Merger or the
other transactions contemplated by this Agreement or  their respective
ability to satisfy their obligations hereunder including, for the avoidance of
doubt, any action that could reasonably be expected to delay or prevent the
satisfaction of the conditions to the Closing set forth in _Sections 7.1(b)_
,  _7.1(c)_ and _7.2(e)_ or the payment of the aggregate Per Share Merger
Consideration; 


 

  (ii) amend, modify, supplement or waive any rights under the Subsequent
Transaction Agreement or any other Contract,  agreement or arrangement of the
type described in _Section 4.6_ without the prior written consent of the
Company (not to be unreasonably withheld or delayed), other than (x) to the
extent necessary for Parent to comply with its obligations  pursuant to
_Section 6.4(d)_ or (y) any amendment, modification or supplement to any
agreement with a third party that has agreed to provide equity capital to
Parent to finance in whole or in part the transactions contemplated hereby
(excluding  the Equity Commitment Letters and the Parent Guarantee) that
would not, or would not reasonably be expected to, individually or in the
aggregate, (1) delay the consummation of the Merger or the other transactions
contemplated by this Agreement or (2)  otherwise be adverse to the interests
of the Company (or any of its Subsidiaries) or the stockholders of the
Company; or 


 

  (iii) enter into any Prohibited Agreement not set forth on _Section 4.6_
of the Parent Disclosure Schedule; _provided_   that, if any Prohibited
Agreement is entered into in violation of this _Section 5.2(a)(ii)_ , then
each of Parent and Merger Sub shall, and shall cause each of its Affiliates
to, immediately terminate such Prohibited Agreement. 


 

  (b) Parent shall, immediately following execution of this  Agreement,
deliver to the Company evidence of its vote or action by written consent, in
its capacity as sole stockholder of Merger Sub, approving and adopting this
Agreement in accordance with the DGCL and the certificate of incorporation and
bylaws of  Merger Sub. 


 

 

Section 5.3. _No Control of Other Party 's Business_. Nothing contained in
this Agreement shall give Parent or Merger Sub, directly or indirectly, the
right to control or direct the Company's or its  Subsidiaries' operations
prior to the Effective Time, and nothing contained in this Agreement shall
give the Company, directly or indirectly, the right to control or direct
Parent's or its Subsidiaries' operations prior to the Effective Time. Prior 
to the Effective Time, each of the Company and Parent shall exercise,
consistent with the terms and conditions of this Agreement, complete control
and supervision over its and its Subsidiaries' respective operations.

 

 

42  

ARTICLE VI

 


 

 

ADDITIONAL AGREEMENTS

 


 

 

Section 6.1. _Acquisition Proposals_.

 


 

  (a) Notwithstanding anything to the contrary contained in this 
Agreement, during the period beginning on the date of this Agreement and
continuing until 11:59 p.m. (New York City time) on November 10, 2020 (the "
_No-Shop Period Start Date_ "), the Company and its Subsidiaries and their
respective directors,  officers, employees, investment bankers, attorneys,
accountants and other advisors or representatives (collectively, "
_Representatives_ ") shall have the right to (i) initiate, solicit, facilitate
and encourage any inquiry or the making of any  proposal or offer that
constitutes, could constitute, or could reasonably be expected to lead to an
Acquisition Proposal, including by providing information (including non-public
information and data) regarding, and affording access to the business, 
properties, assets, books, records and personnel of, the Company and its
Subsidiaries to any Person (and its Representatives, including potential
financing sources) subject to the entry into, and in accordance with, an
Acceptable Confidentiality  Agreement; provided that the Company shall make
available to Parent and Merger Sub any non-public information or data
concerning the Company or its Subsidiaries that is provided to any Person
given such access that was not previously made available to  Parent or Merger
Sub promptly (and in any event within forty-eight (48) hours) after the time
it is furnished to such Person, and (ii) engage in, enter into or otherwise
participate in any discussions or negotiations with any Persons (and their 
respective Representatives, including potential financing sources) with
respect to any Acquisition Proposals (or inquiries, proposals or offers or
other efforts that constitute, could constitute, or could reasonably be
expected to lead to an  Acquisition Proposal, including any Person that has
informed the Company or its Representatives of an intention to make or has
publicly announced an intention to make an Acquisition Proposal) and cooperate
with or assist or participate in or facilitate  or encourage any such
inquiries, proposals, offers, discussions or negotiations or any effort or
attempt to make any Acquisition Proposals, including granting a waiver,
amendment or release under any confidentiality or pre-existing standstill or 
similar provision with respect to the Company or its Subsidiaries; _provided_
, that the Company and its Subsidiaries will not pay, agree to pay or cause to
be paid or reimburse, agree to reimburse or cause to be reimbursed, the
expenses of any  such Person in connection with any Acquisition Proposals or
any inquiries, discussions or requests with respect to or the making of any
proposal or offer that constitutes or would reasonably be expected to lead to
an Acquisition Proposal. No later than  forty-eight (48) hours after the No-
Shop Period Start Date, the Company shall notify Parent in writing of the
number of parties that submitted an Acquisition Proposal after the date of
this Agreement and prior to the No-Shop Period Start Date, which  notice
shall include a summary of all material terms of any pending Acquisition
Proposals (but not, for the avoidance of doubt, the identity of the parties
that submitted such Acquisition Proposals) that were made in writing by any
Excluded Party or  any other Acquisition Proposal which the Board of
Directors (or a duly authorized committee thereof) determined in good faith,
after consultation with its financial advisor and outside legal counsel,
warranted the Board of Directors' (or such duly  authorize committee's)
further discussion. 

 

43   (b) Except as it may relate to any Excluded Party or as permitted  by
this _Section 6.1_ , including the last sentence of this _Section 6.1(b)_ ,
from 11:59 p.m. (New York City time) on the No-Shop Period Start Date until
the Effective Time or, if earlier, the termination of this Agreement in
accordance with  _Section 8.1_ , the Company shall not, shall cause its
Subsidiaries not to and shall direct the Representatives of the Company and
its Subsidiaries not to, (i) initiate, solicit, knowingly facilitate or
knowingly encourage any inquiries or  discussions with respect to, or the
making of, any proposal or offer that constitutes or would be reasonably
likely to result in an Acquisition Proposal, (ii) engage in, enter into,
continue or otherwise participate in any discussions or negotiations 
concerning, or provide access to its business, properties, assets, books and
records or any non-public information or data to, any Person relating to an
Acquisition Proposal, (iii) approve, endorse, declare advisable or recommend,
or propose publicly  to approve, endorse, declare advisable or recommend, any
Acquisition Proposal, (iv) execute or enter into, any merger agreement,
acquisition agreement or similar agreement or binding letter of intent, term
sheet, or similar binding agreement or  understanding (other than an
Acceptable Confidentiality Agreement) with respect to an Acquisition Proposal
or (v) authorize, commit to, agree or publicly propose to do any of the
foregoing; _provided_ that it is understood and agreed that any 
determination or action by the Board of Directors (or a duly authorized
committee thereof) permitted under _Section 6.1(c)_ or _Section 6.1(e)_ shall
not be deemed to be a breach or violation of this _Section 6.1(b)_ or, in the
case  of _Section 6.1(c)_ , give Parent a right to terminate this Agreement
pursuant to _Section 8.1(e)(ii)_. Except as it may relate to any Excluded
Party, the Company also agrees that immediately following 11:59 p.m. (New York
City time) on the  No-Shop Period Start Date it shall cease, and shall cause
its Subsidiaries to cease, and shall direct the Representatives of the Company
and its Subsidiaries to cease, any solicitations, discussions or negotiations
with any Person (other than the  Parties and their respective Representatives
and the parties to the Subsequent Transaction and their respective
Representatives) in connection with any Acquisition Proposal. Except as it may
relate to an Excluded Party, the Company also agrees that  following the No-
Shop Period Start Date it will promptly (and in any event within three (3)
Business Days thereof) request each Person (other than the Parties and their
respective Representatives) that has executed a confidentiality agreement in 
connection with its consideration of a potential transaction involving the
acquisition of the Company to return or destroy all confidential information
furnished to such Person by or on behalf of the Company or any of its
Subsidiaries. Except as it  may relate to an Excluded Party, the Company
shall promptly (and in any event within forty-eight (48) hours thereof) notify
in writing Parent of the receipt of any Acquisition Proposal after the No-Shop
Period Start Date, which notice shall include a  copy of any such Acquisition
Proposal made in writing and any other written terms and proposals provided
(including financing commitments) to the Company or its Representatives and a
written summary of material terms and conditions of any such  Acquisition
Proposal not made in writing. Thereafter, the Company shall keep Parent
reasonably informed of the status and material terms of any such Acquisition
Proposal including any material changes in respect of any such Acquisition
Proposal and  the material terms thereof. Notwithstanding anything to the
contrary herein, the Company may grant a waiver, amendment or release under
any confidentiality or standstill agreement to allow for a confidential
Acquisition Proposal to be made to the  Company or the Board of Directors (or
a duly authorized committee thereof) so long as the Company promptly (and in
any event within forty-eight (48) hours thereof) notifies Parent thereof after
granting any such waiver, amendment or release and, if  requested by Parent,
grants Parent an equivalent waiver, amendment or release under the
Confidentiality Agreement, if applicable. For the avoidance of doubt,
notwithstanding the commencement of the No-Shop Period Start Date, until the
receipt of the  Company Requisite Vote, the Company, its Subsidiaries and
their Representatives may continue to engage in the activities described in
_Section 6.1(a)_ with respect to any Excluded Party so long as such Excluded
Party remains an Excluded Party,  including with respect to any amended or
modified Acquisition Proposal submitted by any Excluded Party following the
No-Shop Period Start Date, and the restrictions in this _Section 6.1(b)_ shall
not apply with respect thereto. 

 

44   (c) Notwithstanding anything to the contrary in _Section 6.3_   or
_Section 6.1(b)_ , and without limiting _Section 6.1(a)_ and _Section 6.1(b)_
, nothing contained in this Agreement shall prevent the Company or its Board
of Directors (or a duly authorized committee thereof) from: 


 

  (i) taking and disclosing to its stockholders a position in accordance
with Rule 14d-9 or Rule 14e-2(a) promulgated  under the Exchange Act (or any
substantially similar communication to stockholders in connection with the
making or amendment of a tender offer or exchange offer), making any "stop-
look-and-listen" communication to the stockholders of the Company  pursuant
to Rule 14d-9(f) under the Exchange Act (or any substantially similar
communications to the stockholders of the Company) or from making any legally
required disclosure to stockholders with regard to the transactions
contemplated by this  Agreement or an Acquisition Proposal; provided that
neither the Company nor the Board of Directors (or a duly authorized committee
thereof) will make a Change of Recommendation in respect of an Acquisition
Proposal unless permitted by _Section  6.1(e)_ ; 


 

  (ii) prior to obtaining the Company Requisite Vote, contacting and
engaging in discussions with any Person or group  and their respective
Representatives who has made an Acquisition Proposal that was not solicited in
material breach of _Section 6.1(b)_ , solely for the purpose of clarifying
such Acquisition Proposal and the terms thereof; 


 

  (iii) prior to obtaining the Company Requisite Vote, providing access to
the Company's or any of its Subsidiaries'  business, properties, assets,
books and records, and providing information or data in response to a request
therefor by a Person or group who has made a bona fide written Acquisition
Proposal that was not solicited in material breach of _Section  6.1(b)_ if
the Board of Directors (or a duly authorized committee thereof) (A) shall have
determined in good faith, after consultation with its outside legal counsel
and financial advisors, that such Acquisition Proposal constitutes or could 
reasonably be expected to constitute, result in or lead to a Superior Proposal
and (B) has received from the Person so requesting such information an
executed Acceptable Confidentiality Agreement; provided that the Company
furnishes any non-public  information provided to the maker of the
Acquisition Proposal only pursuant to an executed Acceptable Confidentiality
Agreement and such furnished information is delivered to Parent promptly (and
in any event within forty-eight (48) hours) after  furnishing to such Person
(to the extent such information has not been previously furnished or made
available by the Company to Parent); or 

 

45   (iv) prior to obtaining the Company Requisite Vote, contacting and
participating and engaging in any negotiations or  discussions with any
Person or group (and their respective Representatives) who has made a bona
fide written Acquisition Proposal that was not solicited in material breach of
_Section 6.1(b)_ (which negotiations or discussions need not be solely  for
clarification purposes, and may include the solicitation of a revised
Acquisition Proposal) if the Board of Directors (or a duly authorized
committee thereof) shall have determined in good faith, after consultation
with its outside legal counsel  and financial advisors, that such Acquisition
Proposal constitutes or could reasonably be expected to constitute, result in
or lead to a Superior Proposal; 


 

  (v) prior to obtaining the Company Requisite Vote, making a Change of
Recommendation (to the extent permitted by _Section  6.1(e)_ ); or 


 

  (vi) resolving or agreeing to take any of the foregoing actions, to the
extent such actions would be permitted by the  foregoing _clauses (i)_
through _(v)_. 


 

  (d) Except as otherwise provided in _Section 6.1(c)_ or as  contemplated
by _Section 6.1(e)_ , the Board of Directors and any committee thereof shall
not (i) (A) withdraw or rescind (or change or qualify, in a manner materially
adverse to Parent or Merger Sub), or publicly propose to withdraw or rescind 
(or change or qualify, in a manner materially adverse to Parent or Merger Sub)
the Recommendation in a manner materially adverse to Parent, (B) fail to
include the Recommendation in the Proxy Statement, (C) approve, adopt or
recommend or publicly  propose to approve, adopt or recommend, any
Acquisition Proposal or (D) fail to announce publicly, within ten (10)
Business Days after a tender offer or exchange offer relating to any
securities of the Company has been commenced, that the Board of  Directors
(or a duly authorized committee thereof) recommends rejection of such tender
or exchange offer (each such action set forth in clauses (A) through (D) above
being a " _Change of Recommendation "_) or (ii) authorize, cause or permit
the  Company to enter into a merger agreement, binding letter of intent,
share purchase agreement, asset purchase agreement, share exchange agreement
or other similar binding agreement (other than any Acceptable Confidentiality
Agreement) relating to any  Acquisition Proposal or recommend any tender
offer providing for, with respect to, or in connection with any Acquisition
Proposal. 

 

46   (e) Notwithstanding anything in this _Section 6.1_ to the  contrary, at
any time prior to obtaining the Company Requisite Vote, (i) the Board of
Directors (or a duly authorized committee thereof) may effect a Change of
Recommendation in response to an Intervening Event or (ii) if the Board of
Directors (or a  duly authorized committee thereof) determines in good faith,
after consultation with its financial advisors and outside legal counsel, in
response to an Acquisition Proposal (whether before or after the No-Shop
Period Start Date) that did not result  from a material breach of _Section
6.1(b)_ , that such proposal constitutes a Superior Proposal and such
Acquisition Proposal is not withdrawn as of such time, the Board of Directors
(or a duly authorized committee thereof) may (1) effect a Change  of
Recommendation on account of such Intervening Event or Superior Proposal or
fail to include the Recommendation in the Proxy Statement and/or (2) terminate
this Agreement pursuant to _Section 8.1(d)(ii)_ to enter into a definitive
agreement  with respect to such Superior Proposal; _provided_ that, (A) prior
to or simultaneously with any such termination by the Company, the Company
pays to Parent any Company Termination Fee required to be paid pursuant to
_Section 8.2(b)(i)_ ,  subject to and in accordance with the terms of
_Section 8.2(b)(i)_ , and (B) after consultation with its financial advisors
and outside legal counsel, the Board of Directors (or a duly authorized
committee thereof) determines that the failure to  make a Change of
Recommendation or to terminate this Agreement pursuant to _Section 8.1(d)(ii)_
would be reasonably likely to be inconsistent with its fiduciary duties under
applicable Law; _provided_ , _further_ , that the Company will  not be
entitled to effect such Change of Recommendation or terminate this Agreement
in accordance with _Section 8.1(d)(ii)_ unless (x) the Company delivers to
Parent a written notice (a " _Company Notice_ "), at least four (4) Business
Days  before the Board of Directors (or a duly authorized committee thereof)
takes such action, advising Parent that the Board of Directors (or a duly
authorized committee thereof) proposes to take such action and containing the
material details of such  Intervening Event or the material terms and
conditions of the Superior Proposal (and shall have provided to Parent a copy
of the available proposed transaction agreement to be entered into in respect
of such Superior Proposal), as applicable, that is  the basis of the proposed
action of the Board of Directors (or a duly authorized committee thereof) and
(y) at or after 5:00 p.m., New York City time, on the fourth (4th)  Business
Day immediately following the day on which the Company delivered the Company
Notice (such period from the time the Company Notice is provided until 5:00
p.m. New York City time on the fourth (4th) Business Day immediately following
the day on which the Company delivered the Company Notice, the " _Notice
Period_ "), the Board of Directors (or a duly authorized committee thereof)
shall have determined in good  faith (after consultation with its outside
counsel and financial advisors and taking into account any changes to the
terms of this Agreement agreed to in writing by Parent during the Notice
Period) that the failure to make a Change of Recommendation or  to terminate
this Agreement pursuant to _Section 8.1(d)(ii)_ would be reasonably likely to
be inconsistent with its fiduciary duties under applicable Law, or in the case
of an Acquisition Proposal, such Acquisition Proposal continues to 
constitute a Superior Proposal; _provided_ , _however_ , that any amendment to
the financial terms or other material terms or conditions (including the
provision of financing) of such Acquisition Proposal (which, after taking into
account any  changes offered and agreed to in writing by Parent during the
Notice Period, ceased to constitute a Superior Proposal) that would reasonably
be likely to result in such Acquisition Proposal again constituting a Superior
Proposal, shall require a new  Company Notice and an additional two (2)
Business Day Notice Period. If requested by Parent, the Company will, and will
cause its Subsidiaries and direct its or their Representatives to, during the
Notice Period, engage in good faith negotiations with  Parent and its
Representatives to make such adjustments to the terms and conditions of this
Agreement so that, (A) in the case of an Acquisition Proposal, such
Acquisition Proposal would cease to constitute a Superior Proposal, and (B) in
the case of  an Intervening Event, the failure of the Board of Directors (or
a duly authorized committee thereof) to make a Change of Recommendation would
not be reasonably likely to be inconsistent with its fiduciary duties under
applicable Law. 


 

  (f) For the avoidance of doubt and notwithstanding anything to the 
contrary set forth in this Agreement, each of Parent and Merger Sub
acknowledges and agrees that any Acquisition Proposal may be evaluated by an
independent committee of disinterested members of the Board of Directors and
each provision of this _Section          6.1_ that is applicable to
the Board of Directors and its financial advisors and outside legal counsel
with respect to the evaluation of an Acquisition Proposal shall apply to such
committee's (and it's financial advisors' and legal counsel's)  evaluation of
such Acquisition Proposal, as applicable. 

 

47   (g) For purposes of this Agreement, the following terms shall have  the
meanings assigned below: 


 

  (i) " _Acquisition Proposal_ " means any proposal or offer from any Person
or group of Persons (other than  Parent, Merger Sub or their respective
Affiliates) relating to (A) any direct or indirect acquisition, purchase,
sale, lease or other disposition of assets of the Company or its Subsidiaries,
in one transaction or a series of related transactions, that  constitutes 15%
or more of the consolidated revenues, net income or assets of the Company and
its Subsidiaries, taken as a whole, (B) any issuance of Shares representing
15% or more of the total voting power of the equity securities of the Company,
(C)  any tender offer or exchange offer that if consummated would result in
any Person beneficially owning 15% or more of the total voting power of the
equity securities of the Company, (D) any merger, reorganization,
consolidation, share exchange, business  combination, recapitalization,
liquidation, dissolution or similar business combination transaction involving
the equity of the Company, or (E) any combination of the foregoing. 


 

  (ii) " _Excluded Party_ " means any Person or group of Persons from whom
the Company, the Board of Directors (or  a duly authorized committee thereof)
or any of their respective Representatives has received a bona fide written
Acquisition Proposal after the execution of this Agreement and prior to the
No-Shop Period Start Date that the Board of Directors (or a  duly authorized
committee thereof) determines in good faith (such determination to be made
prior to the No-Shop Period Start Date and after consultation with its outside
counsel and financial advisor) constitutes or is reasonably likely to result
in a  Superior Proposal; provided that any Person shall immediately and
irrevocably cease to be an Excluded Party (and the provisions of this
Agreement applicable to Excluded Parties shall cease to apply with respect to
such Person) if the Acquisition  Proposal submitted by such Person is
withdrawn or terminated (it being understood that a modification of an
Acquisition Proposal submitted by such Person or group of Persons shall not,
in and of itself, be deemed to be a withdrawal or termination of an 
Acquisition Proposal submitted by such Person or group of Persons). 


 

  (iii) " _Intervening Event_ " means any material event, occurrence,
development or change in circumstances with  respect to the Company and its
Subsidiaries, taken as a whole, which (A) (i) was unknown to, and was not
reasonably foreseeable by, the Board of Directors (or a duly authorized
committee thereof) as of the date hereof, or (ii) if known to, or  reasonably
foreseeable by, the Board of Directors (or a duly authorized committee
thereof) as of the date hereof, the material consequences of which were not
known and reasonably foreseeable to the Board of Directors (or a duly
authorized committee  thereof) as of the date hereof and (B) becomes known to
or by the Board of Directors (or a duly authorized committee thereof) prior to
the time the Company Requisite Vote is obtained; _provided_ , _however_ , that
none of the following will  alone constitute an Intervening Event: changes in
the market price or trading volume of the Shares or the fact that the Company
meets or exceeds internal or published projections, budgets, forecasts or
estimates of revenues, earnings or other financial  results for any period
(provided, however, that the underlying causes of such changes or fact shall
not be excluded by the foregoing). 

 

48   (iv) " _Superior Proposal_ " means a bona fide written Acquisition
Proposal (except that the references therein to  "15%" shall be replaced by
"50%"), in each case, that the Board of Directors (or a duly authorized
committee thereof) in good faith determines, after consultation with its
outside legal counsel and financial advisor, after taking into account all
such  factors and matters deemed relevant in good faith by the Board of
Directors (or a duly authorized committee thereof), including legal, financial
(including the financing terms of any such proposal), regulatory (including
antitrust), timing or other  aspects of such proposal or offer (including any
break-up fee, expense reimbursement provisions, and conditions to
consummation) and the transactions contemplated hereby and after taking into
account any changes to the terms of this Agreement proposed  in writing by
Parent in response to such Superior Proposal pursuant to, and in accordance
with, _Section 6.1(e)_ , to be more favorable from a financial point of view
to the stockholders of the Company than the transactions contemplated
hereby. 


 

 

Section 6.2. _Proxy Statement_. Unless the Board of Directors (or a duly
authorized committee thereof) has made a Change of Recommendation, as promptly
as reasonably practicable after the date hereof,  assuming timely performance
by Parent and Merger Sub of their obligations under this _Section 6.2_ , the
Company shall prepare and file with the SEC the Proxy Statement, and each of
the Company and Parent shall, or shall cause their respective  Affiliates to,
prepare and file with the SEC all other documents required by the Exchange Act
in connection with the Merger and the other transactions contemplated hereby,
and Parent and the Company will cooperate with each other with the
preparation  of the Proxy Statement and any such other filings; _provided_
that in no event shall the Company be required to file with the SEC the Proxy
Statement prior to the No-Shop Period Start Date. Each of Parent and Merger
Sub will, as promptly as  possible, furnish to the Company the information
relating to it required by the Exchange Act and the rules and regulations
promulgated thereunder to be set forth in the Proxy Statement. Unless the
Board of Directors (or a duly authorized committee  thereof) has made a
Change of Recommendation, the Company shall use its reasonable best efforts to
resolve all SEC comments with respect to the Proxy Statement promptly after
receipt thereof. Each of Parent, Merger Sub and the Company agree to  correct
any information provided by it for use in the Proxy Statement which shall have
become false or misleading and the Company and Parent shall cooperate in the
prompt filing with the SEC and dissemination to the stockholders of the
Company of any  necessary amendment of, or supplement to, the Proxy Statement
to the extent required by applicable Law. The Company shall promptly notify
Parent and Merger Sub of the receipt of any comments from the SEC with respect
to the Proxy Statement and any  request by the SEC for any amendment to the
Proxy Statement or for additional information and shall promptly provide to
the Parent copies of all written correspondence with the SEC with respect to
the Proxy Statement or the transactions contemplated  hereby. Subject to
applicable Law, prior to filing or mailing the Proxy Statement (or any
amendment or supplement thereto) or responding to any comments of the SEC with
respect thereto, the Company shall (unless and until a Change of
Recommendation  has occurred or in connection with the matters described in
_Section 6.1_ ) provide Parent with a reasonable opportunity to review and to
propose reasonable comments on such document or response and shall consider in
good faith comments  reasonably proposed by Parent; _provided_ , _however_ ,
that the Company may amend or supplement the Proxy Statement without the
review or comment of Parent in the event of a Change of Recommendation. The
Company shall use its reasonable  best efforts to cause the definitive Proxy
Statement to be mailed as promptly as reasonably practicable, _provided_ ,
that the Company shall not be required to mail the Proxy Statement prior to
the date that is ten (10) Business Days after the  later of (i) the date the
SEC staff confirms that it has no further comments thereon or that it will not
review the Proxy Statement and (ii) the No-Shop Period Start Date. All
documents that the Company is responsible for filing with the SEC in 
connection with the Merger will comply as to form and substance in all
material respects with the applicable requirements of the Exchange Act.

 

 

49  

Section 6.3. _Stockholders Meeting_. Unless the Board of Directors (or a duly
authorized committee thereof) has made a Change of Recommendation, the
Company, acting through its Board of Directors (or a  duly authorized
committee thereof), shall promptly (but no later than ten (10) Business Days
after the later of (a) confirmation by the SEC that the SEC has no further
comments on the Proxy Statement or that it will not review the Proxy Statement
and  (b) the No-Shop Period Start Date, subject to the last sentence of this
_Section 6.3_ ) take all reasonable action required under the DGCL, the
Certificate of Incorporation, the Bylaws and the applicable requirements of
the NYSE necessary to  duly call, give notice of, convene and hold a meeting
of its stockholders for the purpose of adopting this Agreement (including any
adjournment or postponement thereof permitted by this Agreement, the "
_Stockholders Meeting_ "); _provided_   that the Company may postpone, recess
or adjourn such meeting for up to thirty (30) days (i) to the extent required
by Law, (ii) if the Company has notified Parent pursuant to _Section 6.1(e)_
that the Board of Directors (or a duly authorized  committee thereof) intends
to effect a Change of Recommendation or to terminate this Agreement pursuant
to _Section 8.1(d)(ii)_ , (iii) to allow reasonable additional time to solicit
additional proxies to the extent the Company reasonably  believes necessary
in order to obtain the Company Requisite Vote, (iv) if as of the time for
which the Stockholders Meeting is originally scheduled (as set forth in the
Proxy Statement) there are insufficient Shares represented (either in person
or  by proxy) and voting to constitute a quorum necessary to conduct the
business of the Stockholders Meeting or (v) to allow reasonable additional
time for the filing and dissemination of any supplemental or amended
disclosure which the Board of  Directors (or a duly authorized committee
thereof) has determined in good faith after consultation with outside counsel
is necessary under applicable Law or fiduciary duty for such supplemental or
amended disclosure to be disseminated and reviewed by  the Company's
stockholders prior to the Stockholders Meeting. The Company, acting through
its Board of Directors (or a duly authorized committee thereof), shall except
as permitted by _Section 6.1(e)_ , (a) include in the Proxy Statement the 
Recommendation and, subject to the consent of the Financial Advisor, the
written opinion of the Financial Advisor, dated as of the date hereof, as to
the fairness of the Per Share Merger Consideration from a financial point of
view and (b) use its  reasonable best efforts to obtain the Company Requisite
Vote; _provided_ that the Board of Directors (or a duly authorized committee
thereof) may make a Change of Recommendation in accordance with _Section
6.1(e)_ and, following such  Change of Recommendation, may fail to (i)
include in the Proxy Statement the Recommendation or (ii) use such reasonable
best efforts. The Company shall, upon reasonable request by Parent, keep
Parent informed with respect to proxy solicitation  results.

 


 

 

Notwithstanding anything to the contrary contained in this Agreement, the
Company shall not be required to hold the Stockholders Meeting if this
Agreement is terminated.

 

 

50  

Section 6.4. _Regulatory Approvals_.

 


 

  (a) Notwithstanding anything to the contrary contained in this 
Agreement, each Party will (and, in the case of Parent, cause each of its
Subsidiaries and Affiliates (collectively, the " _Parent Group_ ") to) use its
best efforts to take, or cause to be taken, all actions and to do, or cause to
be done, all  things necessary, proper or advisable under applicable Laws and
regulations to consummate the Merger and the other transactions contemplated
by this Agreement. In furtherance and not in limitation of the foregoing, each
Party hereto agrees to (i) as  promptly as practicable and in any event
within seven (7) Business Days after the date hereof, file or cause to be
filed any and all required notifications, applications and other filings with
respect to each of the Healthcare Regulatory Approvals, and  to supply as
promptly as reasonably practicable any additional information and documentary
material that may be requested in connection with obtaining the Healthcare
Regulatory Approvals and to cooperate in all respects with each other in
connection in  connection with obtaining the Healthcare Regulatory Approvals
and (ii) make an appropriate filing of a Notification and Report Form pursuant
to the HSR Act with respect to the transactions contemplated hereby (each, an
" _HSR Filing_ ") as promptly  as practicable and in any event within five
(5) Business Days after the date hereof, and to supply as promptly as
reasonably practicable any additional information and documentary material
that may be requested pursuant to the HSR Act and to take any  and all other
actions necessary, proper or advisable to cause the expiration or termination
of the applicable waiting periods under the HSR Act as soon as practicable.
Parent shall provide to the Company copies of all documents that must be
submitted  to the FTC, the DOJ or any other Governmental Entity in connection
with Parent's HSR Filing, promptly (and, in any event, within one (1) Business
Day) after such documents are identified; _provided_ that, to the extent
appropriate, such documents  may be shared with the Company on an outside
counsel basis only. 


 

  (b) Each of Parent Group and Merger Sub, on the one hand, and the 
Company, on the other hand, shall, in connection with the efforts referenced
in _Section 6.4(a)_ to obtain all requisite approvals and authorizations or
expiration of waiting periods for the transactions contemplated by this
Agreement under the  HSR Act or any other Antitrust Law, use its best efforts
to (i) cooperate in all respects with each other in connection with any filing
or submission and in connection with any investigation or other inquiry,
including any Proceeding initiated by a  private party; (ii) subject to
applicable Law, furnish to the other Party as promptly as reasonably
practicable all information required for any application or other filing to be
made by the other Party pursuant to any applicable Law in connection with 
the transactions contemplated by this Agreement; (iii) promptly notify the
other Party of any communication received by such Party from, or given by such
Party to, the Federal Trade Commission (the " _FTC_ "), the Antitrust Division
of the  Department of Justice (the " _DOJ_ ") or any other U.S. or foreign
Governmental Entity and of any communication received or given in connection
with any Proceeding by a private Party, in each case regarding any of the
transactions contemplated  hereby or the Subsequent Transaction and, subject
to applicable Law, furnish the other Party promptly with copies of all
correspondence, filings (including Item 4(c) and Item 4(d) documents in
connection with the HSR Act filing) and communications  between them and the
FTC, the DOJ, or any other Governmental Entity with respect to the
transactions contemplated by this Agreement or, until the Closing Date, the
Subsequent Transaction; (iv) respond as promptly as reasonably practicable to
any  inquiries received from, and supply as promptly as reasonably
practicable any additional information or documentation that may be requested
by the DOJ, FTC, or by any other Governmental Entity in respect of such
registrations, declarations and filings  or such transactions; and (v) permit
the other Party to review in advance any substantive communication given by it
to, and consult with each other in advance, and consider in good faith the
other Party's reasonable comments in connection with, any  submission,
communication, meeting or conference with, the FTC, the DOJ or any other
Governmental Entity or, in connection with any Proceeding by a private party,
with any other Person; _provided_ , _however_ , that to the extent any of
the  documents or information provided pursuant to this _Section 6.4_ are
commercially or competitively sensitive, the Company, or Parent, as the case
may be, may satisfy its obligations by providing such documents or information
to the other Party's  outside counsel, with the understanding and agreement
that such counsel shall not share such documents and information with its
client in connection with or relating to the transactions contemplated by this
Agreement and, until the Closing Date, the  Subsequent Transaction;
_provided_ , _further_ , that materials may also be redacted (x) to remove
references concerning the valuation of the Company, (y) as necessary to comply
with contractual arrangements, and (z) as necessary to address  reasonable
attorney-client or other privilege or confidentiality concerns, to the extent
that that such attorney-client or other privilege or confidentiality concerns
are not governed by a common interest privilege or doctrine. For purposes of
this  Agreement, " _Antitrust Law_ " means the Sherman Antitrust Act of 1890,
the Clayton Antitrust Act of 1914, the HSR Act, the Federal Trade Commission
Act of 1914 and all other federal, state and foreign, if any, statutes, rules,
regulations, orders,  decrees, administrative and judicial doctrines and
other laws that are designed or intended to prohibit, restrict or regulate
actions having the purpose or effect of monopolization or restraint of trade
or lessening of competition through merger or  acquisition. 

 

51   (c) No Party shall independently participate in any substantive  meeting
or communication with any Governmental Entity in respect of any such filings,
investigation or other inquiry in connection with this Agreement or the
transactions contemplated by this Agreement or the Subsequent Transaction
without giving the  other Parties sufficient prior notice of the meeting or
communication and, to the extent permitted by such Governmental Entity, the
opportunity to attend and/or participate in such meeting or communication,
provided that, such notice and opportunity  obligations specifically relating
to any filings, investigation or other inquiry in connection with the
Subsequent Transaction shall continue only until the Closing Date. 


 

  (d) Notwithstanding anything to the contrary set forth in this 
Agreement, and in furtherance and not in limitation of the foregoing, Parent
shall, and shall cause its Affiliates and Subsidiaries to, take any and all
steps that are (i) necessary or (ii) identified or requested (whether formally
or informally) by  the FTC, the DOJ, or any Governmental Entity to (x)
resolve, avoid, or eliminate impediments or objections, if any, that may be
asserted with respect to the transactions contemplated by this Agreement or
the Subsequent Transaction under any Antitrust  Law or in connection with any
Healthcare Regulatory Approval or (y) avoid the entry of, effect the
dissolution of, and have vacated, lifted, reversed or overturned, any decree,
order or judgment that would prevent, prohibit, restrict or delay the 
consummation of the transactions contemplated by this Agreement, so as to
enable the Parties to close the contemplated transactions expeditiously (but
in no event later than the End Date). Without limiting the generality of the
foregoing, Parent  shall, and shall cause its Affiliates and Subsidiaries to,
(i) propose, negotiate, commit to and effect, by consent decree, hold separate
orders or otherwise, the sale, divesture, disposition, or license of any
assets, properties, facilities, clinics,  products, rights, services or
businesses of Parent, Parent's Subsidiaries, Parent's Affiliates, or the
Company or its Subsidiaries or any interest therein, or agree to any other
structural or conduct remedy, (ii) otherwise take or commit to take any 
actions that would limit Parent's, Parent's Subsidiaries, Parent's Affiliates,
or the Company's or its Subsidiaries' freedom of action with respect to, or
its or their ability to retain or sell any assets, properties, facilities,
clinics, products,  rights, services or businesses of Parent, Parent's
Affiliates, or the Company or its Subsidiaries or any interest or interests
therein, (iii) otherwise commit to take any actions that would limit Parent's,
Parent's Subsidiaries, or Parent's Affiliates  (or, with respect to any
period after the Closing Date, the Company's or its Subsidiaries') freedom of
action with respect to, or its or their ability to acquire, any assets,
properties, facilities, clinics, products, rights, services or businesses of 
any other entity or third party (other than the Company), including the
Subsequent Transaction Buyer; and (iv) modify, restructure, amend, terminate,
or revise, any agreement or arrangement entered into or proposed to be entered
into by Parent or  Parent's Affiliates or to which Parent or Parent's
Affiliates are a party, including with respect to the Subsequent Transaction
or any Financing, in connection with the transactions contemplated by this
Agreement; _provided_ , that the Parties  shall not be obligated to take any
action with respect to the Company the effectiveness of which is not
conditioned on the Closing occurring. For the avoidance of doubt, Parent's
obligations under this _Section 6.4(d)_ are an absolute commitment  not
subject to the best efforts applicable to the remainder of the obligations set
forth in this _Section 6.4_. 

 

52   (e) If on the date that is ninety (90) days after the date of this 
Agreement, the condition set forth in _Section 7.1(c)_ has not been satisfied,
Parent will terminate, or cause to be terminated, any agreement relating to
the Subsequent Transaction (including the Subsequent Transaction Agreement)
and any other  Prohibited Agreement (whether or not set forth on _Section
4.6_ of the Parent Disclosure Schedule). 


 

  (f) Parent shall not, and shall cause its Affiliates not to,  without the
prior written consent of the Company, which may be given or withheld in its
sole discretion, acquire or agree to acquire, transfer or sell, by merging
with or into or consolidating with, or by purchasing or selling a portion of
the assets  of or equity in, or by any other manner, any business or any
corporation, partnership, association or other business organization or
division thereof, or otherwise acquire or agree to acquire, sell or transfer
any assets (including dialysis clinics),  or take any other action (including
with respect to the Subsequent Transaction), if the entering into or amendment
or modification of a definitive agreement relating to, or the consummation of
such transaction, or the taking of any other action, would  reasonably be
expected to (or in the case of the Subsequent Transaction, could reasonably be
expected to) (i) impose any material delay in the obtaining of, or materially
increase the risk of not obtaining, any authorizations, consents, orders or 
declarations of any Governmental Entity necessary to consummate the
transactions contemplated hereby or the expiration or termination of any
applicable waiting period; (ii) materially increase the risk of any
Governmental Entity entering an order  prohibiting the consummation of the
transactions contemplated hereby; (iii) materially increase the risk of not
being able to remove any such order on appeal or otherwise; or (iv) materially
delay or prevent the consummation of the transactions  contemplated hereby.
For the avoidance of doubt, Parent and Merger Sub shall not (and shall cause
their Subsidiaries and Affiliates not to) take or agree to take any action
with respect to the Subsequent Transaction or any other arrangement with 
respect to Fresenius Medical Care Ventures, LLC (the " _Subsequent Transaction
Buyer_ ") or any of its Affiliates (individually or in conjunction with the
Subsequent Transaction Buyer or any of its Affiliates) that would be
reasonably likely to  prevent or materially delay the Closing. 

 

53   (g) In no event shall the Company or any of its Subsidiaries be 
obligated to bear any cost or expense or pay any fee, except of its own legal
and consulting fees, in connection with obtaining any consents, authorizations
or approvals required in order to consummate the transactions contemplated
hereby. For  avoidance of doubt, Parent shall be responsible for the payment
of (i) all filing fees under any Antitrust Laws and (ii) all filing and
license fees in connection with the Healthcare Regulatory Approvals. 


 

  (h) Notwithstanding anything in this Agreement (including this
_Section          6.4_ ) to the contrary, Parent and the Company will
undertake all communications with the FTC, the DOJ, or any Governmental Entity
related to any filings under the HSR Act on the basis of the principles set
forth on _Section 6.4_ of the  Company Disclosure Schedule. 


 

 

Section 6.5. _Access to Information; Confidentiality_.

 


 

  (a) From the date hereof until the earlier of the Effective Time  and the
termination of this Agreement pursuant to _Article VIII_ , upon reasonable
prior written notice from Parent, the Company shall, and shall cause its
Subsidiaries to, (i) afford Parent, the Debt Financing Sources and their
respective  Representatives reasonable access, consistent with applicable
Law, during business hours to the operations of the Company, its principal
personnel and Representatives and properties, offices, and other facilities
and to all books and records, and shall  furnish Parent, the Debt Financing
Sources and their respective Representatives with all financial, operating and
other data and information as Parent and the Debt Financing Sources and their
respective Representatives, may from time to time reasonably  request in
writing in connection with the transactions contemplated by this Agreement and
(ii) afford the Subsequent Transaction Buyer and its respective
Representatives reasonable access to the Clinic Joint Ventures related to the
Subsequent  Transaction and the books, records, principal personnel and
Representatives thereof. Any such access shall be conducted on a basis
consistent with the access provided prior to the execution of this Agreement,
including with regard to the treatment of  items identified as "competitively
sensitive information". Notwithstanding the foregoing, any such access shall
be conducted in such a manner as not to interfere unreasonably with the
business or operations of the Company or its Subsidiaries or  otherwise
result in any significant interference with the prompt and timely discharge by
the Company's officers, employees and other authorized Representatives of
their normal duties and, for the avoidance of doubt, (i) shall not include
any  environmental sampling or invasive environmental testing and (ii) shall
not require the Company to make available access to the Clinic Joint Ventures
or the principal personnel and representatives thereof except as consented to
in writing by the  Company (such consent not to be unreasonably withheld,
conditioned or delayed). Neither the Company nor any of its Subsidiaries shall
be required to provide access or to disclose information where such access or
disclosure would violate or prejudice  its rights or the rights of any of its
officers, directors or employees, jeopardize any attorney-client privilege of
the Company or any of its Subsidiaries, or contravene any applicable Law,
rule, regulation, order, judgment, decree or binding  agreement provided,
however that the Company shall use its commercially reasonable efforts to
allow for such access or disclosure in a manner that does not result in a loss
of attorney-client privilege. All requests for information made pursuant to 
this _Section 6.5(a)_ shall be directed to the General Counsel of the Company
or such other Person as is designated in writing by the Company. No access,
review or notice pursuant to this _Section 6.5_ shall have any effect for the
purpose  of determining the accuracy of any representation or warranty given
by any of the Parties to any of the other Parties. 


 

 

 

54   (b) Each of Parent and Merger Sub will comply with the terms and 
conditions of the Non-Disclosure Agreement, dated December 26, 2019, between
the Company and Nautic Partners, LLC (together with the Addendum to
Confidentiality Agreement, dated January 2, 2020, the Second Addendum to
Confidentiality Agreement, dated  February 1, 2020, the Third Addendum to
Confidentiality Agreement, dated February 3, 2020, the Fourth Addendum to
Confidentiality Agreement, dated August 22, 2020 and the Fifth Addendum to
Confidentiality Agreement dated August 26, 2020 (collectively,  the "
_Confidentiality Agreement_ "), and will hold and treat, and will cause their
respective officers, employees, auditors and other Representatives to hold and
treat, in confidence all documents and information concerning the Company and
its  Subsidiaries furnished to Parent or Merger Sub in connection with the
transactions contemplated by this Agreement in accordance with the
Confidentiality Agreement, which Confidentiality Agreement shall remain in
full force and effect in accordance with  its terms. 


 

 

Section 6.6. _Stock Exchange Delisting_. Prior to the Closing Date, the
Company shall cooperate with Parent and use reasonable efforts to take, or
cause to be taken, all actions, and do or cause to be done  all things,
reasonably necessary, proper or advisable on its part under applicable Laws
and rules and policies of the NYSE to enable the delisting by the Surviving
Corporation of the Shares from the NYSE and the deregistration of the Shares
under the  Exchange Act as promptly as practicable after the Effective Time.

 


 

 

Section 6.7. _Publicity_. The initial press release regarding the Merger shall
be a joint press release of the Parties reasonably acceptable to the Company
and Parent (the " _Announcement_ ").  Thereafter, the Company (except in
connection with (a) any communication principally related to a Superior
Proposal or a Change of Recommendation, (b) any dispute between or among the
Parties regarding this Agreement or the transactions contemplated  hereby or
(c) public statements made by a Party in accordance with this Agreement,
including in investor conference calls, SEC Reports, QandAs or other publicly
disclosed documents, in each case of this clause (c), to the extent such
disclosure is  substantially consistent with prior disclosure and still
accurate), and Parent shall, to the extent practicable, (i) consult with each
other prior to issuing any press releases, participating in any media
interviews, or otherwise making public  announcements with respect to the
Merger and the other transactions contemplated by this Agreement, (ii) provide
to each other for review a copy of any such press release or public statement,
(iii) not issue any such press release or public statement  prior to
providing each other with reasonable period of time to review and comment on
such press release or public statement, and (iv) consult with each other prior
to making any filings with any third party and/or any Governmental Entity
(including  any national securities exchange or interdealer quotation
service) with respect thereto, except for communications that are (A) required
by Law or by obligations pursuant to any listing agreement with or rules of
any national securities exchange or  interdealer quotation service or by the
request of any Governmental Entity (or, in the case of the Company, by the
fiduciary duties of the Board of Directors (or a duly authorized committee
thereof) as reasonably determined by the Board of Directors  (or a duly
authorized committee thereof) after consultation with outside legal counsel
and subject to the terms of _Section 6.1_ ), (B) principally directed to
employees, suppliers, customers, partners or vendors so long as such
communications  are consistent with the previous press releases, public
disclosures or public statements made jointly by the Parties (or individually
if approved by the other Party), or (C) principally related to a Superior
Proposal or Change of Recommendation.  Notwithstanding the foregoing, this
_Section 6.7_ shall not apply to any press release or other public statement
made by the Company or Parent (x) that is substantially consistent with the
Announcement and the terms of this Agreement and does  not contain any
information relating to the Company or Parent that has not been previously
announced or made public in accordance with the terms of this Agreement or (y)
is made in the ordinary course of business and does not relate specifically
to  the signing of this Agreement or the transactions contemplated hereby.

 

 

55  

Section 6.8. _Employee Benefits_.

 


 

  (a) For a period of at least one (1) year following the Effective  Time,
Parent shall provide, or shall cause the Surviving Corporation to provide, to
each employee of the Company or its Subsidiaries who continues to be employed
by the Company or the Surviving Corporation or any Subsidiary or Affiliate
thereof (each a  " _Continuing Employee_ " and collectively, the "
_Continuing Employees_ ") (i) unless otherwise agreed to between a Continuing
Employee and the Company, the Surviving Corporation or any Subsidiary or
Affiliate thereof, salary, wage rate and  target bonus opportunity for each
Continuing Employee immediately prior to the Effective Time that are no less
favorable in the aggregate than the salary, wage rate and target bonus
opportunity that was provided to such Continuing Employee immediately  prior
to the Effective Time and (ii) welfare and other retirement benefits that are
substantially comparable in the aggregate to the welfare and other retirement
benefits provided to such Continuing Employee immediately prior to the
Effective Time. For  a period of at least one (1) year following the
Effective Time, Parent or one of its Affiliates shall maintain for the benefit
of each Continuing Employee a severance or termination arrangement that is
substantially similar to (or more favorable than)  the severance or
termination arrangement that was provided to such Continuing Employee
immediately prior to the Effective Date. 


 

  (b) Parent shall honor and assume, or shall cause to be honored and 
assumed, the terms of all Company Plans, subject to the amendment and
termination provisions thereof. 


 

  (c) Parent shall (i) cause any pre-existing conditions or  limitations
and eligibility waiting periods under any group health plans of Parent or its
Affiliates to be waived with respect to Continuing Employees and their
eligible dependents, (ii) use commercially reasonable efforts to give each
Continuing  Employee credit for the plan year in which the Effective Time
occurs towards applicable deductibles and annual out-of-pocket limits for
medical expenses incurred prior to the Effective Time for which payment has
been made and (iii) to the extent that  such service was recognized under a
similar Company Plan, use commercially reasonable efforts to give each
Continuing Employee service credit for such Continuing Employee's employment
with the Company for purposes of eligibility to participate and  vesting
credit (but excluding benefit accrual under any defined benefit pension plan)
under each applicable Parent benefit plan as if such service had been
performed with Parent; _provided_ that such recognition of service shall not
apply (x) for  purposes of any Parent benefit plan under which similarly
situated employees of Parent and its Subsidiaries do not receive credit for
prior service, (y) to the extent it would result in a duplication of benefits
or (z) for purposes of any plan or  arrangement that is grandfathered or
frozen, either with respect to the level of benefits or participation. 

 

56   (d) Parent and the Surviving Corporation, as applicable, shall pay  or
cause the applicable subsidiary to pay to each eligible employee of the
Company and its Subsidiaries, on the first payroll date following the
Effective Time, or, if later, the date that the Company normally pays annual
bonuses, but in no event later  than March 15, 2021, and subject to such
eligible employee remaining continuously employed through the Effective Time,
any unpaid annual bonus (or other cash incentive award) relating to the entire
2020 fiscal year (or completed performance period  during the 2020 fiscal
year) (the " _2020 Bonuses_ "); _provided_ that, any amounts payable in
respect of the entire 2020 fiscal year or prior period during the 2020 fiscal
year shall be (x) on the basis of the applicable Company Plan and (y)  no
less in the aggregate than the amounts accrued by the Company with respect to
such cash incentive compensation as of the close of the calendar month
immediately preceding the Effective Time. In the event that an eligible
employee is terminated  without "cause" prior to the payment of the 2020
Bonuses, such eligible employee's 2020 Bonus shall be paid as soon as
administratively practicable following such termination of employment. 


 

  (e) Nothing in this Agreement shall confer upon any Continuing  Employee
any right to continue in the employ or service of Parent, the Surviving
Corporation or any Affiliate of Parent, or shall interfere with or restrict in
any way the rights of Parent, the Surviving Corporation or any Affiliate of
Parent, which  rights are hereby expressly reserved, to discharge or
terminate the services of any Continuing Employee at any time for any reason
whatsoever, with or without cause, except to the extent expressly provided
otherwise in a written agreement between  Parent, the Surviving Corporation,
the Company or any Affiliate of Parent and the Continuing Employee or any
severance, benefit or other applicable plan, policy or program covering such
Continuing Employee. Notwithstanding any provision in this  Agreement to the
contrary, nothing in this _Section 6.8_ shall (i) be deemed or construed to be
an amendment or other modification of any Company Plan, (ii) prevent Parent,
the Surviving Corporation or any Affiliate of Parent from amending or 
terminating any Company Plans in accordance with their terms or (iii) create
any third-party rights in any current or former service provider of the
Company or its Affiliates (or any beneficiaries or dependents thereof). 


 

 

Section 6.9. _Directors ' and Officers' Indemnification and Insurance_.

 


 

  (a) From and after the Effective Time and ending on the sixth 
anniversary of the Effective Time, each of Parent and the Surviving
Corporation agrees that it will indemnify and hold harmless each present and
former director and officer of the Company or any of its Subsidiaries (the "
_Indemnified Parties_ "),  against any costs or expenses (including
reasonable attorneys' fees), judgments, fines, losses, claims, damages,
liabilities or awards paid in settlement, incurred in connection with any
actual or threatened claim, action, suit, arbitration, proceeding  or
investigation, whether civil, criminal, administrative or investigative and
whether formal or informal (each, a " _Proceeding_ "), arising out of,
relating to or in connection with matters existing or occurring at or prior to
the Effective Time  (including the fact that such Person is or was a director
or officer of the Company or any of its Subsidiaries or any acts or omissions
occurring or alleged to occur prior to the Effective Time), whether asserted
or claimed prior to, at or after the  Effective Time, to the fullest extent
that the Company would have been permitted under Delaware Law and the
Certificate of Incorporation and Bylaws in effect on the date of this
Agreement to indemnify such Person (and Parent or the Surviving  Corporation
shall advance expenses (including reasonable legal fees and expenses) incurred
in the defense of any Proceeding, including any expenses incurred in enforcing
such Person's rights under this _Section 6.9_ , to the extent that such 
indemnification with respect to or advancement of such expenses is authorized
under the Certificate of Incorporation, the Bylaws or the certificate of
incorporation and bylaws, or equivalent organizational documents, of any
Subsidiary; _provided_   that the Person to whom expenses are advanced
provides an undertaking to repay such advances if it is ultimately determined
by a final and non-appealable determination by a court of competent
jurisdiction that such Person is not entitled to  indemnification pursuant to
this _Section 6.9_ ). In the event of any such Proceeding (x) neither Parent
nor the Surviving Corporation shall settle, compromise or consent to the entry
of any judgment in any Proceeding in which indemnification  could be sought
by such Indemnified Party hereunder, unless such settlement, compromise or
consent includes an unconditional release of such Indemnified Party from all
liability arising out of such Proceeding or such Indemnified Party otherwise 
consents, and (y) the Surviving Corporation shall cooperate in the defense of
any such matter. In the event any Proceeding is brought against any
Indemnified Party and in which indemnification could be sought by such
Indemnified Party under this _Section          6.9_ , (i) the
Surviving Corporation shall have the right to control the defense thereof
after the Effective Time (it being understood that, by electing to control the
defense thereof, the Surviving Corporation will be deemed to have waived any 
right to object to the Indemnified Party's entitlement to indemnification
hereunder with respect thereto), (ii) each Indemnified Party shall be entitled
to retain his or her own counsel, whether or not the Surviving Corporation
shall elect to control  the defense of any such Proceeding, and (iii) no
Indemnified Party shall be liable for any settlement effected without his or
her prior express written consent. 

 

57   (b) Any Indemnified Party wishing to claim indemnification under
_Section          6.9(a)_ , upon learning of any such Proceeding,
shall promptly notify Parent thereof in writing, but the failure to so notify
shall not relieve Parent or the Surviving Corporation of any liability it may
have to such Indemnified Party except to the  extent such failure materially
prejudices the indemnifying Party. 


 

  (c) Unless otherwise prohibited by applicable Law, the provisions  in the
Surviving Corporation's certificate of incorporation and bylaws with respect
to indemnification, advancement of expenses and exculpation of former or
present directors and officers shall be no less favorable to such directors
and officers than  such provisions contained in the Certificate of
Incorporation and Bylaws in effect as of the date hereof, which provisions
shall not be amended, repealed or otherwise modified for a period of six (6)
years after the Effective Time in any manner that  would adversely affect the
rights thereunder of any such individuals. 


 

  (d) Prior to the Effective Time, the Company shall obtain and fully  pre-
pay the premium for (and following the Effective Time, Parent shall maintain,
or shall cause the Surviving Corporation to maintain, at no expense to the
beneficiaries, with reputable and financially sound carriers) a run-off "tail"
policy of the  directors' and officers' liability insurance and fiduciary
liability insurance maintained by the Company (collectively, the " _D andO
Insurance_") in each case for a claims reporting or discovery period
(whichever is greater) of six (6) years from  and after the Effective Time
with respect to any claim arising from facts or events that existed or
occurred at or prior to the Effective Time with terms, conditions, retentions,
coverage limits and limits of liability that are at least as favorable as 
the coverage provided under the Company's existing policies in effect on the
date hereof. If the Company and the Surviving Corporation for any reason fail
to obtain such "tail" insurance policies as of the Effective Time, the
Surviving Corporation  shall, and Parent shall cause the Surviving
Corporation to, continue to maintain in effect for a period of six (6) years
from and after the Effective Time the DandO Insurance in place as of the date
hereof with terms, conditions, retentions, coverage  limits and limits of
liability that are at least as favorable as the coverage provided in the
Company's existing policies as of the date hereof, or the Surviving
Corporation shall, and Parent shall cause the Surviving Corporation to,
purchase  comparable insurance as the DandO Insurance (from reputable and
financially sound carriers) for such six-year period with terms, conditions,
retentions and limits of liability that are at least as favorable as the
coverage provided under the  Company's existing policies as of the date
hereof. Notwithstanding the foregoing, (x) in no event shall the Company or
the Surviving Corporation expend for any such policies pursuant to this
_Section 6.9(d)_ an annual premium amount in excess of  300% of the aggregate
of the annual premiums currently paid by the Company for such insurance, and
(y) if the annual premiums of such insurance coverage exceed such maximum
amount, the Company or the Surviving Corporation shall obtain a policy with
the  greatest coverage available for such maximum amount. 

 

58   (e) Parent agrees to honor and perform under, and to cause the  Surviving
Corporation to honor and perform under, all indemnification agreements entered
into by the Company or any of its Subsidiaries with any Indemnified Party
prior to the date of this Agreement and made available to Parent. 


 

  (f) If Parent or the Surviving Corporation or any of their  respective
successors or assigns (i) shall consolidate with or merge into any other
corporation or entity and shall not be the continuing or surviving corporation
or entity of such consolidation or merger or (ii) shall transfer all or
substantially all  of its properties and assets to any individual,
corporation or other entity, then, and in each such case, proper provisions
shall be made so that the successors and assigns of Parent or the Surviving
Corporation, or the acquiror of such assets  (including its ultimate parent)
shall succeed to the obligations set forth in this _Section 6.9_ _._  


 

  (g) The provisions of this _Section 6.9_ shall survive the  Merger and
are intended to be for the benefit of, and shall be enforceable by, each of
the Indemnified Parties and their heirs and Representatives. Notwithstanding
anything herein to the contrary, if any Proceeding (whether arising before, at
or after  the Effective Time) is made against any Indemnified Party, on or
prior to the sixth anniversary of the Effective Time, the provisions of this
_Section 6.9_ shall continue in effect until the final disposition of such
claim, action, suit,  proceeding or investigation. 


 

  (h) The rights of the Indemnified Parties under this _Section  6.9_ shall
be in addition to any rights such Indemnified Parties may have under the
Certificate of Incorporation or Bylaws or the comparable governing instruments
of any of its Subsidiaries, or under any applicable Contracts or Laws. Nothing
in  this Agreement is intended to, shall be construed to or shall release,
waive or impair any rights to directors' and officers' insurance claims under
any policy that is or has been in existence with respect to the Company or its
officers, directors and  employees, it being understood that the
indemnification provided for in this _Section 6.9_ is not prior to, or in
substitution for, any such claims under any such policies. 

 

59  

Section 6.10. _Transaction Litigation_. Except as set forth in _Section 2.4_
with regard to appraisal rights, in the event that any stockholder litigation
related to this Agreement, the Merger or the  other transactions contemplated
by this Agreement is brought, or to the Company's knowledge, threatened,
against the Company or any members of its Board of Directors (or a duly
authorized committee thereof) on or after the date of this Agreement and 
prior to the Effective Time (the " _Transaction Litigation_ "), the Company
shall promptly notify Parent of any such Transaction Litigation (including by
providing copies of all pleadings with respect thereto) and shall keep Parent
reasonably  informed with respect to the status thereof. The Company shall
(a) give Parent the opportunity to participate, at Parent's expense, in the
defense or settlement of any Transaction Litigation and (b) consult with
Parent with respect to the defense  and settlement of any Transaction
Litigation. The Company shall not settle or agree to settle any Transaction
Litigation without Parent's prior written consent (which consent shall not be
unreasonably withheld, delayed or conditioned).   Notwithstanding anything to
the contrary in this _Section 6.10_ , any litigation or claim relating to
Dissenting Shares shall be governed by _Section 2.4_.

 


 

 

Section 6.11. _Obligations of Merger Sub_. Parent shall take all action
necessary to cause Merger Sub and the Surviving Corporation to perform their
respective obligations under this Agreement, the  Financing and any
Alternative Financing.

 


 

 

Section 6.12. _Rule 16b-3_. Prior to the Effective Time, the Company shall be
permitted to take such steps as may be reasonably necessary or advisable to
cause any dispositions of Company equity securities  (including derivative
securities) pursuant to the transactions contemplated by this Agreement by
each individual (including any Person who is deemed to be a "director by
deputization" under applicable securities Laws) who is subject to the
reporting  requirements of Section 16(a) of the Exchange Act with respect to
the Company to be exempt under Rule 16b-3 promulgated under the Exchange Act.

 


 

 

Section 6.13. _Takeover Statutes_. If any "fair price," "moratorium,"
"business combination," "control share acquisition" or other form of anti-
takeover statute or regulation is or may become applicable to  the Merger or
the other transactions contemplated by this Agreement, each of the Company and
Parent and the members of their respective Boards of Directors shall grant
such approvals and take such actions as are necessary so that such
transactions  may be consummated as promptly as practicable on the terms
contemplated by this Agreement and otherwise act to eliminate or minimize the
effects of such statute or regulation on such transactions. Nothing in this
_Section 6.13_ shall be  construed to permit Parent or Merger Sub to take any
act that would constitute a violation or breach of, or as a waiver of any of
the Company's rights under, any other provision of this Agreement.

 

 

60  

Section 6.14. _Certain Affiliate Agreements_.

 


 

  (a) The Company shall cause each of (i) the Amended and Restated 
Stockholders Agreement, dated as of June 28, 2010, by and among C.P. Atlas
Holdings, Inc., Centerbridge Capital Partners, L.P., Centerbridge Capital
Partners SBS, L.P., Centerbridge Capital Partners Strategic, L.P. and the
other stockholders party  thereto, as amended by Amendment No. 1 thereto,
dated as of April 21, 2016, (ii) the Amended and Restated Registration Rights
Agreement, dated as of May 7, 2010, by and among the Company and the
stockholders party thereto, as amended by Amendment No. 1  thereto, dated as
of April 26, 2016 and (iii) any similar Contracts listed on _Section 6.14_ of
the Company Disclosure Schedule, to be terminated at or prior to the Closing.
For the avoidance of doubt, that certain Tax Receivable Agreement,  dated as
of April 26, 2016, by and between the Company and Centerbridge Capital
Partners, L.P., will remain in full force and effect following the Closing in
accordance with its terms. 


 

 

Section 6.15. _Financing_.

 


 

  (a) During the period commencing on the date hereof and terminating  on
the earlier to occur of the Closing and the termination of this Agreement
pursuant to and in accordance with _Article VIII_ , each of Parent and Merger
Sub shall use their reasonable best efforts to take, or cause to be taken, all
actions and  to do, or cause to be done, all things necessary, proper or
advisable to arrange, obtain and consummate the Financing on the terms and
conditions described in or contemplated by the Commitment Letters (including
complying with any request requiring the  exercise of so-called "market flex"
provisions in the Fee Letter in connection with the Debt Financing), including
using reasonable best efforts to: 


 

  (i) maintain in full force and effect the Commitment Letters (subject to
Parent's right to replace, restate,  supplement, modify, assign, substitute
or amend the Commitment Letters in accordance herewith); 


 

  (ii) negotiate and execute definitive agreements with respect to the Debt
Financing on the terms contained in the  Debt Commitment Letter (including
any "market flex" provisions applicable thereto), or on such other terms that,
taken as a whole, (i) would not reduce the aggregate amount of the Financing
available to be funded at the Closing below the amount  required to fund the
Financing Uses (taking into account any increase in any other Financing and
other available sources) and (ii) are no less favorable in the aggregate to
Parent and Merger Sub than the terms set forth in the Debt Commitment Letter
as  in effect on the date of this Agreement (as determined by Parent in its
reasonable judgment) (including any "market flex" provisions applicable
thereto), in each case, which terms shall not impose, nor permit the
imposition of, any new conditions (or  the modification or expansion of any
existing conditions) or the limitation, amendment or waiver of any applicable
remedies available with respect to the Financing (such definitive agreement,
the " _Definitive Financing Agreements_ "); 

 

61   (iii) satisfy on a timely basis (or obtain the waiver of) all conditions
precedent in the Commitment Letters and such  Definitive Financing Agreements
that are to be satisfied by, and within the control of, Parent and/or Merger
Sub, including (without limitation) the satisfaction of conditions relating to
(A) the preparation and delivery of pro forma financial  statements, (B) the
payment of fees and expenses, (C) the execution and/or delivery of documents
and instruments in connection with the Debt Financing, and (D) the delivery of
any applicable beneficial ownership certification and information under 
applicable "know your customer" and anti-money laundering rules and
regulations, in each case, relating to Parent, Merger Sub and its Affiliates;
and 


 

  (iv) upon the reasonable request of the Company, confirm with the Debt
Financing Sources their intent and ability to  perform, and the availability
of the Debt Financing, under the Debt Commitment Letter, subject in each case
to satisfaction or waiver of the Financing Conditions (including consummation
of the Equity Financing), and that neither Parent nor the Debt  Financing
Sources are aware of any event or condition that could reasonably be expected
to result in the failure of a Financing Condition; and 


 

  (v) in the event that all conditions in Exhibit C to the Debt Commitment
Letter (other than conditions that by their  nature are to be satisfied at
the Closing) have been satisfied (other than those conditions that would be
expected to be satisfied substantially concurrently with the Closing),
consummate or cause to be consummated the Financing at or prior to the 
Closing. 


 

 

Parent shall, upon the Company's reasonable written request, provide the
Company with copies of any Definitive Financing Agreements and such other
information and documentation regarding the Debt Financing as shall be
reasonably necessary to allow  the Company to monitor the progress of such
financing activities. Parent and Merger Sub shall not, and Parent shall cause
its other Subsidiaries not to, take any action (including by incurring any
indebtedness other than the Debt Financing or  Alternative Financing in
accordance with _Section 6.10(b)_ ) that would reasonably be expected to cause
the Debt Financing (or Alternative Financing in accordance with _Section
6.10(b)_ ) not to be available to fund the Financing Uses on  the Closing
Date. Upon the reasonable written request of the Company, Parent shall
promptly, and in any event within two (2) Business Days, inform the Company in
reasonable detail of any material developments concerning the status of its
and Merger  Sub's efforts to arrange the Debt Financing and provide any
information reasonably requested by the Company relating thereto. During the
period commencing on the date of this Agreement and termination on the earlier
to occur of the Closing and the  termination of this Agreement pursuant to
and in accordance with _Article VIII_ , neither Parent nor Merger Sub (nor any
of their Affiliates) will take any action in connection with the Debt
Financing that would require the Company to make any  filings with the SEC or
include information in such filings that the Company would not otherwise
reasonably expect to have included in its filings with the SEC at such time.

 

 

62   (b) In the event that all conditions in Exhibit C to the Debt  Commitment
Letter (other than conditions that by their nature are to be satisfied at the
Closing) have been satisfied (other than those conditions that would be
expected to be satisfied substantially concurrently with the Closing) and the
Debt  Financing shall not have been funded at or prior to the Closing, Parent
shall use commercially reasonable efforts to cause the Debt Financing and the
Person committing to provide the Debt Financing to comply with its obligations
under the Debt  Commitment Letter and the Definitive Financing Agreements to
which they are a party and to cause such Person to fund such Debt Financing. 


 

  (c) In the event that any portion of the Debt Financing becomes 
unavailable on the terms and conditions (including any "market flex"
provisions applicable thereto) contemplated in the Debt Commitment Letter
prior to the earlier to occur of the Closing and the termination of this
Agreement pursuant to and in  accordance with _Article VIII_ (other than by
reason of breach of this Agreement by the Company), Parent shall promptly upon
becoming aware thereof notify the Company, and each of Parent and Merger Sub
shall use their respective reasonable best  efforts to take, or cause to be
taken, as promptly as practicable after the date hereof, all actions and to
do, or cause to be done, all things necessary, proper or advisable to obtain
alternative financing from the same or alternative sources in an  amount
sufficient, when added to the portion of the Financing that is and remains
available to Parent, to consummate the transactions contemplated by this
Agreement and to pay all Financing Uses at the Closing (" _Alternative
Financing_ ") and  provide the Company with a copy of the new financing
commitment that provides for such Alternative Financing (the " _Alternative
Financing Commitment Letter_ ") promptly upon the effectiveness thereof, which
Alternative Financing Commitment Letter  shall not be required to include
terms, fees, interest rates and other costs and conditions (including any
"market flex" provisions applicable thereto) that, taken as a whole, are
materially less beneficial to Parent or Merger Sub than those terms,  fees,
interest rates and other costs and conditions contemplated in the Debt
Commitment Letter (including any "market flex" provisions applicable thereto);
provided, that Parent and Merger Sub shall have no obligation to seek the cash
equity from any  source other than those counter parties to the Equity
Commitment Letter, or in any amount with respect to an investor in excess of
such investor's commitment. As applicable, references in this Agreement (other
than with respect to representations in  this Agreement made by Parent and
Merger Sub that speak as of the date hereof) (i) to Financing or Debt
Financing, as applicable, shall include Alternative Financing, as applicable,
(ii) to Commitment Letter or Debt Commitment Letter, as applicable,  shall
include the Alternative Financing Commitment Letter, as applicable and (iii)
to Definitive Financing Agreements shall include the definitive documentation
relating to any such Alternative Financing. Parent shall promptly deliver to
the Company  true and complete copies of all agreements pursuant to which any
such alternative source shall have committed to provide Parent and Merger Sub
with any portion of the Financing necessary to fund the Financing Uses;
_provided_ , that any specific  fee amounts and any specific "market flex"
provisions applicable thereto set forth therein may be redacted so long as
such redacted terms do not impose, or permit the imposition of, new or
additional conditions precedent or the expansion of any  existing conditions
precedent to the funding of the Debt Financing. 


 

  (d) Without limiting the generality of _Section 6.15(c)_ ,  Parent shall
promptly (and, in any event, within two (2) Business Days) notify the Company
in writing of the occurrence of any of the following: (i) termination,
withdrawal, repudiation, rescission, cancellation or expiration of any
Commitment Letter  of which Parent becomes aware, (ii) any breach or default
under any Commitment Letter by any party to such Commitment Letter of which
Parent becomes aware, and (iii) receipt by any of Parent, Merger Sub or any of
its Affiliates or Representatives of  any written notice or other written
communication from any Debt Financing Source with respect to any (A) actual or
threatened (in writing) breach, default, termination, withdrawal, repudiation,
rescission or cancellation by any party to any Commitment  Letter or (B)
material dispute or disagreement between or among Parent, on the one hand, and
any Debt Financing Source, on the other hand, in each case if as a result
thereof it is reasonably likely that Parent will not be able to obtain all or
any  portion of the Financing on the terms and conditions contemplated by the
Commitment Letters. As soon as reasonably practicable, but in any event within
two (2) Business Days after any such request, Parent shall provide to the
Company and its  Representatives any information reasonably requested by the
Company relating to any of the circumstances referred to in this _Section
6.15(c)_. 

 

63   (e) During the period commencing on the date of this Agreement and 
terminating on the earlier to occur of the Closing and the termination of this
Agreement pursuant to _Article VIII_ , Parent and Merger Sub shall not without
the prior written consent of the Company (such consent not to be unreasonably
withheld,  conditioned or delayed), permit, consent to or agree to (i) any
amendment, restatement, replacement, supplement, termination, reduction,
cancellation or other modification or waiver of any condition, provision or
remedy under, the Equity Commitment  Letter (other than to increase the
amount of Equity Financing available thereunder), (ii) any amendment,
restatement, replacement, supplement, termination, cancellation or other
modification or waiver of any condition, or provision or remedy under, the 
Debt Commitment Letter, if such amendment, restatement, supplement,
termination, cancellation, modification or waiver would (A) impose new or
additional conditions precedent to the funding of the Debt Financing or would
otherwise change, amend, modify  or expand any of the conditions precedent to
the funding of the Debt Financing, in any such case, from those set forth in
the Debt Commitment Letter on the date of this Agreement in such a manner that
could be reasonably expected to materially impair,  materially delay or
prevent the Closing, (B) reduce the aggregate amount of the Debt Financing
below an amount sufficient to fund the Financing Uses on the Closing (taking
into account any increase in any other Financing and other available sources)
or  (C) otherwise materially and adversely affect the ability of the Parent
or Merger Sub to enforce their rights under the Commitment Letters or to
consummate the transactions contemplated by this Agreement; _provided_
_however_ , for the  avoidance of doubt, Parent and Merger Sub may (x) amend,
supplement and/or modify the Debt Commitment Letter solely to add lenders,
lead arrangers, bookrunners, syndication agents or similar entities as parties
thereto who had not executed the Debt  Commitment Letter as of the date
hereof and (y) correct non-substantive typographical errors. Parent shall
furnish to the Company a copy of any amendment, restatement, replacement,
supplement, modification, waiver or consent of or relating to the Debt 
Commitment Letter promptly upon execution thereof. For purposes of this
Agreement (other than with respect to representations in this Agreement made
by Parent and Merger Sub that speak as of the date hereof), references to the
"Debt Commitment Letter"  shall include such document as permitted or
required by this _Section 6.15_ to be amended, restated, replaced,
supplemented or otherwise modified or waived, in each case from and after the
date of such amendment, restatement, replacement,  supplement or other
modification or waiver. 


 

  (f) Notwithstanding anything in this _Section 6.15_ to the  contrary,
each of Parent and Merger Sub acknowledges and agrees that neither the receipt
by Parent or Merger Sub nor the availability to Parent or Merger Sub of the
Financing or any other financing shall be a condition to the obligations of
Parent or  Merger Sub to consummate any of the transactions contemplated
hereby. 

 

64  

Section 6.16. _Financing Assistance_.

 


 

  (a) Prior to the Closing Date, the Company agrees to use reasonable  best
efforts to provide, and shall cause its Subsidiaries and its and their
respective officers, directors and employees to use, reasonable best efforts
to provide and shall use its reasonable best efforts to direct its and their
respective  Representatives to provide, in each case at Parent's and Merger
Sub's sole expense, such cooperation as may be reasonably requested by Parent
or Merger Sub in connection with the arrangement of the Debt Financing
contemplated by the Debt Commitment  Letter, including using reasonable best
efforts to: 


 

  (i) furnish to Parent as promptly as reasonably practicable any
information and documentation regarding the Company  and its Subsidiaries by
Parent to the extent that such information is required or reasonably necessary
and customarily provided for non-syndicated debt financings by direct lenders
of the type contemplated in connection with the Debt Commitment Letter; 
including but not limited to the financial and other information required to
be delivered to satisfy the condition precedent set forth in paragraph 4 of
Exhibit C of each Debt Commitment Letter and any historical financial
information or other data  that is reasonably available to and prepared in
the ordinary course of business of the Company regarding the Company and its
Subsidiaries reasonably required or requested in connection with the
preparation of the pro forma financial statements required  to be delivered
to satisfy the condition precedent in paragraph 5 of Exhibit C of the Debt
Commitment Letter; 


 

  (ii) upon reasonable prior notice, and at reasonable times and locations
to be mutually agreed, cause members of  management of the Company to
participate with Parent and Merger Sub in a reasonable number of meetings,
presentations and diligence sessions with prospective lenders, and sessions
with the ratings agencies, and otherwise reasonably cooperate with  Parent's
or Merger Sub's marketing efforts, in any such case to the extent required or
reasonably necessary or customary for non-syndicated debt financings by direct
lenders of the type contemplated in connection with the arrangement of the
Debt  Financing contemplated by the Debt Commitment Letter; 


 

  (iii) cause members of management of the Company to reasonably assist
Parent, Merger Sub and the Debt Financing  Sources in their preparation of
(A) any bank information memoranda and related lender presentations, and (B)
materials for rating agency presentations, in each case, to the extent
customary for non-syndicated debt financings by direct lenders of the  type
contemplated in connection with the Debt Commitment Letter; 


 

  (iv) provide Parent all customary documentation and other customary
information with respect to the Company and its  Subsidiaries as shall have
been reasonably requested in writing by Parent at least ten (10) Business Days
prior to the Closing Date and that is required in connection with the Debt
Financing by U.S. and foreign regulatory authorities under applicable  "know-
your-customer", anti-money laundering rules and regulations and similar
regulations under applicable foreign jurisdictions, including the Patriot Act,
and that are required by paragraph 7 of Exhibit C of each Debt Commitment
Letter, including if  the Company qualifies as a "legal entity customer"
under 31 C.F.R.  1010.230, a beneficial ownership certification; 


 

 

 

65   (v) execute and deliver any customary pledge and security documents (and
facilitate the pledging of collateral and  the granting of security interests
and the perfection thereof in such collateral) and other definitive financing
documents, assist with the preparation of any schedules, exhibits or annexes
thereto (including with respect to a customary perfection  certificate) or
other certificates or documents solely with respect to information regarding
the Company and its Subsidiaries, and as may be required or requested by
Parent in connection with the satisfaction of a Financing Condition to the
Debt  Financing ( _provided_ that (A) none of the documents or certificates
shall be executed and/or delivered except in connection with the Closing
(other than with respect to the authorization letters as set forth in clause
(vii) below), (B) the  effectiveness thereof (other than with respect to the
authorization letters as set forth in clause (vii) below) shall be conditioned
upon, or become operative after, the occurrence of the Closing and (C) no
liability shall be imposed on the Company,  any of its Subsidiaries or any of
their respective officers, directors or employees involved prior to the
Closing); and 


 

  (vi) obtain customary payoff letters (including those set forth in
_Section 6.17_ below, relating to the  repayment of any existing third party
indebtedness for borrowed money required by the Debt Commitment Letter (as of
the date hereof) to be repaid on or concurrently with the Closing and, upon
repayment of such indebtedness, termination of any related  Liens securing
any such obligations to be repaid and providing any necessary notices to allow
for the payoff, discharge and termination in full at the Closing of any such
indebtedness. 


 

  (b) Notwithstanding anything to the contrary in this _Section  6.16_ (but
without limiting the specific obligations of the Company or its Subsidiaries
pursuant to clause (a)(i) above), nothing will require the Company or its
Subsidiaries to provide (or be deemed to require the Company or the
Subsidiaries to  prepare or assist in the preparation of), in each case prior
to the Closing, any (1) pro forma financial statements, projections or other
prospective information; (2) description of all or any portion of the
Financing and other information customarily  provided by financing sources or
their counsel; (3) risk factors relating to all or any component of the
Financing; (4) "segment" financial information; or (5) financial statements
that are not otherwise required to be filed with the SEC by the Company  ("
_Excluded Information_ "). 


 

  (c) Notwithstanding anything herein to the contrary, (i) such  requested
cooperation shall not (A) unreasonably disrupt or interfere with the business
or the operations of the Company or its Subsidiaries, or (B) cause significant
competitive harm to the Company or its Subsidiaries, if the transactions
contemplated  by this Agreement are not consummated, (ii) nothing in this
_Section 6.16_ shall require cooperation to the extent that it would (A)
subject any of the Company's or its Subsidiaries' respective directors,
managers, officers or employees to any  actual or potential personal
liability prior to the Closing, (B) reasonably be expected to (x) conflict
with, or violate, the Company's and/or any of its Subsidiaries' organization
documents or any Law, or (y) result in the breach of, or default under,  any
Material Contract to which the Company or any of its Subsidiaries is a party,
(C) require any action that would reasonably be expected to cause any
condition to the Closing set forth in _Article VII_ to not be satisfied or (D)
require any  action that would reasonably be expected to cause any breach of
this Agreement, (iii) neither the Company nor any Subsidiary thereof shall be
required to (A) pay any commitment or other similar fee or incur or assume any
liability or other obligation  in connection with the financings contemplated
by the Commitment Letters, the Definitive Financing Agreements or the
Financing or be required to take any action that would subject it to actual or
potential liability, to bear any cost or expense (unless  required to be paid
or reimbursed by the Company pursuant to this Agreement) or to make any other
payment or agree to provide any indemnity in connection with the Commitment
Letters, the Definitive Financing Agreements, the Financing or any
information  utilized in connection therewith, in each case prior to the
Closing, (B) prepare, execute, deliver or obtain opinions of internal or
external counsel, (C) provide access to or disclose information where the
Company reasonably determines that such  access or disclosure would
reasonably be expected to jeopardize the attorney-client privilege or
contravene any Law or material Contract with a third party to which the
Company or any of its Subsidiaries is a party, or (D) waive or amend any terms
of  this Agreement or any other Contract to which the Company or its
Subsidiaries is party, (iv) none of the Company' directors shall be required
to adopt any resolutions or take any other actions approving the agreements,
documents, certificates and  instruments pursuant to which the Financing is
obtained, including any Definitive Financing Agreement (other than resolutions
and consents authorizing the officers and employees of the Company and its
Subsidiaries to take such actions as are necessary  to comply with the
obligations of the Company and its Subsidiaries herein (including, for the
avoidance of doubt, the obligation to deliver the authorization letters
referred to in clause (a)(vii) above), the effectiveness of which is not
contingent  upon the Closing, and (v) none of the Company, its Subsidiaries
or their respective directors, managers, officers or employees shall be
required to execute, deliver or enter into, or perform any agreement,
certificate, document or instrument, or agree  to change or modify any
existing agreement, document, certificate or instrument, including any
Definitive Financing Agreement, with respect to the Financing that is not
contingent upon the Closing or that would be effective prior to the Closing
Date  and the directors and managers of the Subsidiaries of the Company shall
not be required to adopt resolutions approving the agreements, certificates,
documents and instruments pursuant to which the Financing is obtained unless
Parent shall have  determined that such directors and managers are to remain
as directors and managers of the Subsidiaries on and after the Closing Date
and such resolutions are contingent upon the occurrence of, or only effective
as of, the Closing. The Company hereby  consents to the use of logos of the
business in connection with the Debt Financing contemplated by the Debt
Commitment Letter so long as such logos are used solely in (i) a manner that
is not intended to or reasonably likely to harm or disparage the  Company or
its Subsidiaries or the reputation or goodwill of the Company or its
Subsidiaries; and (ii) are used solely in connection with a description of the
Company, its business and products or the Merger (including in connection with
any marketing  materials related to the Debt Financing). 

 

66   (d) Parent shall indemnify, defend and hold harmless each of the 
Company, its Subsidiaries and Affiliates and their respective partners,
officers, directors, employees, accountants, legal counsel and other
Representatives from and against any and all liabilities, losses, (excluding
lost profits and losses from any  consequential, indirect, special or
punitive damages (as opposed to direct or actual damages)) damages, claims,
costs, expenses, interest, awards, judgments and penalties suffered or
incurred by them in connection with the Debt Financing and the  performance
of their respective obligations under this _Section 6.16_ except to the extent
such liabilities or losses arose as a result of any documents, materials or
other information provided by the Company, its Subsidiaries and Affiliates
and  their respective partners, officers, directors, employees, accountants,
legal counsel and other Representatives or the gross negligence, fraud or
willful misconduct of any of the Company, its Subsidiaries and Affiliates and
their respective partners,  officers, directors, employees, accountants,
legal counsel and other Representatives. Parent shall, promptly upon written
request by the Company, reimburse the Company and its Subsidiaries for all
reasonable and documented out-of-pocket fees, costs  and expenses incurred by
the Company or its Subsidiaries (including those of its Affiliates and
Representatives) in connection with the cooperation required by this _Section
6.16_ ; _provided_ , that the Company, and not Parent, shall be  responsible
for (x) fees payable to existing legal, financial or other advisors of the
Company and its Subsidiaries with respect to services provided prior to the
Closing, (y) any ordinary course amounts payable to existing employees of, or
consultants  to, the Company or its Subsidiaries with respect to services
provided prior to the Closing and (z) any amounts that would have been
incurred in connection with the transactions contemplated hereby regardless of
the Financing (including the preparation  and/or delivery of financial
information, payoff letters and Lien releases). Parent's obligations pursuant
to this _Section 6.16(d)_ are referred to collectively as the " _Reimbursement
Obligations_." 


 

  (e) For the avoidance of doubt, the parties hereto acknowledge and  agree
that the provisions contained in this _Section 6.16_ represent the sole
obligation of the Company, its Subsidiaries and other Affiliates, and their
respective partners, officers, directors, employees, accountants, legal
counsel and other  Representatives with respect to cooperation in connection
with the arrangement of the Financing and no other provision of this Agreement
(including the Exhibits and Schedules hereto) shall be deemed to expand or
modify such obligations. 


 

  (f) To the extent that this _Section 6.16_ requires the  Company's and
its Subsidiaries' cooperation with respect to any of the obligations under the
Debt Commitment Letter or relating to the Debt Financing, the Company and its
Subsidiaries shall be deemed to have complied with this _Section 6.16_ if 
the Company and its Subsidiaries have provided Parent and Merger Sub with the
assistance required under this _Section 6.16_ with respect to the Debt
Commitment Letter (as in effect on the date of this Agreement), the Debt
Financing contemplated  thereby and any Alternative Financing Commitment
Letter or Alternative Financing contemplated thereby. 


 

  (g) Notwithstanding anything to the contrary herein, it is  understood
and agreed that the condition precedent set forth in _Section 7.2(b)_ , as
applied to the Company's obligations under this _Section 6.16_ , shall be
deemed to be satisfied unless the Debt Financing has not been obtained as a
direct  result of a failure of a Financing Condition set forth in the Debt
Commitment Letter that is a direct result of the Company's Willful Breach of
its obligations under this _Section 6.16_. 


 

 

Section 6.17. _Payoff Letters_. The Company shall deliver to Parent, at least
two (2)  Business Days prior to the Closing, a payoff letter executed by the
lenders, or the administrative agent (or similar Person) on behalf of the
lenders, with respect to each arrangement identified on _Section 6.17_ of the
Company Disclosure  Schedule, in customary form (each, a " _Payoff Letter_
"), that (a) confirms the aggregate outstanding amount required to be paid to
fully satisfy the obligations payable under each such arrangement as of the
Closing (and the daily accrual of  interest thereafter) (each such amount, a
" _Company Payoff Amount_ "), (b) provides that, upon payment in full of the
Company Payoff Amount indicated therein, (i) all Liens granted to the lenders
pursuant to such arrangements and all loan and  collateral documentation
entered into in connection with evidencing the obligations under such
arrangements shall be automatically released and terminated and be of no
further force and effect and (ii) all collateral in the possession of the
lenders  under such arrangements shall be promptly returned to the Company or
its designees, and (c) contains customary further assurances provisions.

 

 

67  

Section 6.18. _Notification of Certain Matters_. The Company shall give prompt
notice to  Parent, and Parent shall give prompt notice to the Company, of (i)
any notice or other communication received by such party from any Governmental
Entity in connection with this Agreement or the transactions contemplated by
this Agreement or from any  Person alleging that the consent of such Person
is or may be required in connection with the transactions contemplated by this
Agreement, if the subject matter of such communication or the failure of such
party to obtain such consent could be  material to the Company, the Surviving
Corporation or Parent, and (ii) any Proceedings commenced or, to such party's
knowledge, threatened against, relating to or involving or otherwise affecting
such party or any of its Subsidiaries which relate to  this Agreement or the
transactions contemplated by this Agreement.

 


 

 

ARTICLE VII

 


 

 

CONDITIONS OF MERGER

 


 

 

Section 7.1. _Conditions to Obligation of Each Party to Effect the Merger_.
The respective obligations of each Party to effect the Merger shall be subject
to the satisfaction at or prior to the Effective  Time of the following
conditions:

 


 

  (a) _Stockholder Approval_. The Company Requisite Vote shall  have been
obtained; 


 

  (b) _Orders_. No Law (whether temporary, preliminary or  permanent) shall
have been enacted, entered, promulgated or enforced by any Governmental Entity
which prohibits, restrains or enjoins the consummation of the Merger, and
shall remain in effect (each, a " _Legal Restraint_ "); and 


 

  (c) _HSR Approval_. The waiting period (and any extension  thereof)
applicable to the consummation of the Merger under the HSR Act shall have
expired or been earlier terminated and any required approvals thereunder shall
have been obtained (the " _HSR Approval_ "). 


 

 

Section 7.2. _Conditions to Obligations of Parent and Merger Sub_. The
obligations of Parent and Merger Sub to effect the Merger shall be further
subject to the satisfaction (or waiver by Parent) at or  prior to the
Effective Time of the following conditions:

 


 

  (a) Representations and Warranties. Each of (i) the  representations and
warranties of the Company set forth in Section 3.1, Section 3.3(a), Section
3.3(b), Section 3.3(c), Section 3.3(d), Section 3.4 and Section 3.22 (except,
subject to the terms of Section 6.1, in the event that the Company or any of 
its Subsidiaries or the Board of Directors (or a duly authorized committee
thereof) engages another financial advisor in connection with the evaluation
of an Acquisition Proposal) shall be true and correct in all material respects
as of the Closing  Date as if made at such date (except to the extent such
representations and warranties speak as of a specified date, in which case
they need only be true and correct in all material respects as of such
specified date), which in the case of (x) Section  3.3(a), shall mean only
inaccuracies that are de minimis and (y) Section 3.3(d), shall mean only
inaccuracies that would not increase the aggregate consideration payable
pursuant to this Agreement by more than  a de minimis amount; and (ii) the
other representations and warranties of the Company set forth in Article III
shall be true and correct as of the Closing Date as if made at such date
(except to the extent such  representations and warranties speak as of a
specified date, in which case they need only be true and correct as of such
specified date) interpreted without giving effect to the words "materially" or
"material" or to any qualifications based on such  terms or based on the term
"Material Adverse Effect," except where the failure of such representations
and warranties to be true and correct, in the aggregate, would not constitute
or would not reasonably be expected to have a Material Adverse Effect; 

 

68   (b) _Performance of Obligations of the Company_. The Company  shall have
performed and complied with in all material respects all covenants and
obligations required to be performed or complied with under this Agreement at
or prior to the Effective Time; 


 

  (c) _No Material Adverse Effect_. No Material Adverse Effect  shall have
occurred after the date hereof and be continuing; and 


 

  (d) _Certificate_. Parent shall have received a certificate  of an
executive officer of the Company, certifying that the conditions set forth in
_Section 7.2(a)_ , _Section 7.2(b)_ and _Section 7.2(c)_ have been
satisfied. 


 

  (e) _Approvals_. Each of the approvals set forth in _Section   7.2(e)_
of the Parent Disclosure Schedule (the " _Healthcare Regulatory Approvals_ ")
shall have been obtained. 


 

 

Section 7.3. _Conditions to Obligations of the Company_. The obligation of the
Company to effect the Merger shall be further subject to the satisfaction (or
waiver by the Company) at or prior to the  Effective Time of the following
conditions:

 


 

  (a) _Representations and Warranties_. Each of (i) the  representations
and warranties of Parent and Merger Sub set forth in _Section 4.1_ , _Section
4.2_ , _Section 4.5_ , _Section 4.6_ , _Section 4.8_ and _Section 4.11_ shall
be true and correct in all material respects as  of the Closing Date as if
made at such date (except to the extent such representations and warranties
speak as of a specified date, in which case they need only be true and correct
in all material respects as of such specified date); and (ii) the other 
representations and warranties of Parent and Merger Sub set forth in _Article
IV_ shall be true and correct in all respects as of the Closing Date as if
made at such date (except to the extent such representations and warranties
speak as of a  specified date, in which case they need only be true and
correct as of such specified date) interpreted without giving effect to the
words "materially" or "material" or to any qualifications based on such terms,
except where the failures of any such  representations and warranties to be
true and correct, in the aggregate, would not reasonably be expected to
prevent, materially delay or materially impede the consummation of the
transactions contemplated by this Agreement; 

 

69   (b) _Performance of Obligations of Parent and Merger Sub_.   Each of
Parent and Merger Sub shall have performed and complied with in all material
respects all covenants and obligations required to be performed or complied
with under this Agreement at or prior to the Effective Time; and 


 

  (c) _Certificate_. The Company shall have received a  certificate of an
executive officer of Parent, certifying that the conditions set forth in
_Section 7.3(a)_ and _Section 7.3(b)_ have been satisfied. 


 

 

Section 7.4. _Frustration of Closing Conditions_. Neither the Company nor
Parent may rely, either as a basis for not consummating the Merger or
terminating this Agreement and abandoning the Merger, on the  failure of any
condition set forth in _Section 7.1_ , _Section 7.2_ or _Section 7.3_ , as the
case may be, to be satisfied if such failure was caused by such Party's breach
in any material respect of any provision of this Agreement or  failure in any
material respect to use the standard of efforts required from such Party to
consummate the Merger and the other transactions contemplated hereby.

 


 

 

ARTICLE VIII

 


 

 

TERMINATION, AMENDMENT AND WAIVER

 


 

 

Section 8.1. _Termination_. This Agreement may be terminated and the Merger
may be abandoned at any time prior to the Effective Time, notwithstanding the
adoption of this Agreement by the stockholders of  the Company:

 


 

  (a) by mutual written consent of Parent, Merger Sub and the  Company; 


 

  (b) by Parent or the Company by written notice to the other if any  court
of competent jurisdiction or other Governmental Entity located or having
jurisdiction within the United States shall have issued an order, decree or
ruling or taken any other final action restraining, enjoining or otherwise
prohibiting the Merger  and such order, decree, ruling or other action is or
shall have become final and nonappealable; _provided_ that the Party seeking
to terminate this Agreement pursuant to this _Section 8.1(b)_ shall have used
such standard of efforts as may  be required by such Party pursuant to
_Section 6.4_ to prevent, oppose and remove such restraint, injunction or
other prohibition; 


 

  (c) by either Parent or the Company by written notice to the other  if
the Effective Time shall not have occurred on or before 5:00 p.m., New York
City time, on March 1, 2021 (the " _End Date_ "); _provided_ , that the
Company, in its sole discretion, may extend the End Date for up to two (2)
consecutive thirty  five (35) day periods in the aggregate, to May 10, 2021,
if at the initial End Date or the end of the first additional thirty five (35)
day period all conditions set forth in _Section 7.1_ , _Section 7.2_ and
_Section 7.3_ shall have  been satisfied or waived (other than those
conditions that by their nature are to be satisfied at the Effective Time, but
subject to such conditions being capable of being satisfied as of the Closing
Date) other than the condition set forth in _Section     7.1(b)_ (with the
applicable Legal Restraint arising as a result of a Proceeding brought or
initiated by, or which results from the inaction of, a Governmental Entity,
_Section 7.1(c)_ and/or _Section 7.2(e)_ ; _provided_ , _further_ ,  that
Parent, in its sole discretion, may extend the End Date for up to two (2)
consecutive thirty five (35) day periods in the aggregate, to May 10, 2021, if
at the initial End Date or the end of the first additional thirty five (35)
day period all  conditions set forth in _Section 7.1_ , _Section 7.2_ and
_Section 7.3_ shall have been satisfied or waived (other than those conditions
that by their nature are to be satisfied at the Effective Time, but subject to
such conditions  being capable of being satisfied as of the Closing Date)
other than the condition set forth in _Section 7.1(b)_ (solely as a result of
the failure to receive the Healthcare Regulatory Approvals) and/or _Section
7.2(e)_ ; _provided_   that Parent may only exercise such extension right if
it has used such standard of efforts as required by Parent pursuant to
_Section 6.4_ with respect to the Healthcare Regulatory Consents. The right to
terminate this Agreement pursuant to this  _Section 8.1(c)_ shall not be
available to the Party seeking to terminate if any action of such Party (or,
in the case of Parent, Merger Sub) or the failure of such Party (or, in the
case of Parent, Merger Sub) to perform any of its obligations  under this
Agreement required to be performed at or prior to the Effective Time has been
the primary cause of the failure of the Effective Time to occur on or before
the End Date; 

 

70   (d) by written notice from the Company to Parent if: 


 

  (i) there shall have been a breach of any representation, warranty,
covenant or agreement on the part of Parent or  Merger Sub contained in this
Agreement, or any such representation or warranty shall be untrue, such that
the conditions set forth in _Section 7.3(a)_ or _Section 7.3(b)_ would not be
satisfied and, in either such case, such breach or  condition is not curable
or, if curable, is not cured prior to the earlier of (A) thirty (30) days
after written notice thereof is given by the Company to Parent or (B) two (2)
Business Days prior to the End Date; _provided_ that the Company  shall not
have the right to terminate this Agreement pursuant to this _Section
8.1(d)(i)_ if the Company is then in breach of any of its representations,
warranties or covenants contained in this Agreement so as to cause the
conditions set forth  in _Section 7.2(a)_ or _Section 7.2(b)_ not to be
satisfied; or 


 

  (ii) prior to obtaining the Company Requisite Vote, in accordance with,
and subject to, and in compliance with, all  of the terms and conditions of,
_Section 6.1(e)_ in order to enter into a definitive agreement with respect to
a Superior Proposal, if prior to or concurrently with such termination, the
Company pays the Company Termination Fee due under _Section  8.2(b)(i)_ ; 


 

  (e) by written notice from Parent to the Company if: 


 

  (i) there shall have been a breach of any representation, warranty,
covenant or agreement on the part of the Company  contained in this
Agreement, or any such representation or warranty shall be untrue, such that
the conditions set forth in _Section 7.2(a)_ or _Section 7.2(b)_ would not be
satisfied and, in either such case, such breach or condition is not  curable
or, if curable, is not cured prior to the earlier of (A) thirty (30) days
after written notice thereof is given by Parent to the Company or (B) two (2)
Business Days prior to the End Date; _provided_ that Parent shall not have the
right  to terminate this Agreement pursuant to this _Section 8.1(e)(i)_ if
Parent or Merger Sub is then in breach of any of its representations,
warranties or covenants contained in this Agreement so as to cause the
conditions set forth in _Section  7.3(a)_ or _Section 7.3(b)_ not to be
satisfied; or 

 

71   (ii) the Board of Directors (or a duly authorized committee thereof) shall
have made, prior to obtaining the Company  Requisite Vote, a Change of
Recommendation in a manner adverse to Parent or Merger Sub (it being agreed
that the taking of any action by the Company, its Board of Directors (or a
duly authorized committee thereof) or any of its Representatives  permitted
by _Section_ _6.1(c)_ (other than clause (v) thereof) shall not give rise to a
right to terminate pursuant to this clause (ii)); 


 

  (f) by either Parent or the Company if the Company Requisite Vote  shall
not have been obtained at the Stockholders Meeting duly convened therefor or
at any adjournment or postponement thereof, at which a vote on the adoption of
this Agreement was taken; or 


 

  (g) by the Company, if (i) the conditions set forth in _Section  7.1_ and
_Section 7.2_ (other than those conditions that by their nature are to be
satisfied at the Closing, each of which is capable of being satisfied at the
Closing, but subject to the fulfillment or waiver of those conditions at the 
Closing) have been and continue to be satisfied or waived in accordance with
this Agreement; (ii) Parent and Merger Sub fail to consummate the Merger on
the date on which Parent is required to consummate the Merger pursuant to
_Section 1.2_ ;  (iii) the Company has notified Parent in writing that it is
ready, willing and able to consummate the Closing and intends to terminate
this Agreement pursuant to this _Section 8.1(g)_ at the end of the one (1)
Business Day period set forth in the  following clause (iv); and (iv) Parent
and Merger Sub fail to consummate the Closing within one (1) Business Day
following the delivery of such written notice by the Company. 


 

 

Section 8.2. _Effect of Termination_.

 


 

  (a) In the event of the termination of this Agreement pursuant to
_Section          8.1_ , this Agreement shall forthwith become void
and there shall be no liability or obligation on the part of any Party (or any
partner, member, manager, stockholder, director, officer, employee, Affiliate,
agent or other Representative of such  Party) to the other Parties, as
applicable, except as provided in _Section 6.5(b)_ , _Section 6.7_ , this
_Section 8.2_ , _Section 8.3_ and _Article IX_ , which shall survive such
termination in accordance with their terms; _provided_   that, nothing herein
shall relieve any Party hereto of any liability for damages resulting from
actual and intentional fraud or Willful Breach of this Agreement prior to such
termination by any Party hereto (which damages the Parties acknowledge and 
agree shall not be limited to reimbursement of expenses or out-of-pocket
costs, and in the case of any damages sought by the Company from Parent or
Merger Sub, including for any actual and intentional fraud or Willful Breach,
such damages can be based  on the actual and/or potential damages incurred by
the Company's stockholders in the event such stockholders would not receive
the benefit of the bargain negotiated by the Company on their behalf as set
forth in this Agreement, taking into  consideration relevant matters
including other combination opportunities and the time value of money);
_provided_ , _further_ , that except in the case of actual and intentional
fraud, under no circumstances shall the liability for damages,  including
upon a Willful Breach, exceed the Liability Cap. The Parties acknowledge and
agree that nothing in this _Section 8.2_ shall be deemed to affect their right
to specific performance under _Section 9.12_. The Confidentiality  Agreement
and Parent Guarantee shall not be affected by the termination of this
Agreement and shall continue in full force and effect in accordance with their
terms. 

 

72   (b) In the event that: 


 

  (i) this Agreement is terminated by the Company pursuant to _Section
8.1(d)(ii)_ or by Parent pursuant to _Section  8.1(e)(ii)_ , then the Company
shall pay to Parent (or its designee) the Company Termination Fee, on or prior
to the date of termination in the case of a termination pursuant to _Section
8.1(d)(ii)_ or as promptly as reasonably practicable in  the case of a
termination pursuant to _Section 8.1(e)(ii)_ (and, in any event, within two
(2) Business Days following such termination), payable by wire transfer of
immediately available funds. 


 

  (ii) this Agreement is terminated by either Parent or the Company pursuant
to _Section 8.1(f)_ or by Parent  pursuant to _Section 8.1(e)(i)_ and (A) at
any time after the date of this Agreement and prior to the taking of a vote to
approve this Agreement at the Stockholders Meeting or any postponement or
adjournment thereof an Acquisition Proposal shall  have been made directly to
the Company's stockholders or an Acquisition Proposal shall have otherwise
become publicly known or, in the case of a termination pursuant to _Section
8.1(e)(i)_ , an Acquisition Proposal shall have been provided to the  Company
or the Board of Directors (or a duly authorized committee thereof), and such
Acquisition Proposal shall have not been withdrawn prior to such taking of a
vote to approve this Agreement or, in the case of a termination pursuant to
_Section  8.1(e)(i)_ , prior to the breach that forms the basis of such
termination and (B) within nine (9) months after such termination, the Company
shall have consummated an Acquisition Proposal or entered into a definitive
agreement with respect to an  Acquisition Proposal (which is subsequently
consummated, whether within such nine (9) month period or thereafter), then,
in any such event, the Company shall pay to Parent (or its designee) the
Company Termination Fee, such payment to be made within  two (2) Business
Days from the consummation of an Acquisition Proposal, by wire transfer of
immediately available funds. For the purpose of this _Section 8.2(b)(ii)_ ,
all references in the definition of the term Acquisition Proposal to "15% or 
more" will be deemed to be references to "more than 50%". 


 

  (c) In the event that this Agreement is terminated (A) by either  Parent
or the Company pursuant to _Section 8.1(b)_ and the applicable Legal Restraint
giving rise to such termination arises in connection with a Proceeding brought
or initiated by, or the inaction of, a Governmental Entity; (B) by either
Parent  or the Company pursuant to _Section 8.1(c)_ and either (i) the
condition to the Parties' obligation to close set forth in _Section 7.1(b)_
arises in connection with a Legal Restraint resulting from a Proceeding
brought or initiated by, or  the inaction of, a Governmental Entity or
_Section 7.1(c)_ is not satisfied (or there is an agreement not to consummate
the transaction contemplated by this Agreement with any Governmental Entity
with authority over the HSR Approval) or the  condition set forth in _Section
7.2(e)_ shall not have been satisfied or otherwise waived by Parent or (ii)
the Company could have terminated this Agreement pursuant to _Section
8.1(d)(i)_ or _Section 8.1(g)_ ; or (C) by the Company  pursuant to _Section_
_8.1(d)(i)_ or _Section_ _8.1(g)_ , then Parent shall pay to the Company (or
its designee) a fee of $32,237,669 (the " _Parent Termination Fee_ ") by wire
transfer of immediately available funds, such  payment to be made within two
(2) Business Days of the applicable termination. 

 

73   (d) The Parties hereto acknowledge and hereby agree that in no  event
shall either the Company be required to pay the Company Termination Fee, or
Parent be required to pay the Parent Termination Fee, as the case may be, on
more than one occasion. 


 

  (e) Each of the Company, Parent and Merger Sub acknowledges that  (i) the
agreements contained in this _Section 8.2_ are an integral part of the
transactions contemplated by this Agreement, (ii) the damages resulting from
termination of this Agreement under circumstances where the Company
Termination Fee,  Parent Termination Fee, and/or other amounts payable under
this _Section 8.2_ are payable are uncertain and incapable of calculation and,
therefore, the amounts payable pursuant to this _Section 8.2_ are not a
penalty, but are liquidated  damages, in a reasonable amount that will
compensate the Company, Parent, their respective Affiliates and their
respective Representatives for the efforts and resources expended and
opportunities foregone while negotiating this Agreement and other  documents
contemplated hereby and in reliance on this Agreement and on the expectation
of the consummation of the transactions contemplated by this Agreement and
(iii) without these agreements, the Parties would not enter into this
Agreement. If the  Company fails to promptly pay an amount due pursuant to
_Section 8.2(b)_ , or Parent fails to promptly pay an amount due pursuant to
_Section 8.2(c)_ , and, in order to obtain such payment, Parent, on the one
hand, or the Company, on the  other hand, commences a suit that results in a
judgment against the Company for the amount set forth in _Section 8.2(b)_ , or
any portion thereof, or a judgment against Parent for the amount set forth in
_Section 8.2(c)_ , or any portion  thereof, the Company shall pay to Parent,
on the one hand, or Parent shall pay to the Company, on the other hand, its
costs and expenses (including reasonable attorneys' fees and the fees and
expenses of any expert or consultant engaged by the Company)  in connection
with such suit, together with interest on the amount of such payment from the
date such payment was required to be made until the date of payment at the
prime rate as published in The Wall Street Journal,  Eastern Edition, in
effect on the date of such payment (any costs and expenses described in this
clause (f), the " _Collection Costs_ "). 


 

  (f) Notwithstanding anything to the contrary in this Agreement, in  any
circumstance in which this Agreement is terminated and Parent is entitled to
receive the Company Termination Fee from the Company pursuant to this _Section
8.2_ , the Company Termination Fee and, if applicable, the Collection Costs
and  Reimbursement Obligations, shall, subject to _Section 9.12_ , be the
sole and exclusive remedy of Parent, Merger Sub, and their respective
Affiliates against the Company, its Subsidiaries and any of their respective
former, current, or future  general or limited partners, stockholders,
directors, officers, managers, members, Affiliates, employees, representatives
or agents (collectively, the " _Company Related Parties_ ") for any loss
suffered as a result of any breach of any covenant or  agreement in this
Agreement giving rise to such termination, or in respect of any representation
made or alleged to be have been made in connection with this Agreement, and
upon payment of such amounts, none of the Company, its Subsidiaries or any
of  their respective former, current, or future general or limited partners,
stockholders, directors, officers, managers, members, Affiliates, employees,
representatives or agents shall have any further liability or obligation
relating to or arising out of  this Agreement or in respect of
representations made or alleged to be made in connection herewith, whether in
equity or at law, in contract, in tort or otherwise. For the avoidance of
doubt, notwithstanding anything to the contrary in this Agreement,  under no
circumstances will Parent or any other Parent Related Parties be entitled to
any monetary damages or other monetary remedies for any losses, damages or
liabilities suffered as a result of the failure of the transactions
contemplated by this  Agreement to be consummated or for a breach or failure
to perform hereunder (in any case, whether willfully, intentionally,
unintentionally or by Willful Breach or otherwise) or for any representation
made or alleged to have been made in connection  herewith, and Company's and
the other Company Related Parties' maximum aggregate liability in connection
with this Agreement and the transactions contemplated hereby shall not in any
case exceed an amount equal to the Liability Cap, other than in the  case of
actual and intentional fraud. 

 

74   (g) Notwithstanding anything to the contrary in this Agreement, in  any
circumstance in which this Agreement is terminated and the Company is paid the
Parent Termination Fee from Parent pursuant to this _Section 8.2_ , the Parent
Termination Fee and, if applicable, the Collection Costs and the
Reimbursement  Obligations, shall, subject to _Section 9.12_ , be the sole
and exclusive remedy of the Company against Parent, Merger Sub or any of their
respective former, current or future general or limited partners,
shareholders, controlling Persons,  managers, members, directors, officers,
employees, Affiliates, affiliated (or commonly advised) funds,
representatives, agents or any their respective assignees or successors or any
former, current or future general or limited partner, shareholder, 
controlling Person, manager, member, director, officer, employee, Affiliate,
affiliated (or commonly advised) fund, representative, agent, assignee or
successor of any of the foregoing (collectively, the " _Parent Related
Parties_ ") or any Debt  Financing Source Related Party for any loss or
damage suffered as a result of the failure of the Merger to be consummated or
for a breach of, or failure to perform under, this Agreement or any
certificate or other document delivered in connection  herewith or otherwise
or in respect of any oral representation made or alleged to have been made in
connection herewith or therewith and upon payment of such amounts, none of the
Parent Related Parties or Debt Financing Source Related Parties shall  have
any further liability or obligation relating to or arising out of this
Agreement or in respect of representations made or alleged to be made in
connection herewith, whether in equity or at law, in contract, in tort or
otherwise, except that  nothing shall relieve Parent of its obligations under
_Section 6.5(b)_ , _Section 6.7_ and _Section 6.16(d)_. Notwithstanding
anything to the contrary contained in this Agreement, and without limiting the
Company's rights under _Section          9.12_ , under no
circumstances will the Company be entitled to monetary damages under this
Agreement or in connection with the transactions contemplated hereby from (i)
Parent in excess of the amount equal to the Parent Termination Fee (and any 
costs, expenses, interest and other amounts payable pursuant to _Section
6.4(g)_ , _Section 6.16(d)_ and _Section 8.2(e)_ ) or (ii) any Parent Related
Parties (other than Parent), other than pursuant to, and in accordance with
the terms  of, the Parent Guarantee, the Equity Financing Commitment or the
Confidentiality Agreement. For the avoidance of doubt, notwithstanding
anything to the contrary in this Agreement, (i) under no circumstances will
the Company or any other Company Related  Parties be entitled to any monetary
damages or other monetary remedies for any losses, damages or liabilities
suffered as a result of the failure of the transactions contemplated by this
Agreement to be consummated or for a breach or failure to perform  hereunder
(in any case, whether willfully, intentionally, unintentionally or by Willful
Breach or otherwise) or for any representation made or alleged to have been
made in connection herewith, and Parent's and the other Parent Related
Parties' maximum  aggregate liability in connection with this Agreement and
the transactions contemplated hereby shall not in any case exceed an amount
equal to the Liability Cap, other than in the case of actual and intentional
fraud and (ii) the Company shall be  entitled to seek specific performance to
cause the Closing to occur in accordance with _Section 9.12_ prior to
terminating this Agreement and triggering payment of the Parent Termination
Fee, but the Company shall not be entitled to both specific  performance to
cause the Closing to occur pursuant to _Section 9.12_ and payment of the
Parent Termination Fee or any other amounts from Parent or the Parent Related
Parties. 

 

75   (h) This Agreement may only be enforced against, and any claims or 
causes of action that may be based upon or under this Agreement, or the
negotiation, execution or performance of this Agreement may only be made
against the entities that are expressly identified as Parties hereto and no
other Parent Related Party,  Debt Financing Source Related Party or Company
Related Party shall have any liability for any obligations or liabilities of
the Parties to this Agreement or for any claim against the Parties to this
Agreement (whether in tort, contract or otherwise)  based on, in respect of,
or by reason of, the Merger or the other transactions contemplated by this
Agreement or in respect of any oral representations made or alleged to be made
in connection herewith, except, in the cases of the Guarantors or the  other
Parent Related Parties, pursuant to, and in accordance with the terms of, the
Parent Guarantee, the Equity Commitment Letter or the Confidentiality
Agreement, and in the case of the Debt Financing Source Related Parties, the
Debt Commitment  Letter. 


 

 

Section 8.3. _Expenses_. Except as otherwise specifically provided herein,
each Party shall bear its own expenses in connection with this Agreement and
the transactions contemplated hereby. Expenses  incurred in connection with
obtaining any consent, approval, authorization, permit, action, filing or
notification shall be borne by Parent. Expenses incurred in connection with
the filing, printing and mailing of the Proxy Statement shall be shared 
equally by Parent and the Company.

 


 

 

ARTICLE IX

 

 


 

  GENERAL PROVISIONS

 


 

 

Section 9.1. _Non-Survival of Representations, Warranties, Covenants and
Agreements_. None of the representations, warranties, covenants and agreements
in this Agreement or in any instrument delivered  pursuant to this Agreement,
including any rights arising out of any breach of such representations,
warranties, covenants and agreements, shall survive the Effective Time, except
for (a) those covenants and agreements contained herein that by their  terms
apply or are to be performed in whole or in part after the Effective Time and
(b) those contained in this _Article IX_.

 


 

 

Section 9.2. _Modification or Amendment_. Subject to the provisions of
applicable Law, at any  time prior to the Effective Time, the Parties may
modify or amend this Agreement by written agreement, executed and delivered by
duly authorized officers of the respective Parties; provided, that after
receipt of the Company Requisite Vote, if any  such amendment shall by
applicable Law require further approval of the stockholders of the Company,
the effectiveness of such amendment shall be subject to the approval of the
stockholders of the Company. Notwithstanding anything to the contrary 
contained in this Agreement, _Section 8.2(g)_ , _Section 9.3_ , _Section 9.7_
, _Section 9.17_ and this _Section 9.2_ and any related definitions (solely as
used in such sections) may not be amended or modified in a manner  that is
materially adverse to the Debt Financing Sources without the prior written
consent of the Debt Financing Sources.

 

 

76  

Section 9.3. _Waiver; Extension_. The conditions to each of the Parties'
obligations to consummate the Merger are for the sole benefit of such Party
and may be waived by such Party (without the approval of  the stockholders of
the Company) in whole or in part to the extent permitted by applicable Law. At
any time prior to the Effective Time, any Party hereto may, subject to the
immediately following sentence, (a) waive or extend the time for the 
performance of any of the obligations or other acts of the other Parties
hereto, (b) waive any inaccuracies in the representations and warranties
contained herein or in any document delivered pursuant hereto and (c) subject
to the requirements of  applicable Law, waive compliance with any of the
agreements or conditions contained herein. Any such extension or waiver shall
be valid if set forth in an instrument in writing signed by the Party or
Parties to be bound thereby and specifically  referencing this Agreement. The
failure of any Party to assert any rights or remedies shall not constitute a
waiver of such rights or remedies. Notwithstanding anything to the contrary
contained in this Agreement, _Section 8.2(g)_ , _Section  9.2_ , _Section
9.7_ , _Section 9.17_ and this _Section 9.3_ and any related definitions
(solely as used in such sections) may not be amended or waived in a manner
that is materially adverse to the Debt Financing Sources without  the prior
written consent of the Debt Financing Sources.

 


 

 

Section 9.4. _Notices_. All notices, requests, claims, demands and other
communications hereunder shall be in writing and shall be given (and shall be
deemed to have been duly given upon receipt) by  delivery in person or by
overnight courier, by facsimile or e-mail or by registered or certified mail
(postage prepaid, return receipt requested) to the respective Parties at the
following addresses (or at such other address for a Party as shall be 
specified by like notice):

 


 

 

(a) if to Parent or Merger Sub:

 


 

 

IRC Superman Midco, LLC

 

c/o Nautic Partners

 

50 Kennedy Plaza, 12th Floor

 

Providence, RI 02903

 

        


 

    |  

Attention:

    |  

Scott F. Hilinski / Daniel P. Killeen 
 

    
---|---|--- 
    

 

         |  

Facsimile:

    |  

(401) 278-6387 
 

    
---|---|--- 
    

 

         |  

E-Mail:

    |  

shilinski@nautic.com;

 

dkilleen@nautic.com 
 

    
---|---|--- 
    

 


 

 

with an additional copy (which shall not constitute notice) to:

 


 

 

Goodwin Procter LLP

 

100 Northern Avenue

 

Boston, Massachusetts 02210

 

         |  

Attention:

    |  

Mark S. Opper / Adam P. Small

    
---|---|--- 
    

 

         |  

Facsimile:

    |  

(617) 523-1231

    
---|---|--- 
    

 

         |  

E-Mail:

    |  

mopper@goodwinlaw.com;

 

ASmall@goodwinlaw.com

    
---|---|--- 
    

 


 

 

 

77  

(b) if to the Company:

 


 

 

American Renal Associates Holdings, Inc.

 

500 Cummings Center, Suite 6550 
 

 

Beverly, Massachusetts 01915 
 

 

         |  

Attention:

    |  

Victoria A. Labriola 
 

    
---|---|--- 
    

 

         |  

Facsimile:

    |  

(978) 232-0864 
 

    
---|---|--- 
    

 

         |  

E-Mail:

    |  

vlabriola@americanrenal.com

    
---|---|--- 
    

 


 

 

with an additional copy (which shall not constitute notice) to:

 


 

 

Latham and Watkins LLP

 

885 Third Avenue

 

New York, New York 10022

 

         |  

Attention:

    |  

Charles Ruck / Thomas Malone

    
---|---|--- 
    

 

         |  

Facsimile:

    |  

(212) 751-4864

    
---|---|--- 
    

 

         |  

E-Mail:

    |  

charles.ruck@lw.com;

 

thomas.malone@lw.com

    
---|---|--- 
    

 


 

 


 

 

or to such other persons or addresses as may be designated in writing by the
Party to receive such notice as provided above.

 


 

 

All notices and other communications given in accordance with the provisions
of this Agreement shall be deemed to have been given and received when
delivered by hand or transmitted by facsimile or e-mail (with  acknowledgment
received), five (5) Business Days after the same are sent by registered or
certified mail, postage prepaid, return receipt requested or one (1) Business
Day after the same are sent by a reliable overnight courier service, with 
acknowledgment of receipt.

 


 

 

Section 9.5. _Certain Definitions_. For purposes of this Agreement, the term:

 


 

  (a) " _Acceptable Confidentiality Agreement_ " means a  confidentiality
agreement on terms substantially similar in the aggregate to those contained
in the Confidentiality Agreement (except for such changes specifically
necessary in order for the Company to be able to comply with _Section 6.1_
). 


 

  (b) " _Affiliate_ " means, with respect to any Person, any other  Person
directly or indirectly, controlling, controlled by, or under common control
with, such Person. 


 

  (c) " _Business Day_ " means any day other than a Saturday or  Sunday or
a day on which banks are required or authorized to close in the City of New
York, New York. 


 

  (d) " _Clinic Joint Venture_ " means the Persons listed in
_Section          9.5(d)_ of the Company Disclosure Schedule and any
other actively operated dialysis facility formed or acquired after the date of
the Agreement, in which the Company has a direct or indirect ownership
interest. 

 

78   (e) " _Company Termination Fee_ " means, (i) $5,037,136 if the  Company
Termination Fee is payable pursuant to _Section 8.2(b)(i)_ due to a
termination of this Agreement pursuant to _Section 8.1(d)(ii)_ by the Company
in order to enter into a definitive agreement for a Superior Proposal with an
Excluded  Party, and (ii) $12,089,126 in all other circumstances. 


 

  (f) " _Contract_ " means any legally binding written or oral  agreement,
contract, subcontract, real property lease, understanding, instrument, note,
option, warranty, sales order, purchase order, license, sublicense, insurance
policy, benefit plan or commitment or undertaking of any nature, excluding any
Permit. 


 

  (g) " _control_ " (including the terms " _controlling_ ", " _controlled_
",          " _controlled by_ " and " _under common control with_ ")
means the possession, directly or indirectly, of the power to direct or cause
the direction of the management policies of a Person, whether through the
ownership of voting securities, by  Contract or otherwise. 


 

  (h) " _Credit Facilities_ " means the agreements listed in
_Section          9.5(h)_ of the Company Disclosure Schedule, and any
replacements or refinancings thereof entered into after the date hereof in the
ordinary course of business. 


 

  (i) " _Debt Financing Sources_ " means each of the Persons that  have
committed to provide, or otherwise entered into agreements in connection with,
the Debt Financing, including the parties to the Debt Commitment Letter and
any person that has not executed the Debt Commitment Letter as of the date
hereof, but  becomes a party thereto after the date hereof, in accordance
with the terms thereof (other than Parent, Merger Sub or any of their
Affiliates) or any party that has committed to provide Alternative Financing
under any Alternative Financing Commitment  Letter. 


 

  (j) " _Debt Financing Sources Related Party_ " means the Debt  Financing
Sources, together with their respective Affiliates, and the respective
officers, directors, officers, employees, agents, advisors, controlling
Persons and the other Representatives and successors of each of the
foregoing. 


 

  (k) " _ERISA Affiliate_ " means any entity that would be  considered a
single employer with the Company under Section 4001(b) of ERISA or part of the
same "controlled group" as the Company for purposes of Section 302(d)(3) of
ERISA. 


 

  (l) " _Exchange Act_ " means Securities Exchange Act of 1934, as 
amended. 


 

  (m) " _GAAP_ " means the generally accepted accounting  principles set
forth in the opinions and pronouncements of the Accounting Principles Board of
the American Institute of Certified Public Accountants and statements and
pronouncements of the Financial Accounting Standards Board or in such other 
statements by such other entity as may be approved by a significant segment of
the accounting profession in the United States, in each case, as applicable,
as of the time of the relevant financial statements referred to herein. 

 

79   (n) " _Governmental Entity_ " means any governmental,  quasi-governmental
or regulatory (including stock exchange) authority, agency, court, commission
or other governmental body, whether foreign or domestic, of any country,
nation, republic, federation or similar entity or any state, county, parish
or  municipality, jurisdiction or other political subdivision thereof. 


 

  (o) " _Health Care Laws_ " means all applicable Laws relating to  the
regulation, provision, management, administration of, and payment for,
healthcare services and items, including: (1) 42 U.S.C.  1320a7, 7a and 7b;
(2) 42 U.S.C.  1395nn; (3) 31 U.S.C.  37293733; (4) 18 U.S.C.  286, 287
and 666; (5) 42  U.S.C.  1320a through 7b(b); (6) the Health Insurance
Portability and Accountability Act of 1996 (42 U.S.C.  1320d et seq.), as
amended by the Health Information Technology for Economic and Clinical Health
Act (42 U.S.C.  17921 et seq.) and state  health information data breach
notification, privacy and security Laws; (7) the Controlled Substances Act (21
U.S.C.  801 et seq.); (8) the Medicare statute (Title XVIII of the Social
Security Act) and the Medicaid statute (Title XIX of the Social  Security
Act); (9) any federal, state or local Laws with respect to healthcare related
fraud and abuse, false claims, self-referral, anti-kickback, billing, coding,
documentation and submission of claims, dispensing medicines or controlled
substances,  healthcare professional credentialing and licensing, sales and
marketing, healthcare quality and safety, the corporate practice of medicine,
fee-splitting, and healthcare facility or agency licensing; and (10) in each
case, all regulations promulgated  under such Laws and any other similar
federal, state or local Laws. 


 

  (p) " _HSR Act_ " means Hart-Scott-Rodino Antitrust Improvements  Act of
1976, as amended. 


 

  (q) " _Intellectual Property_ " means all intellectual property  and
proprietary rights, including all (i) patents, methods, processes, inventions,
copyrights and copyrighted works, trademarks, service marks, trade names,
corporate names, domain names, logos, trade dress and other source indicators
and the goodwill  of the business symbolized thereby, trade secrets and know-
how, and (ii) registrations, applications, provisionals, divisions,
continuations, continuations-in-part, re-examinations, re-issues, renewals and
foreign counterparts for any of the foregoing. 


 

  (r) " _Joint Venture Agreements_ " means (i) the material  partnership,
limited liability, operating agreements or other similar organizational
documents governing each Clinic Joint Venture, (ii) any material agreement
with one or more physicians or physician groups providing for medical director
services with  respect to each Clinic Joint Venture, and (iii) the material
management services agreement with respect to each Clinic Joint Venture,
between an Affiliate or Subsidiary of the Company, on the one hand, and the
Clinic Joint Venture, on the other hand. 


 

  (s) " _knowledge_ " (i) with respect to the Company means the  actual
knowledge of any of the individuals listed in _Section 9.5(r)_ of the Company
Disclosure Schedule and (ii) with respect to Parent or Merger Sub means the
actual knowledge of any of the individuals listed in _Section 9.5(r)_ of the 
Parent Disclosure Schedule, in each case after reasonable inquiry. 

 

80   (t) " _Law_ " means any federal, state, local, municipal,  foreign or
other law, statute, constitution, principle of common law, ordinance, code,
decree, order, judgment, rule, regulation, ruling or requirement issued,
enacted, adopted, promulgated, implemented or otherwise put into effect by or
under the  authority of any Governmental Entity and any order or decision of
an applicable arbitrator or arbitration panel. 


 

  (u) " _Liability Cap_ " means an aggregate amount equal to 
$38,000,000. 


 

  (v) " _Material Adverse Effect_ " means any fact, event,  development,
change, effect, circumstance or occurrence (each, an " _Effect_ ") that,
individually or in the aggregate with all other Effects, (A) has had or would
reasonable be expected to have a material adverse effect on or with respect to
the  business, results of operation or financial condition of the Company and
its Subsidiaries taken as a whole or (B) would reasonably be expected to
prevent or materially delay the consummation of the Merger past the End Date;
_provided_ that, with  respect to clause (A) only, no Effects relating to,
arising out of or in connection with or resulting from any of the following
shall be deemed, either alone or in combination, to constitute or contribute
to a Material Adverse Effect (subject to the  limitations set forth below):
(i) general changes or developments in the economy, political conditions in
the United States or elsewhere in the world (including protests or political
unrest) or the financial, debt, capital, credit, commodities or  securities
markets in the United States or elsewhere in the world, (ii) general changes
or developments in the industries in which the Company or its Subsidiaries
operate, (iii) the negotiation, execution or delivery of this Agreement or the
public  announcement or pendency of the Merger or other transactions
contemplated hereby, including any impact thereof on relationships,
contractual or otherwise, with customers, suppliers, patients, payors,
regulators, lenders, partners, employees, joint  venture partners or similar
relationships of the Company and its Subsidiaries, or the compliance with the
terms of this Agreement and the transactions contemplated hereby, including
compliance with the covenants set forth herein (except that this  clause
(iii) shall not apply to the representations and warranties made in _Section
3.5_ (and to the extend related to _Section 3.5_ , the condition in _Section
7.2(a)_ ), (iv) any action taken or omitted to be taken by the Company at 
the written request of or with the written consent of Parent or Merger Sub or
expressly required by this Agreement, (v) changes or prospective or
anticipated changes, occurring after the date of this Agreement, in any
applicable Laws (including any  Health Care Laws) or applicable accounting
regulations or principles or interpretation or enforcement thereof, (vi) any
hurricane, tornado, earthquake, flood, tsunami, mudslide or other natural
disaster, weather condition, explosion or fire or other  force majeure event
or act of God or other comparable events or outbreak or escalation of
hostilities or war (whether or not declared), military actions or any, act of
sabotage, terrorism, epidemics or pandemics (including COVID-19), disease
outbreaks  or national or international political or social conditions
(including social unrest) or any escalation or worsening relating to the
foregoing, including any escalation or worsening of any stoppages or
shutdowns, or any response of any Governmental  Entity (including
requirements for business closures or "sheltering-in-place"), related to any
of the foregoing, (vii) any matter (including actions taken by the SEC or the
DOJ) relating to the restatement of the Company's financial statements filed
in  the Company's Annual Report on Form 10-K on September 5, 2019 or the
underlying causes thereof and all related claims, investigations, proceedings,
actions or actions taken by a Governmental Entity with respect thereto, (viii)
any change in the market  price or trading volume of the Shares or the credit
rating of the Company or any of its Subsidiaries, (ix) any failure by the
Company to meet any published analyst estimates or expectations of the
Company's revenue, earnings or other financial  performance or results of
operations for any period, in and of itself, or any failure by the Company to
meet its internal or published projections, budgets, plans or forecasts of its
revenues, earnings or other financial performance or results of  operations,
in and of itself (it being understood that the underlying facts, events or
circumstances giving rise to or contributing to such change or failure may be
deemed to constitute, and may be taken into account in determining, whether
there has  been a Material Adverse Effect), (x) any determination or decision
by, or delay of a determination or decision by, or any recommendation,
statement or other pronouncement made or proposed by, any Governmental Entity
or any panel or advisory body  empowered or appointed thereby with respect to
the uses, reimbursement scheme, pricing, or status for any services offered by
the Company or any of its Subsidiaries, or any such determinations, decisions,
recommendations, statements or pronouncements  with respect thereto or (xi)
any matter disclosed in the Company Disclosure Schedule; except in the cases
of clauses (i), (ii), (v), (vi) or (x), to the extent that the Company and its
Subsidiaries, taken as a whole, are materially disproportionately  affected
thereby as compared with other participants operating in the industry in which
the Company and its Subsidiaries conduct business (in which case solely the
incremental disproportionate impact or impacts may be taken into account in
determining  whether there has been a Material Adverse Effect). 

 

81   (w) " _Permit_ " means governmental licenses, permits,  certificates,
approvals, billing and authorizations. 


 

  (x) " _Person_ " means an individual, corporation (including  not-for-
profit), general or limited partnership, limited liability company, joint
venture, estate, trust, association, organization, unincorporated
organization, other entity or group (as defined in Section 13(d)(3) of the
Exchange Act). 


 

  (y) " _Subsequent Transaction_ " means the proposed sale or  transfer of
certain assets of the Company to Fresenius Medical Care Ventures, LLC,
pursuant to the Subsequent Transaction Agreement. 


 

  (z) " _Subsequent Transaction Agreement_ " means the August  Newco Unit
Purchase Agreement, dated as of October 1, 2020, by and between Parent and
Fresenius Medical Care Ventures, LLC. 


 

  (aa) " _Subsidiary_ " or " _Subsidiaries_ " means, with  respect to any
Person (a) any corporation, association or other business entity (other than a
partnership, joint venture or limited liability company) of which more than
50% of the total voting power of shares of stock or other equity interests of
such  Person entitled (without regard to the occurrence of any contingency)
to vote in the election of directors, managers or trustees thereof is at the
time of determination owned or controlled, directly or indirectly, by such
Person or one or more of the  other subsidiaries of that Person or a
combination thereof and (b) any partnership, joint venture or limited
liability company of which (i) more than 50% of the capital accounts,
distribution rights, total equity and voting interests or general and 
limited partnership interests, as applicable, are owned or controlled,
directly or indirectly, by such Person or one or more of the other
subsidiaries of that Person or a combination thereof, whether in the form of
membership, general, special or  limited partnership interests or otherwise
and (ii) such Person or any subsidiary of such Person is a controlling general
partner or otherwise controls such entity. 

 

82   (bb) " _Willful Breach_ " means with respect to any breaches or  failures
to perform any of the covenants or other agreements contained in this
Agreement, a material breach that is a consequence of an act or failure to act
undertaken by the breaching Party with actual knowledge (after reasonable
inquiry) that such  Party's act or failure to act would, or would reasonably
be expected to, result in or constitute a breach of this Agreement. For the
avoidance of doubt, a Party's failure to consummate the Closing when required
pursuant to _Section 1.2_ shall be  a Willful Breach of this Agreement. 


 

 

Section 9.6. _Severability_. The provisions of this Agreement shall be deemed
severable and the invalidity or unenforceability of any provision shall not
affect the validity or enforceability of the other  provisions hereof. If any
term or other provision of this Agreement is found by a court of competent
jurisdiction to be invalid, illegal or incapable of being enforced by any rule
of Law or public policy, all other conditions and provisions of this 
Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not
affected in any manner adverse to any Party. Upon such determination that any
term or other  provision is invalid, illegal or incapable of being enforced,
the Parties hereto shall negotiate in good faith to modify this Agreement so
as to effect the original intent of the Parties as closely as possible in an
acceptable manner to the end that  the transactions contemplated hereby are
fulfilled to the fullest extent possible.

 


 

 

Section 9.7. _Entire Agreement; Assignment_. This Agreement (including the
Exhibits hereto and the Company Disclosure Schedule and the Parent Disclosure
Schedule), the Commitment Letters, the Parent  Guarantee and the
Confidentiality Agreement constitute the entire agreement among the Parties
with respect to the subject matter hereof and supersede all prior agreements
and undertakings, both written and oral, among the Parties, or any of them, 
with respect to the subject matter hereof and thereof. This Agreement shall
not be assigned by operation of law or otherwise without the prior written
consent of each of the other Parties, and any assignment without such consent
shall be null and  void; provided, that Parent and Merger Sub and, after the
Closing, the Company and its Subsidiaries, may, without the prior written
agreement of any other Party, assign any or all of their respective rights
hereunder to the Debt Financing Sources  (including for collateral security
purposes) so long as Parent remains liable hereunder.

 


 

 

Section 9.8. _Parties in Interest_. This Agreement shall be binding upon and
inure solely to  the benefit of each Party hereto, and nothing in this
Agreement, express or implied, is intended to or shall confer upon any other
Person any rights, benefits or remedies of any nature whatsoever under or by
reason of this Agreement, other than (a)  with respect to the provisions of
_Section 6.9_ which shall inure to the benefit of the Persons or entities
benefiting therefrom who are intended to be third-party beneficiaries thereof,
(b) at and after the Effective Time, the rights of the  holders of Shares to
receive the Per Share Merger Consideration in accordance with the terms and
conditions of this Agreement, (c) at and after the Effective Time, the rights
of the holders of Options, Restricted Stock and RSU Awards to receive the 
payments contemplated by the applicable provisions of _Section 2.2_ at the
Effective Time in accordance with the terms and conditions of this Agreement,
and (d) prior to the Effective Time, the rights of the holders of Common Stock
to pursue  claims for damages and other relief, including equitable relief,
for Parent's or Merger Sub's breach of this Agreement; _provided_ that the
rights granted to the holders of Common Stock pursuant to the foregoing clause
(d) of this _Section  9.8_ shall only be enforceable on behalf of such
holders by the Company in its sole and absolute discretion. The
representations and warranties in this Agreement are the product of
negotiations among the Parties hereto and are for the sole  benefit of the
Parties hereto. Any inaccuracies in such representations and warranties are
subject to waiver by the Parties in accordance with _Section 9.3_ without
notice or liability to any other Person. In some instances, the 
representations and warranties in this Agreement may represent an allocation
among the Parties hereto of risks associated with particular matters
regardless of the knowledge of any of the Parties hereto. Consequently,
Persons other than the Parties  hereto may not rely upon the representations
and warranties in this Agreement as characterizations of actual facts or
circumstances as of the date hereof or as of any other date.

 

 

83  

Section 9.9. _Governing Law_. This Agreement shall be governed by, and
construed in accordance with, the Laws of the State of Delaware (without
giving effect to choice of Law principles thereof).

 


 

 

Section 9.10. _Headings_. The descriptive headings contained in this Agreement
are included for convenience of reference only and shall not affect in any way
the meaning or interpretation of this  Agreement.

 


 

 

Section 9.11. _Counterparts_. This Agreement may be executed and delivered
(including by facsimile transmission, ".pdf," or other electronic
transmission) in one or more counterparts, and by the different  Parties in
separate counterparts, each of which when executed shall be deemed to be an
original but all of which taken together shall constitute one and the same
agreement.

 


 

 

Section 9.12. _Specific Performance_.

 


 

  (a) Each Party acknowledges that (i) money damages would be an 
insufficient remedy for any actual or threatened breach of this Agreement by
such Party, (ii) any such breach or threatened breach would cause the other
Party irreparable harm and (iii) in addition to any other remedies available
at Law or in equity  that are expressly provided to a Party under this
Agreement, the Parties will be entitled to equitable relief by way of
injunction, specific performance or other equitable relief, without posting
any bond or other undertaking, for any actual or  threatened breach of this
Agreement by such Party. Neither Party will (i) contest the appropriateness or
granting of any injunction or specific performance as a remedy for a breach of
this Agreement or (ii) assert that a remedy of specific enforcement  is
unenforceable, invalid, contrary to Law or inequitable for any reason, nor to
assert that a remedy of monetary damages would provide an adequate remedy,
subject in all cases to the terms and conditions of _Section 9.12(b)_. 

 

84   (b) Notwithstanding anything in this Agreement to the contrary, the 
Parties hereby further acknowledge and agree that prior to the Closing, the
Company shall be entitled to specific performance to enforce specifically the
terms and provisions of, and to prevent or cure any actual or threatened
breach, of this Agreement  by Parent or Merger Sub and to cause Parent or
Merger Sub to consummate the transactions contemplated hereby and comply with
its obligations hereunder (including with respect to the Debt Financing).
Notwithstanding anything in this Agreement to the  contrary, the Parties
hereby further acknowledge and agree that prior to the Closing, the Company
shall be entitled to specific performance to cause the Equity Financing to be
funded and to cause Parent to effect the Closing, if but only if (i) all of 
the conditions in _Section 7.1_ and _Section 7.2_ have been satisfied or
waived (other than those conditions that by their nature are to be satisfied
at the Closing, but subject to such conditions being satisfied if the Closing
were to  occur at such time), (ii) the Company has irrevocably confirmed in a
written notice to Parent that if specific performance to cause the Equity
Financing to be funded is granted and the Debt Financing is funded, then the
Closing will occur, (iii) the  amounts committed to be funded under the Debt
Commitment Letter (or the Alternative Financing Commitment Letters) either
have been funded or will be funded (or the conditions to such funding will be
satisfied) at the Closing if the amounts under the  Equity Commitment Letter
are funded at Closing, and (iv) Parent fails to consummate the Closing within
one (1) Business Day after the delivery of the written notice set forth in
clause (ii). Notwithstanding anything to the contrary contained in this 
Agreement, while the Company may concurrently seek (i) specific performance or
other equitable relief, subject in all respects to this _Section 9.12_ and
(ii) payment of the Parent Termination Fee or monetary damages in accordance
with _Section          8.2(a)_ , if, as and when required pursuant to
this Agreement, under no circumstances shall the Company be entitled to
receive both a grant of specific performance to cause the Equity Financing to
be funded, on the one hand, and payment of the  Parent Termination Fee and/or
any of the other amounts, if any, as and when due, pursuant to _Section
8.2(a)_ , on the other hand. In addition, notwithstanding anything in this
Agreement to the contrary: (x) no Person other than the Company shall  be
entitled to seek specific performance of this Agreement against Parent; and
(y) no Person other than the Company shall be entitled to seek payment of the
Parent Termination Fee and any Collection Costs and Reimbursement
Obligations. 


 

 

Section 9.13. _Jurisdiction_. Each of the Parties irrevocably (a) consents to
submit itself to the personal jurisdiction of the Delaware Court of Chancery
and any state appellate court therefrom within the  State of Delaware (unless
the Delaware Court of Chancery shall decline to accept jurisdiction over a
particular matter, in which case, in any Delaware state or federal court
within the State of Delaware), in connection with any matter based upon or 
arising out of this Agreement or any of the transactions contemplated by this
Agreement or the actions of Parent, Merger Sub or the Company in the
negotiation, administration, performance and enforcement hereof and thereof,
(b) agrees that it will  not attempt to deny or defeat such personal
jurisdiction by motion or other request for leave from any such court, (c)
agrees that it will not bring any action relating to this Agreement or any of
the transactions contemplated by this Agreement in  any court other than the
courts of the State of Delaware, as described above, and (d) consents to
service being made through the notice procedures set forth in _Section 9.4_.
Each of the Company, Parent and Merger Sub hereby agrees that  service of any
process, summons, notice or document by delivery in person or by overnight
courier to the respective addresses set forth in _Section 9.4_ shall be
effective service of process for any suit or Proceeding in connection with
this  Agreement or the transactions contemplated hereby. Each Party hereto
hereby irrevocably waives, and agrees not to assert, by way of motion, as a
defense, counterclaim or otherwise, in any action or Proceeding with respect
to this Agreement, any  claim that it is not personally subject to the
jurisdiction of the above-named courts for any reason other than the failure
to serve process in accordance with this _Section 9.13_ , that it or its
property is exempt or immune from jurisdiction  of any such court or from any
legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment,
execution of judgment or otherwise), and to the fullest extent  permitted by
applicable Law, that the suit, action or Proceeding in any such court is
brought in an inconvenient forum, that the venue of such suit, action or
Proceeding is improper, or that this Agreement, or the subject matter hereof
or thereof,  may not be enforced in or by such courts and further irrevocably
waives, to the fullest extent permitted by applicable Law, the benefit of any
defense that would hinder, fetter or delay the levy, execution or collection
of any amount to which the  Party is entitled pursuant to the final judgment
of any court having jurisdiction. Each Party expressly acknowledges that the
foregoing waiver is intended to be irrevocable under the Laws of the State of
Delaware and of the United States of  America; _provided_ that each such
Party's consent to jurisdiction and service contained in this _Section 9.13_
is solely for the purpose referred to in this _Section 9.13_ and shall not be
deemed to be a general submission to said  courts or in the State of Delaware
other than for such purpose.

 

 

85  

Section 9.14. _WAIVER OF JURY TRIAL_. EACH OF PARENT, MERGER SUB AND THE
COMPANY HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON  CONTRACT, TORT OR
OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THE ACTIONS OF PARENT OR THE COMPANY IN THE
NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF OR THEREOF.

 


 

 

Section 9.15. _Transfer Taxes_. All transfer, documentary, sales, use, stamp,
registration and other such Taxes and fees (including penalties and interest)
incurred in connection with the Merger shall be  paid by Parent and Merger
Sub when due and Parent and Merger Sub shall prepare and timely file all Tax
Returns and other documentation with respect to such Taxes, and Parent and
Merger Sub will indemnify the Company against liability for any such  Taxes.

 


 

 

Section 9.16. _Interpretation_. When reference is made in this Agreement to a
Section, such reference shall be to a Section of this Agreement unless
otherwise indicated. Whenever the words "include",  "includes" or "including"
are used in this Agreement, they shall be deemed to be followed by the words
"without limitation." The words "hereof," "herein," "hereby" and "hereunder"
and words of similar import when used in this Agreement shall refer  to this
Agreement as a whole and not to any particular provision of this Agreement.
The word "or" shall not be exclusive. References to "dollars" or "$" are to
United States of America dollars. The phrases "transactions contemplated by
this  Agreement", "transactions contemplated hereby" and similar terms shall
refer only to the Merger and the related transactions expressly contemplated
by this Agreement and shall not include the Subsequent Transaction. For the
purposes of _Article  III_ of this Agreement, the term "made available", with
respect to any document or item made available to Parent and its
Representatives, shall mean such document or item has been made available to
Parent and its Representatives in the  electronic data room maintained or via
email or other physical or electronic format by the Company on or before the
time that is one day immediately prior to the Closing Date. References to any
statute, rule or regulation, or any other applicable  Law, shall be deemed to
refer to such statute, rule or regulation, or other applicable Law, as amended
or supplemented from time to time, including through the promulgation of
applicable rules or regulations. References to any Contract are to that 
Contract as amended, modified or supplemented from time to time in accordance
with the terms hereof and thereof. The phrase "to the extent" shall mean the
degree to which a subject or other thing extends, and such phrase shall not
mean simply "if".   This Agreement shall be construed without regard to any
presumption or rule requiring construction or interpretation against the Party
drafting or causing any instrument to be drafted.

 

 

86  

Section 9.17. _Debt Financing Sources_. Notwithstanding anything in this
Agreement to the contrary, the Company on behalf of itself and its
Subsidiaries hereby: (i) agrees that any Proceeding, whether in  Law or in
equity, whether in contract or in tort or otherwise, involving any Debt
Financing Sources Related Party, arising out of or relating to, this
Agreement, the Debt Financing or any of the agreements entered into in
connection with the Debt  Financing, or any of the transactions contemplated
hereby or thereby or the performance of any services thereunder shall be
subject to the exclusive jurisdiction of any federal or state court in the
Borough of Manhattan, New York, New York, so long  as such forum is and
remains available, and any appellate court thereof and the Company on behalf
of itself and its Subsidiaries hereto irrevocably submits itself and its
property with respect to any such Proceeding to the exclusive jurisdiction
of  such court, and such action (except to the extent relating to the
interpretation of any provisions in this Agreement (including any provision in
any documentation related to the Debt Financing that expressly specifies that
the interpretation of such  provisions shall be governed by and construed in
accordance with the Law of the State of Delaware)) shall be governed by the
Laws of the State of New York (without giving effect to any conflicts of Law
principles that would result in the application  of the Laws of another
jurisdiction), (ii) agrees not to bring or support any action of any kind or
description, whether in Law or in equity, whether in contract or in tort or
otherwise, against any Debt Financing Sources Related Party in any way 
arising out of or relating to, this Agreement, the Debt Financing or any of
the transactions contemplated hereby or thereby or the performance of any
services thereunder in any forum other than any federal or state court in the
Borough of Manhattan,  New York, New York, (iii) agrees that service of
process upon the Company or its Subsidiaries in any such action or Proceeding
shall be effective if notice is given in accordance with _Section 9.4_ , (iv)
irrevocably waives, to the fullest  extent that it may effectively do so, the
defense of an inconvenient forum to the maintenance of such action in any such
court, (v) knowingly, intentionally and voluntarily waives to the fullest
extent permitted by applicable Law trial by jury in any  action brought
against the Debt Financing Sources in any way arising out of or relating to,
this Agreement, the Debt Financing or any of the transactions contemplated
hereby or thereby or the performance of any services thereunder, (vi) agrees
that  none of the Debt Financing Sources Related Parties will have any
liability to the Company or any of its Subsidiaries (in each case, other than
the Surviving Corporation and its Subsidiaries) relating to or arising out of
this Agreement, the Debt  Financing or any of the transactions contemplated
hereby or thereby or the performance of any services thereunder, whether in
Law or in equity, whether in contract or in tort or otherwise ( _provided_
that, notwithstanding the foregoing, nothing  herein shall affect the rights
of Parent and Merger Sub against the Debt Financing Sources Related Parties
with respect to the Debt Financing or any of the transactions contemplated
thereby or the rights of the Surviving Corporation and its  Subsidiaries
following the Merger), and (vii) agrees that the Debt Financing Sources
Related Parties are express third party beneficiaries of, and may enforce, any
of the provisions in this Agreement reflecting the foregoing agreements in
this _Section          9.17_ or in _Section 8.2(g)_ , _Section 9.2_ ,
_Section 9.3_ , and _Section 9.7_ and such provisions and the definition of
"Debt Financing Sources" and "Debt Financing Sources Related Parties" shall
not be amended, modified  or waived in any way material and adverse to the
Debt Financing Sources Related Parties without the prior written consent of
the Debt Financing Sources Related Parties.

 


 

 

[Remainder of Page Intentionally Left Blank]

 

 

87  

IN WITNESS WHEREOF, Parent, Merger Sub and the Company have caused this
Agreement to be executed as of the date first written above by their
respective officers thereunto duly authorized.

 


 

 

         |  

COMPANY:

    
---|--- 
    
    |   |   
      |  

AMERICAN RENAL ASSOCIATES HOLDINGS, INC.

    
     

    |  

    |  

    
     

    | By:  |  

/s/ Joseph A. Carlucci 
 

    
      |   |  

Name: Joesph A. Carucci 
 

    
     

    |  

    |  

Title: Chief Executive Officer and Chairman of the Board of Directors 
 

    
    

 


 

 

 


 

 

         |  

PARENT:

    
---|--- 
      |   |   
      |  

IRC SUPERMAN MIDCO, LLC, 
 

 

a Delaware limited liabilty company 
 

    
     

    |  

    |  

    
     

    | By:  |  

/s/ Scott Hilinski 
 

    
      |   |  

Name: Scott Hilinski

    
     

    |  

    |  

Title: President 
 

    
    

 


 

 

 


 

 

 

         | MERGER SUB: 
    
---|--- 
      |   |   
      |  

SUPERMAN MERGER SUB, INC., 
 

 

a Delaware corporation 
 

    
     

    |  

    |  

    
     

    | By:  |  

/s/ Scott Hilinski

    
      |   |  

Name: Scott Hilinski

    
     

    |  

    |  

Title: President 
 

    
    

 

 


 

 

 

Signature Page-Merger Agreement

       '

